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ABSTRACT 
 
Polina Feldman 
 
The Role of High Mobility Group Box 1 and Toll like Receptor 4 in a Rodent 
Model of Neuropathic Pain 
 
 Neuropathic pain is a serious health problem that greatly impairs quality of 
life. The International Association for the Study of Pain (IASP) defines 
neuropathic pain as ‘pain arising as a direct consequence of a lesion or disease 
affecting the nervous system’. It is important to note that with neuropathy the 
chronic pain is not a symptom of injury, but rather the pain is itself a disease 
process. Novel interactions between the nervous system and elements of the 
immune system may be key facets to a chronic disease state. One of particular 
note is the recent finding supporting an interaction between an immune response 
protein high mobility group box 1 (HMGB1) and Toll like receptor 4 (TLR4). 
HMGB1 is an endogenous ligand for TLR4 that influences the induction of 
cytokines in many non-neuronal cells. After tissue damage or injury, HMGB1 may 
function as a neuromodulatory cytokine and influence the production of pro-
nociceptive mediators altering the state of sensory neurons. Very little is known 
about the HMGB1-TLR4 interaction in sensory neurons and whether chronic 
changes in endogenous HMGB1 signaling influence the establishment of 
neuropathic pain. This thesis aims to determine whether a physiologically 
relevant neuroimmune interaction involving endogenous HMGB1 and TLR4 in 
the dorsal root ganglia is altered following a tibial nerve injury model of 
neuropathic pain. I hypothesized that sensitization of sensory neurons following a 
peripheral nerve injury is dependent on endogenous HMGB1 and TLR4.  
 x 
 The studies presented here demonstrate that HMGB1 undergoes 
subcellular redistribution from the nucleus to the cytoplasm in primary afferent 
neurons following peripheral nerve injury. Further, the presence of extracellular 
HMGB1 may directly contribute to peripheral sensitization and injury-induced 
tactile hyperalgesia. Though thought to be important as a pivotal receptor for 
HMGB1 activation, neuronal protein expression of TLR4 does not appear to 
influence the effects of HMGB1-dependent behavioral changes following 
peripheral nerve injury. Taken together, these findings suggest that extracellular 
HMGB1 may serve as an important endogenous cytokine that contributes to 
ongoing pain hypersensitivity in a rodent model of neuropathic pain.  
 
Gerry S. Oxford, Ph.D., Chair 
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CHAPTER I  
INTRODUCTION  
A. Pain 
 The International Association for the Study of Pain (IASAP), defines pain 
as ‘an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage’ (Merskey, 1994). As a sensory experience, pain is often 
categorized as “good pain” -nociceptive pain, or “bad pain” -pathophysiological 
pain (Devor, 2006). As an emotional (affective) experience, pain is a moment-to-
moment conscious and cognitive process that brings forth feelings of fear and 
suffering and often times results in withdrawal and avoidance behaviors (Price, 
2000). 
 In the most primitive form, pain functions as an early warning mechanism 
to detect and protect against potentially tissue-damaging noxious stimuli. 
Because this pain has a direct behavioral response to sensing noxious stimuli (i.e. 
rapid withdrawal reflex), it is often referred to as nociceptive pain (Woolf, 2010). 
Pain can also function as a critical indication for proper recovery after injury or 
illness. Acute pain is a state that is adaptive, protective and encourages the 
healing process. For instance, inflammatory pain is an acute pain state that is 
caused by the activation of the immune system during tissue injury or infection 
and serves as a protective response (Devor, 2006). The etiology of acute pain 
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may arise from a number of medical conditions; however, when pain becomes 
chronic condition, it can be considered a disease (Costigan et al., 2009).  
 A chronic pain state is no longer protective, but instead maladaptive, 
resulting from abnormal neurobiological processing in the nervous system. 
Chronic pain can arise from damage to the nervous system (neuropathic pain) 
but can also arise without damage to the nervous system or inflammation 
(dysfunctional pain) (Costigan et al., 2009). Each pain state, whether acute or 
chronic is highly subjective, depends greatly on past pain experience, physical 
health, psychological/mental status, genetic predisposition, and current pain 
phenotype (von Hehn et al., 2012).   
 
1. Types of pain 
Pain can be viewed on a spectrum ranging from acute to chronic. At first, 
acute pain is experienced rapidly in response to disease or injury and serves to 
alert the body that something is wrong and responds accordingly, such as 
removing your hand from a hot stove. Acute pain often resolves within a short 
time once the underlying condition is treated. However, acute pain can be a sign 
of a serious disease or condition. A good example is cardiac pain or angina 
pectoris that precipitates moments leading up to a myocardial infarction. When 
nerves from the damaged heart tissue convey pain signals to spinal cord levels 
at thoracic (T) T1-T4 on the left side, they happen to converge with nerve fibers 
from the throat, neck and left arm at the same spinal cord levels and pain is 
transmitted and felt in those somatic structures (Foreman, 1999). Crushing, 
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burning, or squeezing pain sensations are felt that can radiate to the throat, neck, 
and left arm. Pain that originates in one part of the body but felt in another part of 
the body is known as referred pain.  
Unlike somatic pain that arises from muscles, bones and other soft tissues, 
visceral pain arising from problems with internal organs, such as the heart, liver, 
gall bladder, kidney, or lungs, is generally referred, diffuse, and poorly localized 
to the source (Sikandar & Dickenson, 2012). Moreover, pain may also act as a 
signal of disease, such as cancer. For instance, pain is present in 30-50% of all 
cancer patients (Mercadante & Arcuri, 1998) and the frequency and intensity of 
pain tends to increase with advancing stages of cancer (Portenoy et al., 1999).  
Progressing along the spectrum of pain, chronic pain often begins as 
acute pain continues to linger beyond the natural course of healing or after steps 
have been taken to address the cause of pain. Chronic pain is defined as lasting 
more than three months beyond the initiation of pain (Turk & Okifuji, 2009) and 
may develop from localized tissue damage, acute injury/disease (e.g. 
osteoarthritis) or damage to the nervous system-neuropathic pain (e.g. painful 
diabetic neuropathy, post-stroke pain, spinal cord injury) (Turk et al., 2011).  
 
2. Chronic pain symptoms and burden 
Clinically, chronic pain symptoms are described as spontaneous, shooting, 
burning, or aching pain. For instance, neuropathic pain is a subset of chronic 
pain caused by damage to the nervous system and is often perceived as tingling, 
burning, and pins-and-needles sensations called paresthesias (Baron, 2009). 
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Patients report some degree of discomfort, soreness, tightness and stiffness. 
Pain can also lead to other symptoms such as fatigue, sleeplessness, irritability, 
and a weakened immune system (Turk et al., 2011). Additionally, chronic pain is 
highly associated with other chronic co-morbidities including depression and 
anxiety (Berger et al., 2004). The daily quality of life is greatly compromised and 
individuals can become impatient, hopeless, and unmotivated. Often times the 
symptoms are so debilitating that daily activities, such as going to work/school, 
can no longer carry on. In 2008, the Medical Expenditure Panel Survey estimated 
about 100 million adults in the United States were affected by some degree of 
chronic pain with the estimated national total health care costs of $560-$635 
billion annually in the United States (Gaskin & Richard, 2012). Given the 
magnitude of the economic costs of pain, understanding the mechanisms of 
chronic pain to develop effective pain management therapies are needed to 
reduce the impact of pain on society. 
 
3. Pain treatment 
Pharmaceutical drugs are by far the most popular treatment for chronic 
pain. In 2010, the annual cost of pharmaceuticals for pain management was 
$16.4 billion (Gaskin & Richard, 2012). Antidepressant drugs, such as tricyclic 
antidepressants (TCAs)- amitriptyline and cyclobenzaprine, selective serotonin 
reuptake inhibitors (SSRIs), and selective serotonin and noradrenaline reuptake 
inhibitors (SNRIs), are widely used for the treatment of neuropathic pain, lower 
pack pain, and fibromyalgia. In some clinical studies, beneficial effects have been 
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reported; however, side-effects and toxicity reduce their functional effect (Verdu 
et al., 2008). Although nonsteroidal anti-inflammatory drugs (NSAIDs) are widely 
prescribed for most pain states, NSAIDs are less effective for neuropathic pain 
and fibromyalgia (Vo et al., 2009). Opioids are generally the gold standard for 
pain management; however, given their adverse side effects are now reserved 
for a second- or third- line treatment for chronic pain (Dworkin et al., 2010). 
Anticonvulsant drugs- gabapentin, pregabalin, and carbamazepine or 
oxcarbazepine- has had some success for the treatment of chronic pain and 
display greater efficacy in neuropathic pain patients (Dworkin et al., 2010; 
Finnerup et al., 2010). 
Other treatments for chronic pain may involve skeletal muscle relaxants, 
topical agents, nerve blocks, implantable devices, and alternative/holistic 
medicine. Of all the treatments available for chronic pain, the best evidence for 
pain reduction averages roughly 30% in about half of treated patients (Turk et al., 
2011). Thus a great need exists for personalized medicine to determine the 
effectiveness of combining pain treatments and generating novel therapeutic 
targets that account for the variability in chronic pain phenotypes.  
 
B. Sensory neuron 
The sensation of pain begins with the primary afferent neuron. The cell 
body of primary afferent neurons is located lateral to the spinal cord in the dorsal 
root ganglion (DRG). The primary afferent neuron (or sensory neuron) conveys 
thermal, mechanical, or chemical information from the physical environment to 
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the dorsal horn of the spinal cord. Primary afferent fibers can be distinguished by 
fibre conduction velocity that further correlate with fiber cross-sectional diameter 
(Harper & Lawson, 1985b). Primary afferent neurons are categorized as either A- 
(myelinated) and C- (unmyelinated) fibres. A- (myelinated) fibers comprise large 
Aα- (12-20µm), medium Aβ- (6-12µm), and small Aδ- (4-36µm) fibers that have a 
rapid conduction velocity of 72-120m/s, 36-72m/s, and 4-36m/s, respectively. C- 
(unmyelinated) fibers have the slowest conduction velocity at 0.4-2m/s with the 
smallest cross-sectional diameter (0.2-1.5µm) (Bessou & Perl, 1966; Boyd & 
Kalu, 1979). Primary afferent fibers also correlate with the size of the primary 
afferent cell body; Aβ-fibers correspond to large cell body diameters (>40µm), 
Aδ/C fibers correspond to medium (30-40µm), and small (<30µm) sized cell 
bodies (Harper & Lawson, 1985a).   
 Primary afferent neurons transduce mechanical, thermal, proprioceptive, 
and chemical information by specialized receptors. Those that innervate the skin 
may contain peripheral nerve endings that are encapsulated by a non-neural 
structure to mediate somatic modalities of touch, stretch, and proprioception (e.g. 
Meissner’s corpuscle or Pacinian corpuscle) (Munger & Ide, 1988). Aβ-fibers 
terminate in the dermis or epidermal layer of the skin depending on the 
peripheral nerve ending (Lumpkin & Caterina, 2007). Mainly, innocuous sensory 
information is transmitted by low threshold (high sensitivity) mechanoreceptors 
that are innervated by Aβ- and some Aδ-fibers. Additionally, innocuous stimuli 
light, such as pleasant touch may be represented by low threshold C-fibers 
mechanoreceptors (Olausson et al., 2002; Fang et al., 2005). Whereas, pain and 
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thermal information are transmitted by high threshold (low sensitivity) 
mechanoreceptors, nociceptors, and thermoreceptors innervated by Aδ/C fibers 
(Kruger et al., 1981; Light & Perl, 2003). Aδ-fibers innervate the dermis and 
parallel to the epithelial surface, whereas C-fibers innervate different epidermal 
layers of glabrous and hairy skin (MacIver & Tanelian, 1993b; a).  
 
1. Nociceptive sensory neuron 
 There are several classes of nociceptors: mechanical, thermal, mechano-
thermal, polymodal, and silent. Mechanical nociceptors are high threshold 
mechanoreceptors that correspond to Aδ-fibers and respond to extreme 
mechanical perturbations to the skin felt as sharp, pricking sensation (Cain et al., 
2001). Thermal nociceptors are activated by extreme temperatures (> 45°C or < 
5°C), which most commonly correspond to Aδ/C fiber conduction velocity 
(Burgess & Perl, 1967; Lynn & Carpenter, 1982).  
Mechano-thermal Aδ nociceptors are further functionally subdivided into 
two categories, Type I and Type II. Type I Aδ-nociceptors can be activated by 
intense mechanical stimuli or noxious heat at temperatures greater than 52°C 
(Meyer & Campbell, 1981; Treede et al., 1995). Type II Aδ-nociceptors are also 
activated by mechanical and heat stimuli but at a lower temperature threshold of 
43°C, similar to that of nociceptive C-fibers (Beitel et al., 1977; Meyer & 
Campbell, 1981; Leem et al., 1993; Treede et al., 1995). Moreover, there is 
evidence to suggest that a fraction of A-fiber nociceptors may also conduct in the 
Aβ conduction velocity range (Lawson, 2002; Djouhri & Lawson, 2004).  
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Polymodal nociceptors respond to high intensity mechanical, chemical, or 
thermal stimuli and mostly correspond to C-fiber conduction velocity (~72% of 
polymodal nociceptors) (Lynn & Carpenter, 1982; Lawson et al., 2008). For 
instance, C-polymodal fibers responsive to noxious heat (~10% of C-nociceptors) 
are presented as a slow, burning pain (Croze et al., 1976; Schmidt et al., 1995; 
Dubin & Patapoutian, 2010). Finally, silent nociceptors are activated by chronic 
stimulation (tissue damage, inflammation), and unresponsive during brief noxious 
stimuli (Neugebauer et al., 1989; Handwerker et al., 1991; Schmidt et al., 1995).  
 
2. Sensory transduction 
 The seminal work of Max Von Frey revealed that discrete areas of the skin 
yielded different sensory experiences (pressure, cold, warmth, and pain) and 
corresponded to structurally defined neural endings (Perl, 2007). Recent 
investigations have begun to uncover the cellular and molecular events that 
generate somatosensation. A range of ion channels present on peripheral nerve 
endings have been identified that mediate the transduction of sensory signals 
into electrical signals, which include transient receptor potential (TRP) channels, 
two pore potassium channels-TREK, P2X3 ATP-gated cation channels, and other 
voltage-gated channels (VGCs) (Patel et al., 1998; Bertrand & Bornstein, 2002; 
Chung & Caterina, 2007; Morris & Juranka, 2007). 
Most notably, the large family of TRP channels is tuned to a particular 
temperature range. For instance, acute thermal nociception in healthy skin 
involves the transient receptor potential cation channel subfamily V member 1 
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channel (TRPV1). TRPV1 was identified as the receptor for capsaicin (main 
active component of spicy peppers) to which activation of channel may occur at 
temperatures greater the 42°C. (Caterina et al., 1997; Caterina & Julius, 2001).  
On the other hand TRPM8, ion channel specific to C-fibres, is activated by cool 
temperatures (about 30-32°C) and menthol (McKemy et al., 2002; Peier et al., 
2002).   
 
3. Cytochemical classification  
 Primary afferent neurons are either A- (myelinated) or C- (unmyelinated) 
fibres, were initially distinguished by Nissl staining. Dorsal root ganglion sensory 
neurons with large ‘light’ myelinated neurons display uneven staining with lightly 
stained cytoplasmic regions due to the abundance of interspersed neurofilaments, 
whereas ‘small dark’ unmyelinated neurons had dense staining (Lawson et al., 
1974; Sommer et al., 1985). Antibodies against neurofilament 200 and peripherin 
have had some specificity to ‘light’ and ‘small dark’ sensory neurons in the rat, 
respectively (Lawson et al., 1984; Ferri et al., 1990). However, neurofilament 
antibodies display a varying degree of colocalization making it difficult to classing 
sensory neurons (Goldstein et al., 1991).  
 Several cell surface, cytoplasmic, and enzymatic markers that delineate 
sensory neuron subpopulations of small nociceptive sensory and large non-
nociceptive neurons have been identified (Jessell & Dodd, 1985; Snider & 
McMahon, 1998). Antibodies against TRPV1 have specificity to small and 
medium neurons (Aδ/C fibers) and do not display immunoreactivity in large 
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primary afferent neurons (Aβ-fibers) (Caterina et al., 1997). Antibody LA4, 
directed against α-galactose and α-fucose extended glycolipid also labels small 
DRG neurons (Dodd & Jessell, 1985; Alvarez et al., 1991).  
Most C-fibers fall into one of two categories, one population that contains 
pro-inflammatory peptides-peptidergic and the other population are non-
peptidergic (Snider & MacMahon, 1998). The pro-inflammatory peptidergic 
population is identified by peptides, calcitonin gene-related (CGRP) peptide (40% 
of DRG neurons CGRP-positive) and substance P (20% of DRG neurons) 
(Hokfelt et al., 1976; Ju et al., 1987). Somatostatin also labels a similar 
subpopulation as substance P (Hokfelt et al., 1976). Peptidergic DRG neurons 
are dependent on nerve growth factor (NGF) for neurotrophic support during 
embryogenesis and postnatal survival (Molliver et al., 1997).  
The nonpeptidergic population can also be identified histologically by the 
presence of specific enzyme fluoride-resistant acid phosphatase or binding sites 
for isolectin B4 (IB4) (30% of DRG population IB4-positive) (Knyihar-Csillik & 
Csillik, 1981; Silverman & Kruger, 1990). However, experimental finding using 
fluoride-resistant acid phosphatase displays differences in relative numbers and 
distribution (Hunt & Rossi, 1985). On the other hand, IB4 is derived from the 
plant Griffonia simplicifolia that preferentially binds to nonpeptidergic small DRG 
neurons through α-d-galactose carbohydrate residues on their soma membranes 
(Silverman & Kruger, 1990; Fullmer et al., 2004), however only one study has 
identified IB4 in both Aδ- and C-fibers (Gerke & Plenderleith, 2001). Although IB4 
subpopulation may not necessarily represent a specific functional subpopulation 
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of sensory neurons, IB4 subpopulation co-localizes with functional ATP-activated 
purinergic P2X3 receptor (67.5% IB4 and P2X3 colocalization) providing an 
additional marker for nonpeptidergic population (Bradbury et al., 1998) and high 
voltage-gated sodium channel (NaV)1.9 expression (Fang et al., 2006). Recent 
studies have identified Mas-related G-protein coupled receptor member D 
(MRGPRD), a G-protein coupled receptor, to define a population of non-
peptidergic nociceptive C-fibres in the mouse (Zylka et al., 2005). While 
nonpeptidergic neurons are NGF-dependent during embryogenesis, their 
neurotrophic dependence switches during early postnatal life and instead require 
glial cell line-derived neurotrophic factor (GDNF) (Molliver et al., 1997; Bennett et 
al., 1998).  
 The differences in neurotrophic dependency is further identified by the 
major discovery of TrkA- the high affinity receptor for NGF, which is expressed in 
mainly peptidergic CGRP and/or substance P populations independent of 
somatostatin, IB4, or LA4 binding afferent (Verge et al., 1989; Averill et al., 1995; 
Molliver et al., 1995; Kashiba et al., 1996). Whereas, GDNF -dependent 
subpopulations express a GDNF receptor Ret- (rearranged in transformation- a 
tyrosine kinase transmembrane receptor) and maintain the IB4 binding 
phenotype and somatostatin expression in adult DRG neurons (Bennett et al., 
1998; Bennett et al., 2000).   
 Furthermore, activated or injured primary afferent neurons are often 
identified by an additional set of neurochemical markers. Activating transcription 
factor 3 (ATF3), neuron specific enolase, and heat shock protein (HSP) 72 are a 
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neuronal markers of nerve injury or damage (Gonzalez et al., 1989; Hans et al., 
1993; Tsujino et al., 2000). c-FOS, cytochrome oxidase is a marker for metabolic 
neuronal activity or stimulation (Wong-Riley & Kageyama, 1986; Bullitt, 1990). 
Fluoro-Jade B is a high affinity fluorescent marker of neurodegeneration 
(Schmued & Hopkins, 2000). Taken together, these markers provide useful tools 
to distinguish subpopulations of DRG neurons, however many variables, such as, 
species, age, treatment condition may affect their specificity (Alvarez & Fyffe, 
2000).   
 
C. Nociceptive pathway 
Pain is transmitted from the periphery by nociceptive primary afferent 
neurons to the dorsal horn of the spinal cord. The spinal cord is the first relay site 
in the transmission of nociceptive information from the periphery to the brain. The 
signal is further transmitted to higher centers in the brain, where noxious signals 
can be perceived as pain (Figure 1).  
The cell body of primary afferent neurons is located lateral to the spinal 
cord in the DRG. Given this unique position, primary afferent neurons have 
morphologically evolved as pseudounipolar neurons with a single axon that 
projects bi-directionally, with one branch projecting the dorsal horn of the spinal 
cord and another branch projecting to peripheral tissues, such as skin, muscle, 
and viscera. Nociceptors on sensory neuron terminals transduce painful thermal, 
mechanical, chemical stimuli into electrical energy to transduce the signal to 
neurons and interneurons residing in the dorsal horn of the spinal cord (Woolf, 
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2010). The speed at which the signal is transmitted is related to the diameter of 
the fiber. The small-diameter and slow-conducting fibers, C-unmyelinated fibers 
and Aδ-myelinated fibers generally transmit signals from nociceptors (Bessou & 
Perl, 1966). Primary afferent neurons terminate in dorsal horn of the spinal cord 
and release the excitatory neurotransmitter glutamate to activate second order 
neurons and interneurons in the dorsal horn of the spinal cord.   
Primary afferent neurons project to the ipsilateral dorsal horn of the spinal 
cord to defined regions. Anatomical laminar organization of the dorsal horn is 
divided into a series of Laminae (I-V) that receive input from primary afferent 
neurons; Lamina (L)I- marginal zone, LII- substania gelatinosa, LIII-IV- nucleus 
proprius, and LV (Rexed, 1952; Brown, 1983). Lamina II is further subdivided into 
LIIo and LIIi. Nociceptive and thermoreceptive Aδ/C fibers innervate LI-II and 
Aδ/β myelinated low-threshold fibers innervate much of LIIi-V (Light & Perl, 1979; 
Brown et al., 1981; Shortland et al., 1989; Lawson et al., 1997). Specifically, Aδ- 
nociceptors innervate LI with some branches extending to V, X (Light & Perl, 
1979). Aδ/C peptidergic fibres innervate LI-IIo (Lawson et al., 1997), where as C- 
non-peptidergic fibres innervate mainly LIIi (Zylka et al., 2005; Lorenzo et al., 
2008). Overall, nociceptive primary afferent neurons convey ‘nociceptive’ 
information to second order neurons and polysynaptic interneurons in the spinal 
cord, which are essential for processing noxious information as a conscious 
experience and eliciting a nociceptive withdrawal reflex. 
Second order neurons cross the midline in the spinal cord and project via 
the spinothalamic tract to the thalamus and cortical areas (somatosensory cortex, 
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cingulate cortex, and insula) generating the perception of pain (Price, 2000). At 
the same time, nociceptive information activates interneurons (inhibitory or 
excitatory) in the spinal cord to facilitate a nociceptive motor withdrawal reflex, 
via motor neurons (Todd, 2010), resulting in avoidance and protective behavior. 
Descending control from midbrain periaqueductal gray (PAG), rostroventral 
medulla, and locus coeruleus modulate spinal dorsal horn neurons (Millan, 2002). 
Overall, the nociceptive information conveyed at the level of the spinal cord is 
dependent on the activity of primary afferent neurons, the influence of local 
excitatory and inhibitory interneurons, and descending input from the brainstem 
(D'Mello & Dickenson, 2008).  
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Figure 1:  
 
 
Figure 1: Nociceptive Pathway. Noxious stimuli evoke the pain pathway 
stimulating nociceptive primary afferent neurons. Nociceptive neurons comprise 
Aδ/C fibers that transduce the nociceptive signal into an electrical signal. The cell 
body of a primary afferent neuron is located in the dorsal root ganglion (DRG). 
First order, primary afferent neurons terminate onto second order neurons and 
interneurons in Laminae I-II of the dorsal spinal cord. In the presence of noxious 
stimuli polysynaptic spinal interneurons elicit motor reflexes via motor neurons of 
the ventral horn of the spinal cord. Second order neurons transmit the pain signal 
along the spinothalamic tract and synapse in the ventrolateral nucleus of the 
thalamus that further project to cortical areas; somatosensory cortex, cingulate 
cortex, and insula. Descending control originates from the midbrain; peri-
aqueductal gray (PAG), rostroventral medulla, and locus coeruleus to inhibit 
spinal dorsal horn neurons. Spinal cord adapted from SpringerImage, Muscle 
image-3Dscience.com, brain clip art-clker.com, Fire-Hazard-Warning-Sign 
adapted from Featurepics.com-490091.jpg 
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D. Neuropathic pain 
 The Institute of Medicine reports approximately 21 million American adults 
suffer from neuropathic pain (Toth et al., 2009). Neuropathic pain as defined by 
the IASP Special Interest Group on Neuropathic Pain (NeuPSIG) as ‘pain arising 
as a direct consequence of a lesion or disease affecting the somatosensory 
system’ (Treede et al., 2008). The etiology of neuropathic pain is quite diverse 
ranging from metabolic disorders, direct injuries, infections, and exposure to 
neurotoxins (von Hehn et al., 2012). Often times diagnosing neuropathic pain is 
quite challenging, recently a clinical grading system has been devised to aid in 
determining with certainty the presence or absence of neuropathic pain (Figure 
2). The grading system takes into account neuroanatomical pain distribution, 
history of lesion or disease, pain symptoms, and diagnostic tests to diagnosis 
neuropathic pain (Geber et al., 2009).   
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Figure 2: 
 
 
Figure 2: Flow chart of clinical grading system for neuropathic pain. 
The grading system can be used to decide with a level of certainty the presence 
or absence of neuropathic pain in an individual patient. *Additional testing 
continues either immediately or in later follow-up visits is necessary to obtain a 
diagnosis. Adapted from (Treede et al., 2008; Geber et al., 2009). 
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1. Pain symptoms, sensitivity, and nociception  
Negative symptoms or deficit in function (i.e. numbness after nerve injury) 
are the first indication of damage to nervous system. Negative symptoms reflect 
reduced impulse conduction in the neural tissues, and include hypoesthesia -a 
decreased sensitivity and weakness. Neuropathic pain patients often report 
positive symptoms, such as, deep and aching sensation (i.e. nerve trunk pain). 
Dysesthetic pain is usually presented and described as an unfamiliar or abnormal 
sensation such as burning, tingling, electric, searing, drawing, or crawling. 
Positive symptoms reflect an abnormal level of excitability in the nervous system 
and include pain, paresthesia, dysesthesia, and spasms (Baron, 2009). 
Spontaneous pain is non-evoked and is one of the most prevalent clinical 
symptoms in neuropathic pain (Backonja & Stacey, 2004). For instance, patients 
with trigeminal neuralgia experience minimal sensory loss but experience a vast 
degree of spontaneous pain. Collectively, negative symptoms, such as sensory 
loss may be mild and generally overshadowed by positive symptoms, such as 
allodynia, hyperalgesia and hyperpathia, and paroxysmal spontaneous pain. 
Pain sensitivity can be described as allodynia or hyperalgesia. First, 
allodynia is a type of hypersensitivity that is defined by the IASP as ‘pain due to a 
stimulus that does not normally provoke pain’ (Merskey, 1994) or pain in 
response to non-nociceptive stimuli. Second, hyperalgesia is defined by IASP as 
increased pain from a stimulus that normally provokes pain (Merskey, 1994) or 
an increased pain response to a nociceptive stimulus. Hyperalgesia and 
allodynia are key features of nociceptive pain are further classified according to 
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the type of stimulus; thermal (heat or cold) stimuli or mechanical brush, pinch, or 
pressure stimuli are most often used. Weakly myelinated (Aδ-fibers), 
unmyelinated (C-fibers) high-threshold fibers and few heavily myelinated Aβ-low 
threshold fibers convey nociceptive pain information (Djouhri & Lawson, 2004). 
According to the IASP task force, all forms of pain amplification including 
lowering in thresholds to stimuli are considered hyperalgesia. When low-
threshold fibers are involved the term allodynia can be used, however, the term 
hyperalgesia may also be applied if it is not known whether low- or high-threshold 
sensory nerve fibers are involved (Sandkuhler, 2009). Table 1  provides 
definitions of pain terminology.    
However, pain is a conscious experience that is a highly complex, 
subjective experience accompanied with obligatory affective, autonomic, and 
cognitive components (Barrot, 2012). In patients, pain is most often assessed 
and quantified by verbal expression, which is not possible in rodents. Nociceptive 
pain assessments that measure hyperalgesia and allodynia provide an objective 
analysis of the nociception. Nociception includes the mechanisms by which 
noxious stimuli are detected by the peripheral nervous system, encoded, 
transferred, and unconsciously interpreted by the nervous system (Barrot, 2012). 
In response to peripheral damage to the nervous system, pain threshold 
decreases, pain hypersensitivity persists, and duration and amplitude to noxious 
stimuli are amplified in nociceptive neurons (Costigan et al., 2009). Thus, when 
studying neuropathic pain assessing the mechanisms that are altered in 
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nociception may become a critical component for the overall conscious 
perception of pain.  
Many nociceptive tests are utilized in accessing animal models of 
neuropathic pain. Evoked nociceptive pain can be measure using thermal and 
mechanical stimuli. Thermal stimulation includes; a tail flick test, the hot- or cold-
plate tests, and the radiant heat paw-withdrawal test (Le Bars et al., 2001). 
Nociceptive tests can also rely on the stimulus threshold necessary to elicit an 
avoidance or withdrawal behavior. These tests utilize mechanical stimulation and 
include the von Frey filaments, the Randall-Selitto analgesimeter, and strain 
gauges held by forceps or fingers (Barrot, 2012). Thermal and mechanical 
nociceptive tests that access nociception following direct damage to the 
peripheral afferent neurons in rodents are in many ways comparable to 
nociceptive pain symptoms of neuropathic pain patients.  
However, nociception is an unconscious process dependent on nociceptor 
activity, when transitioning to translational pain treatments combining cognitive 
and affective tests in rodents is critical. Recent experimental strategies that 
address cognitive and affective pain states include an experimental setting that 
allows the animal the choice between environments that are or not associated 
with painful experiences (i.e. conditioned place preference/aversion) (Sufka, 
1994; Barrot, 2012). Additionally, the affective state of a rodent can be assessed 
by examining specific facial expression signatures (i.e. grimace scale), and a 
fairly novel test of vocalizations for chronic pain states (Kurejova et al., 2010; 
Langford et al., 2010).  
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Table 1: 
 
 
Table 1: Pain terminology. (Merskey, 1994; Loeser & Treede, 2008). 
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2. Rodent models of peripheral neuropathic pain 
 Experimental rodent models of neuropathy provide the means to examine 
the pathological changes in neuropathic pain mechanisms. Several models have 
been developed to mimic different neuropathic disease states. Wall and 
colleagues first developed a chronic pain model by producing a sciatic nerve 
transection and described pathophysiological mechanisms in chronic pain that 
were distinct from acute noxious pain (Wall & Gutnick, 1974). From this initial 
model a variety of peripheral nerve injury models have been developed in 
animals as surrogates for neuropathic pain.   
Axotomy or neuroma model is the oldest model of neuropathic pain in 
animals, which involves a complete transection of the sciatic nerve at mid-thigh 
level (Wall et al., 1979a). Animals develop anesthesia dolorosa- pain is present 
with the absence of sensory input in that area. Since the hindpaw is completely 
denervated, evoked pain behavior cannot be measured. Autotomy is observed in 
this model, which was originally believed to occur due to spontaneous activity of 
C-fibers and/or excessive grooming (Wall et al., 1979b; Rodin & Kruger, 1984; 
Devor, 1991). The major limitation of the axotomy model is that it is relatively 
uncommon in patients, with the exception of amputation resulting in phantom 
limb pain. Similar to this model is the partial nerve ligation or Seltzer model 
where a single ligature is made distal to where the posterior biceps-
semitendinosus nerve branch off (Seltzer et al., 1990). Seltzer model is less 
severe; therefore, tactile and thermal hyperalgesia is readily detectable. Animals 
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lack autotomy; however, the degree of nerve injury is not standardized and there 
is considerable mixing of injured and uninjured fibres (Ossipov et al., 2006).  
 One of the most common animal models of neuropathic pain is the chronic 
constriction injury (CCI) (Bennett & Xie, 1988). Four loose ligatures of chromic 
gut are placed around the sciatic nerve proximal to the sciatic trifurcation. 
Behavioral changes in mechanical and thermal hyperalgesia, and cold allodynia 
develop within a week reaching a maximum two weeks post surgery (Bennett & 
Xie, 1988; De Vry et al., 2004). Inflammation, intraneural edema, focal ischemia, 
and Wallerian degeneration occur in the constricted region of the nerve. Proximal 
to the constricted area, swelling is evident that most likely hinders axoplasmic 
transport from the soma (Bennett & Xie, 1988). CCI results in degeneration of 
myelinated (94%) and unmyelinated fibers (74%) within 14 days (Kajander & 
Bennett, 1992; Coggeshall et al., 1993). However the substantial loss in primarily 
A?/? fibers is less likely to account for hyperalgesia, since injury induced 
hyperalgesia lasts up to 56 days and A?-fibers remain absent. Instead, CCI-
induced hyperalgesia may arise from sensitized A?- (lightly myelinated) and C-
fibers to regenerate to near normal levels (Kajander & Bennett, 1992; Coggeshall 
et al., 1993). The advantage to CCI is the observed pain-symptoms closely 
correspond to causalgia or complex regional pain syndrome and carpal tunnel 
syndrome in patients (Bennett & Xie, 1988). A major caveat to this model is that 
chromic gut sutures placed next to the sciatic nerve, instead of around the nerve, 
result in similar behavioral hypersensitivity (Maves et al., 1993).  
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Chung and colleagues developed an alternative approach that involves L5 
and L6 spinal nerve ligation (SNL) distal to the DRG, a variation is also 
performed with only L5 SNL. In this model, pain-related behavior (mechanical, 
thermal, and cold hypersensitivity) develops within 24hr and persists for 10-16 
weeks (Kim & Chung, 1992; Choi et al., 1994; LaBuda & Little, 2005). Although 
the surgery for this model is more complex and labor intensive, a principal 
advantage of this model is the ability to delineate injured and uninjured spinal 
nerves. Additionally, tactile hypersensitivity is robust allowing for time-dependent 
behavioral analysis.  
 The spared nerve injury (SNI) animal model of neuropathic pain involves 
axotomy of two of the three terminal branches of the sciatic nerve; common 
peroneal and tibial nerves, while leaving the sural nerve intact (Decosterd & 
Woolf, 2000; Shields et al., 2003). Variations of SNI, include transection of the 
common peroneal and sural nerves, tibial and sural nerve, or each nerve 
separately (Lee et al., 2000; Hofmann et al., 2003; Brittain et al., 2011), all of 
which display mechanical hypersensitivity within 4 days of injury that persists for 
several weeks.  The key advantage of this model is that behavioral changes in 
injured and uninjured nerves may be assessed by testing corresponding 
receptive fields (Decosterd & Woolf, 2000). Although the innervation territories of 
the saphenous and sural nerve overlap, the corresponding DRG are separate.  
Variations of the SNI model are useful; animals display less guarding behavior 
with similar observations of pain hypersensitivity allowing for undisturbed 
behavioral assessment (Lee et al., 2000; Brittain et al., 2011). Overall, SNI pain-
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related behavior is robust, long-lasting, and mimics many symptoms of clinical 
neuropathic pain.    
 Taken together, current models used provide unique advantages in 
understanding the etiology, progression and severity of neuropathic pain.  
Peripheral nerve damage results in pathological neural plasticity at all levels of 
the nociceptive pathway; sensory neurons, spinal cord, and brain in the form of 
peripheral and central sensitization. 
 
E. Initial response to peripheral nerve injury 
1. Acute and neurogenic inflammation 
When peripheral nerve injury first occurs, there is tissue and nerve 
damage resulting in an acute inflammatory response by the activation of 
keratinocytes, mast cells, neutrophils, and macrophages (Scholz & Woolf, 2007). 
Immediately after injury, resident macrophages are activated and release 
cytokines, which recruit neutrophils (within 24hrs) and monocytes (within 48hrs) 
from the peripheral blood to the injury site (Mueller et al., 2001; Perrin et al., 
2005). Activated macrophages and denervated Schwann cells secrete matrix 
metalloproteases that disrupt the blood-nerve barrier promoting leukocyte 
extravasation (Shubayev et al., 2006). Vasoactive mediators, such as CGRP, 
substance P, bradykinin and nitric oxide are further released from injured axons 
resulting in hyperemia and swelling (Fried et al., 1989; Zochodne & Ho, 1992; 
Zochodne et al., 1995; Lopes & Couture, 1997; Zochodne et al., 1999). 
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In parallel, an ‘inflammatory soup’ of pro-inflammatory mediators of 
bradykinins, substance P, hydrogen ions, NGF, prostaglandins, histamine, 
adenosine 5'-triphosphate (ATP), cytokines, and chemokines are released from 
damaged and immune competent cells following tissue damage or nerve injury 
(McMahon et al., 2006). Substances released from sensory neurons can further 
act on surrounding cells and tissue contributing to inflammation. These bioactive 
substances generate the cardinal signs of inflammation, which are characterized 
by redness and warmth, swelling, and hypersensitivity (Richardson & Vasko, 
2002; Marchand et al., 2005). The redness (rubor) and heat (calor) are due to 
increased blood flow and body core temperature to the inflamed site resulting in 
neurogenic inflammation, swelling (tumor) is caused by accumulation of fluid 
arising from the extravasation induced by neurogenic inflammation, and pain 
(dulor) is due to release of sensitizing agents that stimulate nerve endings.  
 
2. Peripheral sensitization  
 Peripheral sensitization is the direct result of peripheral inflammation and 
comprises a reduction in threshold and an increase in the excitability of the 
peripheral terminals of nociceptors in response to sensitizing inflammatory 
mediators in the injured endoneurial environment (Kessler et al., 1992; Costigan 
et al., 2009). For instance, the release of substance P into the endoneurial 
environment increases the excitability of small nociceptive sensory neurons 
(Abdulla et al., 2001). Released substances, such as protons, prostaglandins, or 
bradykinin can also sensitize Aδ-nociceptors; however, NGF and GDNF have a 
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delayed nociceptive response, since both are retrogradely transported to the cell 
bodies of primary sensory neurons to regulate gene transcription (Fang & Luo, 
1996; Leitner et al., 1999; Shu & Mendell, 1999; Malin et al., 2006) potentially by 
increasing TRPV1 expression and transduction properties (Chuang et al., 2001; 
Shu & Mendell, 2001; Ji et al., 2002), further contributing to peripheral 
sensitization.   
 Another group of sensitizing agents are cytokines, which mediate the 
inflammatory response between cells over short distances. Pro-inflammatory 
cytokines include interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF) α, while 
others such as IL-10 are anti-inflammatory (Moalem & Tracey, 2006). All three 
pro-inflammatory cytokines may sensitize nociceptors and elicit hyperalgesia 
(Sommer & Kress, 2004). For instance, in an in vitro nerve skin preparation, IL-
1β was able to sensitize nociceptors by facilitating the release of CGRP and 
further evidence demonstrates that intraplantar injections of IL-1β were capable 
of eliciting hyperalgesia (Follenfant et al., 1989; Fukuoka et al., 1994). Moreover, 
topical application of TNFα to the sciatic nerve elicits ectopic activity of Aδ/C 
fibres and intraneural injections led to thermal hyperalgesia and mechanical 
allodynia (Sorkin et al., 1997; Zelenka et al., 2005). Although TNFα, which acts 
through TNFR1, can activate NaV channels, there does not appear to be direct 
features of the cytokine in sensitizing nociceptors (Jin & Gereau, 2006). In fact, 
most clinical trials of anti-TNFα therapy have been unsuccessful in alleviating 
neuropathic pain.  
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A third group of sensitizing agents is chemokines, which are chemotactic 
cytokines that function to recruit immune cells to damaged sites and activate 
GPCRs (G-protein coupled receptors). This group includes (but not limited to) 
monocyte chemotactic protein (MCP1), stromal derived factor (SDF)1, 
chemokine (C-C motif) ligand CCL3, chemokine (C-X-C motif) ligand CXCL8, 
and fractalkine (Abbadie, 2005; White et al., 2005a). Similar to proinflammatory 
cytokines, chemokines may also modulate acute nociceptor activity and 
sensitivity (Oh et al., 2001; Zhang et al., 2005; Bhangoo et al., 2007b). Oh and 
colleagues demonstrated that chemokines acting on all three families of 
chemokine receptors; CXCR, CCR, and CX3CR mobilized intracellular calcium 
(an indication of neuronal function) in DRG neurons. Further, intradermal 
administration of SDF1 reduced baseline evoked mechanical sensitivity (Oh et al., 
2001).  
 Additionally, pro-inflammatory cytokines and chemokines may indirectly 
modulate nociceptor sensitization by inducing the expression of other 
inflammatory mediators (Schweizer et al., 1988; Nicol et al., 1997a). Additional 
inflammatory mediators include, prostaglandin E2 and prostaglandin I2 that may 
enhance the sensitivity of primary afferents to mechanical stimuli and lower firing 
threshold of DRG neurons (Birrell et al., 1991; Nicol et al., 1997b). Taken 
together, initially after nerve injury peripheral sensitization alters the state of 
sensory neurons by lowering activation threshold for thermal and mechanical 
stimuli and enhancing the responsiveness of nociceptors that may lead to long 
lasting hyperalgesia (Sommer & Kress, 2004; Costigan et al., 2009).   
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F. Injured sensory neuron 
 In addition to the initial inflammatory response to tissue damage and nerve 
injury, other significant interdependent processes occur in primary afferent 
neurons that contribute to nociceptor sensitization and the generation of a 
neuropathic pain state. This involves a heavily intertwined interaction with 
immune cells, glia cells and sensory neurons at the site of injury, the DRG soma, 
and in the spinal cord that in combination impact the nociceptive pain processing 
(Scholz & Woolf, 2007). The major events include: (1) ectopic neuronal activity in 
injured and intact neighboring uninjured neurons, (2) Wallerian degeneration and 
axonal regeneration.  
 
1. Maladaptive ectopic activity 
  The sensitization of nociceptors following nerve injury changes many 
electrophysiological properties of primary afferent neurons. Injured sensory 
neurons display an increase in excitability by demonstrating a reduction in action 
potential threshold (Xie et al., 1995; Zhang et al., 1997; Zhang et al., 1999; Ma & 
LaMotte, 2005). Nerve injury may lead to an increase in primary afferent activity 
in the absence of an identifiable stimulus (Study & Kral, 1996). Such 
spontaneous activity in nociceptors can originate from the neuroma that develops 
at the site of injury (Govrin-Lippmann & Devor, 1978; Liu et al., 2000) and from 
DRG cell bodies of injured neurons (Wall & Devor, 1983; Kajander et al., 1992). 
The DRG soma is exposed to similar endoneurial environment as in the neuroma, 
interestingly the DRG lacks a blood-nerve barrier and a tissue-nerve barrier 
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(Allen & Kiernan, 1994; Shinder & Devor, 1994; Byrod et al., 2000) and is thought 
to have a specialized chemosensory role (Devor, 2006).  
Furthermore, the ectopic activity generated or transmitted to the cell body 
of nociceptive sensory neurons may provide signals generating spontaneous 
pain (Amir et al., 2005). Another interesting feature of spontaneous pain arising 
from nerve injury, is the ectopic activity of low-threshold large myelinated 
afferents (Aβ-fibers) (Campbell et al., 1988). Aβ-fibers generally signal innocuous 
sensation, however following injury Aβ-fibers undergo a phenotypic switch and 
increase neuronal activity that may contribute to spontaneous pain and tactile 
allodynia (Tal et al., 1999; Truini et al., 2009; Song et al., 2012; Zhu & Henry, 
2012). Pharmacologically blocking Aβ-fibers prevents injury-induced tactile 
allodynia (Yamamoto et al., 2008). Nerve injury may impact only a fraction of 
axons; the remaining uninjured axons are consequently exposed to the same 
inflammatory and degenerative products. As a result, residual neighboring intact 
afferent fibres also demonstrate spontaneous ectopic firing (Wu et al., 2001; Wu 
et al., 2002; Djouhri et al., 2012). Taken together, nerve injury induces 
electrophysiological changes in injured and uninjured nociceptive and non-
nociceptive DRG neurons.  
Specific ion channels have been identified to contribute significantly to 
altered neuronal function following a nerve injury. For instance, following a nerve 
injury, the two-pore domain K+ channel TRESK is downregulated by 30-40% 
leading to a steady depolarization of the sensory neuronal membrane potential 
(Tulleuda et al., 2011). In conjunction, subthreshold membrane potential 
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oscillations, largely carried by the persistent component of the sodium current, 
INaP, are frequently seen in injured sensory neurons and may be a major 
contributor to ectopic spike discharge (Kovalsky et al., 2009).  
Membrane potential oscillations and spontaneous activity have also been 
attributed to the mixed cation current Ih conducted by hyperpolarization-activated 
cyclic nucleotide-gated (HCN) channels. Large sensory neurons mainly express 
HCN1, while small sensory neurons predominantly express HCN2 (Biel et al., 
2009). Recently it has been demonstrated that sensory-specific HCN2 deficient 
animals show hardly any signs of neuropathic pain (Emery et al., 2011). The 
current model suggests that HCN channels in concert with T-type calcium 
channels generate repeated cycles of depolarization and hyperpolarization, 
which leads to activation of Ih, contributing to the receptive firing patterns in 
injured neurons (Biel et al., 2009).  
Furthermore, voltage-gated sodium channels (VGSC) have been 
substantially implicated in altering neuronal activity following injury. There is 
evidence that NaV1.3, NaV1.6, NaV 1.7-1.9 are involved in injured and uninjured 
sensory neurons (Dib-Hajj et al., 2010). Most notably, expressed in nearly all 
sensory neurons Nav1.7 plays an important role in nociception, such that gain-of-
function mutations of Nav1.7 demonstrates ectopic firing of C-fibers in the 
absence of nerve injury and in spontaneous pain conditions (Cox et al., 2006).  
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2. Nerve degeneration and regeneration 
Within two days of injury, immune cells participate in the removal of distal 
degenerating axon/myelin debris and formation of a neuroma (Scholz & Woolf, 
2007). Injured afferent axons distal to site of nerve injury begin to degenerate in a 
process referred to as Wallerian (anterograde) degeneration. At the same time, 
this allows for the reorganization of Schwann cells for regrowth of injured axons. 
Schwann cells release NGF and GDNF to promote axonal growth and 
remyelination (Ebadi et al., 1997; Chan et al., 2004).   
Axonal degeneration is believed to be an intrinsic process of self-
destruction that is triggered by impaired axonal transport followed by axonal 
fragmentation within 48 hours (Mack et al., 2001; Beirowski et al., 2005; Saxena 
& Caroni, 2007). During axonal fragmentation, Schwann cells lose axonal contact 
and initiate degeneration of their own myelin sheaths.  The axonal and myelin 
debris is phagocytized by recruited macrophages. Chemokines play an essential 
role in early recruitment of macrophages to the site of injury (Taskinen & Roytta, 
2000). For instance, the chemokine MCP1 is unregulated very early after nerve 
injury to participate in macrophage chemotaxis (Perrin et al., 2005). In addition, 
many axonal growth inhibitors are released in degenerating axon/myelin sheath, 
thus clearance of axonal and myelin debris is critical for induction of possible 
axonal regeneration (Schafer et al., 1996; Shen et al., 1998). Moreover, the 
proximal segment of injured nerve is spared and remains functionally coupled to 
the cell body. Retrograde signals from the proximal segment induce cell body 
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swelling and chromatolysis (Wells & Vaidya, 1989). The proximal segment of the 
injured sensory neuron is now destined for survival or neuronal cell death.  
Induction of axonal growth is influenced by the cytokines and neurotrophic 
factors present at the time of Wallerian degeneration (Golz et al., 2006). For 
example, transgenic mice that display slow Wallerian degeneration demonstrate 
slow myelin clearance, deficient NGF production, differentially regulated 
cytokines TNFα and IL-1α/β (Brown et al., 1991; Shamash et al., 2002). 
Peripherally, collateral sprouting of intact nociceptor endings has been suggested 
to promote reconnection to peripheral targets (Kinnman & Aldskogius, 1986; 
Inbal et al., 1987) and enhance sensitivity to circulating adrenaline and 
sympathetic activity (Sato & Perl, 1991; Rajan et al., 2003). 
 Although regeneration occurs, a fraction of injured sensory neurons do 
not survive and the remainder of the proximal segment degenerates.  In rats, 
there is a detectable decrease in small unmyelinated neurons 8 weeks after 
injury (Tandrup et al., 2000; Okamoto et al., 2001b).  Whereas, in mice 24% of 
DRGs are lost within 7 days of nerve injury and this loss continues to increase to 
more than 50% by 4 weeks post injury (Shi et al., 2001).  
During Wallerian degeneration the surrounding inflammatory endoneurial 
environment (i.e. cytokines, chemokines, and growth factors) both from neuroma 
that develops at the site of injury and injured dorsal root ganglion may prolong 
peripheral sensitization of primary afferent nociceptors that may result in long 
lasting hyperalgesia. Overall, the injured nerve fiber produces negative signals 
including cell death, compromised transduction due to terminal atrophy, a 
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compromised conduction due to loss of peripheral axons and compromised 
neurotransmission due to loss of central terminals. Loss of function can manifest 
across the whole sensory spectrum (e.g. global numbness after a traumatic 
nerve injury) or it can affect specific sensory modalities. 
 
G. Central sensitization 
 Following peripheral nerve injury, functional changes in primary and 
second order neurons are strongly believed to contribute to pain hypersensitivity 
associated with neuropathic pain. After a peripheral nerve injury, degeneration of 
C-fiber terminals occurs in Lamina II (Arvidsson et al., 1986; Kapadia & LaMotte, 
1987). Moreover, second order neurons in the spinal cord receive multiple inputs 
from A/Ç fibers and develop an increased responsiveness to their normal afferent 
input, a phenomenon known as central sensitization.  
The concept of central sensitization was first developed by a set of 
fundamental experiments performed by Clifford Woolf, which demonstrated that 
after repeated peripheral noxious heat stimuli sufficient to generate mild 
inflammation of the hind paw resulted in an increased excitability of the motor 
neurons that lasted for several hours, and included a reduction in threshold and 
enlargement of the cutaneous receptive fields. Moreover, the motor neurons 
were now no longer nociceptive-specific but could be activated by low-threshold 
(innocuous) peripheral inputs by Aβ-fibers (Woolf, 1983). Overall, these 
experiments led to a general hypothesis that activating C-fiber nociceptors 
produced activity-dependent changes in the functional properties of neurons in 
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the dorsal horn of the spinal cord (i.e. central plasticity) capable of responding to 
stimuli outside of the injury area and to low-threshold afferents that previously did 
not activate the nociceptive system further contributing to pain hypersensitivity 
(Woolf, 1983; Woolf & King, 1989).  
Following nerve injury, primary afferent neurons develop or increase in 
spontaneous activity, display reduction in threshold for activation and 
enlargement of nociceptive neuron receptive fields (Woolf & Salter, 2000; Devor, 
2009). Spontaneous activity is likely to be an important component of 
neuropathic pain, because it is a major contributor to spontaneous pain and to 
central changes in the nociceptive pathway that amplify pain. 
In neuropathic pain states central sensitization is not only initiated but 
maintained by altered and sensitized primary afferent neurons. The altered 
functional status of nociceptive and non-nociceptive neurons leads to excitability 
of dorsal horn neurons (Dalal et al., 1999; Kohno et al., 2003), heterosynaptic 
facilitation (Mendell & Wall, 1965; Willis, 2002; Sandkuhler, 2007), and 
decreases in inhibitory transmission (disinhibition) in the dorsal horn of the spinal 
cord(Yaksh, 1989; Sivilotti & Woolf, 1994; Baba et al., 2003), contributing to 
many pain symptoms in neuropathic pain (Campbell & Meyer, 2006; Latremoliere 
& Woolf, 2009) (Figure 3). 
Heterosynaptic facilitation is particularly prominent in central sensitization 
and means that a nociceptor-specific conditioning input can enable subsequent 
long lasting facilitation of responses to inputs from low-threshold A/C fibers. This 
occurs due to changes in synaptic strength from activated to neighboring non-
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activated synapses. Heterosynaptic facilitation after brief nociceptor triggering 
input can last for hours (Mendell & Wall, 1965; Willis, 2002; Sandkuhler, 2007). 
A loss of inhibition in the dorsal horn can also play an important role in 
central sensitization. For example, inhibiting GABA (gamma-aminobutyric acid) 
and glycine in the spinal cord increases A-fiber-mediated excitatory transmission 
in the superficial dorsal horn and following a partial peripheral nerve injury can 
result in a reduction of GABA-induced IPSCs in the dorsal horn (Sivilotti & Woolf, 
1994; Baba et al., 2003). Moreover, it is strongly believed that central 
sensitization is in part mediated by the interactions of non-neuronal cells (i.e. 
microglia and astrocytes) and nociceptive neurons (Garrison et al., 1991; Colburn 
et al., 1997). Sensitized nociceptive neurons release a host of substances in the 
dorsal horn, including substance P, glutamate, CGRP, ATP, and fractalkine, that 
may activate astrocytes and microglia in the spinal cord (Watkins & Maier, 2002). 
Taken together, central sensitization provides a mechanistic explanation for how 
low threshold A- or C-fibers can begin to produce pain, why there is a spread of 
sensitivity beyond areas of tissue injury or outside a damaged nerve territory, 
why repeated stimuli at a fixed intensity can lead to a progressive increase in 
pain, and why pain may long outlast a peripheral stimulus.  
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Figure 3: 
 
 
 
 
 
 
 
 
Figure 3: Overview of maladaptive changes that occur after peripheral nerve injury. In the peripheral 
nervous system, injury leads to the sensitization of nociceptors and ectopic activity of primary afferent 
neurons. In the central nervous system, altered activity of primary afferent neurons leads to central 
sensitization of dorsal horn neurons and may present as hyperalgesia, allodynia, spontaneous pain, 
paresthesia, or dysesthesia. Adapted from (Devor, 2006; Costigan et al., 2009) 
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H. Transition from nerve injury to neuropathic pain 
 Only a fraction of patients with nerve damage develop neuropathic pain. 
For instance, sectioning the sciatic nerve or multiple intercostal nerves during 
thoracotomy produces neuropathic pain in 30-60% of patients (Maguire et al., 
2006; Ketz, 2008). Understanding the differences that underlie the susceptibility 
to neuropathic pain is critical in deciphering the progression to a 
pathophysiological neuropathic pain state. At the forefront, a genetic 
predisposition may serve to enhance susceptibility to the development of 
neuropathic pain. Recent findings have identified several genetic polymorphisms 
that are associated with neuropathic pain states (Lacroix-Fralish & Mogil, 2009).  
Polymorphisms in TRP channels, CACNG2- a trafficking protein of glutamatergic 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, and 
the potassium subunit KCNS1 have been suggested as potential genetic 
indicators of chronic pain (Costigan et al., 2010; Nissenbaum et al., 2010; Binder 
et al., 2011). It is equally important to discern phenotypical changes in the 
nociceptive pathway that contribute to the progression of an irreversible 
neuropathic pain state.  
 Compared to inflammatory pain, neuropathic pain exhibits a substantial 
change in gene expression in injured and uninjured neurons that alter membrane 
properties, growth, and neurotransmitter function (Costigan et al., 2002; Xiao et 
al., 2002; Obata et al., 2003; Rodriguez Parkitna et al., 2006). For instance, 
several ion channels have been identified to contribute significantly to signal 
transmission and neuronal excitability along the pain axis, including Nav1.3, 
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Nav1.7-1.9 (Dib-Hajj et al., 2010). Reduction in potassium channels (Kim et al., 
2002; Chien et al., 2007) and auxiliary subunits of voltage-gated calcium 
channels (Luo et al., 2001; Newton et al., 2001) are also evident after peripheral 
nerve injuries. 
After injury, sensory neurons display a phenotypic switch (Decosterd et al., 
2002) that may involve differences in gene expression and signals from the 
injured environment (Wu et al., 2002). For instance, CGRP, and substance P are 
downregulated in injured sensory neurons (Marchand et al., 1994; Nahin et al., 
1994; Sommer & Myers, 1995; Hofmann et al., 2003), where as large sensory 
neurons begin to express and respond to substance P (Baranowski et al., 1993; 
Noguchi et al., 1995), such that substance P receptor antagonists (NK-1 
receptor) can attenuate or delay the onset of pain-related behaviors in response 
to nerve injury (Jang et al., 2004). Another example is GDNF family receptor 
components (GFα1-4), GFα2 is reduced in in small diameter DRG neurons, 
where as GFα3 is increased in small diameter DRG neurons after injury, such 
changes may influence the regenerative properties of sensory neurons and 
response to neurotrophic factors after injury (Bennett et al., 2000; Wang et al., 
2011a). Many of these changes in gene expression are under the control of 
master transcriptional regulators such as Sox11, c-Jun, and ATF3 (Lindwall & 
Kanje, 2005; Jankowski et al., 2006; Seijffers et al., 2007; Hunt et al., 2012).  
Global changes in gene expression may further contribute to the presence of pro-
nociceptive mediators in the injured extracellular environment.   
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 Several pro-inflammatory mediators have been implicated in neuropathic 
pain; bradykinin, ATP, serotonin, eicosanoids, neurotrophins, reaction oxygen 
species (ROS), and cytokines (Moalem & Tracey, 2006). For instance, NGF 
antagonism at the site of nerve injury may attenuate or delay the onset of 
hyperalgesia after chronic compression injury (Herzberg et al., 1997; Ro et al., 
1999). In previous work by White and colleagues, following demyelinated injury 
model of neuropathic pain, primary sensory neurons were directly sensitized by 
chemokine MCP1 and continued to express C-C chemokine receptor type -CCR2, 
a receptor for chemokine MCP1 (White et al., 2005b; Jung et al., 2009). An 
additional example is the cytokine IL-1β, which is unregulated in the sciatic nerve 
following nerve injury, and intrathecal administration of neutralizing antibodies to 
IL-1R can alleviate nerve injury-induced pain behavior (Gillen et al., 1998; 
Sommer et al., 1999; Okamoto et al., 2001a). Recently, long-term exposure to IL-
1β has been shown to increase the excitability of small and medium non-
peptidergic sensory neurons (Stemkowski & Smith, 2012). Thus, cytokines play 
an integral role in sensitizing primary sensory neurons possibly by transactivation 
of TRP channels (Bandell et al., 2004; Jung et al., 2008; Ruparel et al., 2008).  
Moreover following a peripheral nerve injury, primary afferent synaptic 
transmission and glia activation in the spinal cord also promotes induction of 
proinflammatory cytokines (i.e. IL-1β, IL-6, IL-10, and TNFα) that can directly act 
on central terminals of primary sensory afferents and alter the function of second 
order neurons in the dorsal horn (Watkins & Maier, 2002; Tsuda et al., 2005; 
Beggs & Salter, 2007). Taken together, when inflammation subsides and 
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neuropathic pain persists many of these pro-nociceptive mediators may continue 
to impact nociceptive signaling in sensory neurons and at the level of the spinal 
cord. A better understanding of which extracellular pro-nociceptor mediators and 
cytokines present (i.e. post inflammatory resolution) can aid in understanding 
progressive changes in sensory neurons that lead to neuropathic pain. 
 
I. Maintenance of pro-nociceptive cytokines 
 Very little is known in regards to the maintenance of cytokine networks 
and the progression of neuropathic pain (Sommer & Kress, 2004). A prime 
candidate is a class of endogenous molecules, known as alarmins that signal 
tissue and cell damage (Yang & Oppenheim, 2004; Oppenheim & Yang, 2005). 
Alarmins belong to a family of molecules known as damage associated molecular 
patterns (DAMPs), which also include exogenous molecules- pathogen 
associated molecular pattern (PAMPs) that can trigger the rapid activation of the 
immune system and production of pro-inflammatory cytokines (Oppenheim & 
Yang, 2005; Bianchi, 2007). Several distinguishing characteristics of alarmins 
include: (1) rapidly released following non-programmed cell death, (2) cells may 
produce and release alarmins without dying, (3) recruit and activate cells thereby 
directly or indirectly promote cellular responses, (4) restore homeostasis by 
promoting reconstruction of tissue and resolution of inflammation (Bianchi, 2007). 
Alarmins are structurally diverse multifunctional molecules that include but not 
limited to S100 proteins, HSPs, defensins, IL-1α, and high mobility group box 1 
(HMGB1) (Oppenheim & Yang, 2005; Chan et al., 2012). Some of the alarmins 
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engage classical receptors leading to inflammatory and immune response, TLRs 
and IL-1R. RAGE is another prominent receptor for some S100s and HMBG1. 
Collectively, alarmins interaction with TLRs, IL-1R and RAGE lead to NFκB 
activation, suggesting overlapping downstream signaling pathways (Bianchi, 
2007; Sakaguchi et al., 2011).  
At one level alarmins have beneficial qualities; such as, facilitating wound 
repair (Straino et al., 2008; Hirsch et al., 2009; Zhang et al., 2012). For instance, 
topical application of HMGB1 to wounds of diabetic mice enhanced arteriole 
density, granulation tissue deposition, and enhanced wound healing.  
Interestingly, diabetic mice at baseline display a lower level of endogenous 
HMGB1 compared to normal mice (Straino et al., 2008). However, excessive 
release of alarmins contributes to a host of inflammatory, autoimmune conditions, 
and cancers (Sims et al., 2010). For instance, the release of extracellular S100 
proteins by chrondrocytes results in increased production of matrix-degrading 
enzymes leading to cartilage degradation and further development of arthritis 
(Yammani, 2012). In some cases, S100B protein has a dose-dependent effect, at 
a low dose S100B promotes neurite outgrowth and at a high dose leads to 
neuronal apoptosis (Huttunen et al., 2000). It has been hypothesized that in 
settings in which alarmins may accumulate in microenvironments, both by failure 
of clearance or perpetuation of signals eliciting their release, tips the biological 
balance to favor the development of chronic disease (Ramasamy et al., 2011). 
Taken together, the relationship between the level of alarmins and degree 
of disease pathology appear to coincide. It is unclear in pathologies such as 
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neuropathic pain, which involve both beneficial (i.e. axonal regeneration) and 
detrimental processing (i.e. peripheral/central sensitization), whether the chronic 
presence of alarmin-induced events maintains altered cytokine profiles 
contributing to maladaptive nociceptive signaling. 
 
J. Unconventional cytokine: High mobility group box 1 
 HMGB1 was discovered and identified as a nuclear factor to enhance 
DNA transcription (Goodwin et al., 1973; Goodwin et al., 1975). HMGB1 was 
rediscovered under a different name p30 or amphoterin, while studying neuronal 
development and neurite outgrowth (Daston & Ratner, 1991; Merenmies et al., 
1991). HMGB1 has also been called HMG-1, p30, sulphoglucuronyl carbohydrate 
binding protein-1 (SBP1) and differentiation enhancing factor (DEF) (Huttunen & 
Rauvala, 2004). The nomenclature was revised to HMGB1 (Bustin, 2001).  
HMGB1 belongs to a family of non-histone chromosomal proteins, 
including HMGB2-4 (Stros et al., 2007). Expressed as a single polypeptide chain 
of 215 amino acids, HMGB1 contains two N-terminal DNA binding domains HMG 
Box A and Box B, and an acidic C-terminal domain. Interestingly, HMGB1 lacks 
an endoplasmic reticulum (ER) localization sequences, but instead had two 
nuclear localization sequences (NLS) (Figure 4) (Read et al., 1993; Weir et al., 
1993; Hardman et al., 1995; Bonaldi et al., 2003). Inside the cell, HMGB1 can 
bind to DNA regulating transcription and chromosomal architecture.  
 About 25 years after HMGB1 was discovered, Tracey and colleagues 
determined that HMGB1 is released from primary monocytes and functions as a 
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critical cytokine to mediate the immune response to infection and injury (Wang et 
al., 1999). HMGB1 can be released from monocytes, tissue macrophages, 
astrocytes, microglia, and neurons (Passalacqua et al., 1998; Wang et al., 1999; 
Faraco et al., 2007; Kim et al., 2008; Gao et al., 2011). In this way, HMGB1 
orchestrates different cellular functions in consequence to environmental and 
homeostatic cues to act as a signal for tissue damage, injury and/or infection. 
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Figure 4: 
 
 
 
Figure 4: Schematic of High mobility group box 1 protein. HMGB1 is composed of two DNA binding domains, 
HMG Box A, HMG Box B, and an acidic tail region. Intracellular shuttling of HMGB1 between the cytoplasm and 
nucleus is regulated by post-translational modifications of lysine residues in the nuclear localization sequence (NLS). 
Truncation of the full length HMGB1 demonstrates that the extracellular cytokine activity resides with the Box B 
domain. The cysteine (C) in position 106 in the Box B domain is critical for its cytokine role, such that oxidation or 
selective mutation of C106 abolishes the activity of HMGB1 signaling to active cytokine release. The Box A domain 
can competitively inhibit the binding of HMGB1 to its receptors and attenuate the proinflammatory effect of HMGB1 
and the Box B domain. Box A is considered a specific competitive antagonist of HMGB1. C106 is necessary for 
HMGB1 to bind to TLR4. A disulfide bond between C23 and C45 is also required for interaction of HMGB1 with TLR4. 
HMGB1 residues 150-183 interact with RAGE. Adapted from (Rauvala & Rouhiainen, 2010). 
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1. Function in DNA transcription and recombination  
 As a nuclear molecule, HMGB1 contains two N-terminal DNA binding 
domains HMG Box A and B that demonstrate nonspecific interaction with DNA 
and transcription factors to alter chromosomal architecture. Specifically, the Box 
A and B regions of HMGB1 bind to linker DNA bulges between nucleosomes and 
unfold chromatin structure to alter DNA transcription (Bianchi et al., 1989; 
Hardman et al., 1995; Saito et al., 1999; Gaillard & Strauss, 2000). Animals that 
lack HMGB1 have impaired transcriptional control of the glucocorticoid receptor 
and die within 24hrs after birth due to hypoglycemia (Calogero et al., 1999). 
Moreover, HMGB1 may also regulate transcription of viral promoters, including 
adeno-assoicated virus, herpes virus, and human immunodeficiency virus 
(Costello et al., 1997; Naghavi et al., 2003; Song et al., 2004). 
HMGB1 is known to interaction with transcription factors and chromatin, 
although this interaction is generally transient or unstable (Ueda & Yoshida, 
2010). For instance, HMGB1 interacts with numerous transcriptional regulators, 
such as p53, HOX proteins, Rel, NFAT2, and PU.1 to facilitate expression or 
repression of targeted genes (Zappavigna et al., 1996; McKinney & Prives, 2002; 
Agresti et al., 2003; Mouri et al., 2008; Liu et al., 2009). For instance, recent 
evidence demonstrates that HMGB1 may bind to TNFα promoter and promotes 
the transcriptional repressor RelB, which is the repressive form of NFκB protein, 
aiding in endotoxin tolerance (El Gazzar et al., 2009). Furthermore, there is 
substantial evidence demonstrating that HMGB1 and histone H1, a chromatin-
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binding protein, compete for binding sites on chromatin further regulating 
transcriptional activation (Ogawa et al., 1995; Catez et al., 2004; Ju et al., 2006).  
HMGB1 is also involved in V(D)J recombination during early stages of 
immunoglobulin T-cell receptor production (Stros, 2010), which enables the 
immune system to recognize and adapt to new pathogens. Specifically, HMGB1 
stimulates the RAG-RSS complex to initiate V(D)J recombination by introducing 
a double stranded cleavage (Agrawal & Schatz, 1997; Kwon et al., 1998). 
Collectively, HMGB1 can interact directly with DNA, chromatin, and transcription 
factors to regulate transcription and genetic recombination.  
 
2. Functions as a cytokine through active and passive release 
 Through a series of truncation experiments, the proinflammatory activity of 
HMGB1 was determined to reside in the Box B domain (Figure 4) . The first 20 
amino acid residues (position 89-108) represent the minimal peptide sequence 
that retains cytokine-inducing activity (Li et al., 2003). Although Box A has a 40% 
sequence homology to Box B, Box A lacks proinflammatory activity. Instead, the 
Box A domain acts as an antagonist to Box B, where it competes for HMGB1 
binding sites preventing the induction of pro-inflammatory mediators TNFα and 
IL-1β (Yang et al., 2004) (Figure 4) .  
During tissue damage, infection, injury, or by other inflammatory stimuli, 
HMGB1 is released and mediates systemic inflammatory responses in immune 
cells and endothelial cells to produce proinflammatory mediators, such as TNFα, 
IL-1β, and Interferon (IFN)-γ (Andersson et al., 2000; Bianchi, 2007). As a 
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cytokine, HMGB1 is not limited to immune cells but is also released from 
neuronal and non-neuronal cell types following tissue damage or injury (Kim et 
al., 2006; Faraco et al., 2007). The manner in which HMGB1 is released is 
through active or passive secretion from the nucleus into the extracellular space.  
Proinflammatory mediators and endotoxin- lipopolysaccharide (LPS) can 
promote the active secretion of HMGB1 (Wang et al., 1999). The translocation of 
nuclear HMGB1 into the cytosol is facilitated by the acetylation on one of its 
nuclear localization signals, which prevents re-entry into the nucleus (Bonaldi et 
al., 2003). In macrophages, acetylated HMGB1 migrates to cytoplasmic secretory 
lysosomes for subsequent release into the extracellular space (Gardella et al., 
2002a). Nucleocytoplasmic shuttling of HMGB1 is further regulated by protein 
kinase C (PKC) or by calcium/calmodulin-dependent protein kinase (CaMK) IV 
phosphorylation of HMGB1 (Youn & Shin, 2006; Zhang et al., 2008; Oh et al., 
2009). 
 For those cell types that do not contain secretory lysosomes (i.e. 
neurons), active HMGB1 secretion may involve non-vesicular translocation from 
the cytoplasm to the plasma membrane (Nickel & Rabouille, 2009). Additionally, 
HMGB1 secretion may be mediated by inflammasome assembly, which is 
cytosolic multiprotein complex that proteolytically activates caspase-1 to facilitate 
the release of cytokines, such as IL-1β and IL-18 (Lamkanfi et al., 2010). 
However, not all cell types undergo active section of HMGB1. LPS stimulation in 
kidney cells, adrenal cells, and primary T cells does not facilitate release of 
HMGB1 (Wang et al., 1999). 
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 On the other hand, necrotic inflammatory cells, neurons and astrocytes 
undergo passive secretion of HMGB1, where loosely bound nuclear HMGB1 
rapidly diffuses across a permeabilized plasma membrane (Giancotti et al., 1996; 
Scaffidi et al., 2002; Tsung et al., 2007; Kim et al., 2008). For instance in 
neutrophils, post-translational mono-methylation of HMGB1 or poly (ADP)- 
riboslylation alters its DNA binding activity resulting in redistribution of HMGB1 by 
passive diffusion out of the nucleus (Giancotti et al., 1996; Ditsworth et al., 2007; 
Ito et al., 2007). Whether through active or passive cytoplasmic and extracellular 
release, HMGB1 is a versatile cytokine responding to its environment.   
 
3. Extracellular HMGB1 
Extracellular HMGB1 may form a complex with other molecules to 
enhance proinflammatory responses, including LPS, IL-1, bacterial DNA, 
CXCL12, CD24, and viral RNA (Sha et al., 2008; Campana et al., 2009; Chen et 
al., 2009; Hreggvidsdottir et al., 2011). Interestingly in some cases, application of 
recombinant HMGB1 alone was shown to lack cytokine function (Tsan, 2011). 
Molecular properties of three cysteine residues have been implicated to be 
involved in HMGB1 cytokine activity; the redox state of cysteine (C) 106, and a 
disulfide bond between C23 and C45 (Hoppe et al., 2006; Sahu et al., 2008). In 
mild oxidative conditions an intramolecular disulfide bond is formed between C23 
and C45 in HMG Box A domain, while C106 remains redox-inactive (Hoppe et al., 
2006; Sahu et al., 2008). Both disulfide and reduced HMGB1 have been detected 
in supernatants following LPS treatment in THP-1 (human acute monocytic 
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leukemia cell line) cells (Venereau et al., 2012). Moreover, Schiraldi and 
colleagues demonstrated that the formation of a completely reduced HMGB1-
CXCL12 (all-thiol-HMGB1) heterocomplex (Schiraldi et al., 2012) is necessary for 
monocyte recruitment, compared to disulfide-HMGB1 (Venereau et al., 2012). 
Extracellular HMGB1 has chemotactic qualities to recruit enterocytes, smooth 
muscle, and endothelial, and stem cells (Degryse et al., 2001; Sappington et al., 
2002; Palumbo et al., 2004; Mitola et al., 2006; Yang et al., 2007; Vezzoli et al., 
2010).  
During inflammation the predominant form of HMGB1 is C106 thiol 
(reduced) and disulfide bond C23 and C45 (disulfide-HMGB1); however, when 
inflammation begins to subside, HMGB1 is terminally oxidized cysteine residues 
rendering its biological activity (oxidized-HMGB1) (Antoine et al., 2010; Vezzoli et 
al., 2010; Yang et al., 2011). An oxidizing environment following inflammation or 
injury may promote HMGB1 cytokine activity, instead of cellular repair by 
monocyte recruitment (Vezzoli et al., 2011). Table 2 provides a summary of 
HMGB1 redox states and associated biological activity.  
Less is known about HMGB1-mediated degradation. Extracellular HMGB1 
undergoes limited proteolysis by serine proteinases that are secreted by 
stimulated cells.  Interesting, the degradation of HMGB1 can produce a 10 amino 
acid fragment that retains some functional activity in erythroleukaemia cells 
(Sparatore et al., 2001). Further investigation is needed to determine the 
biological properties of extracellular HMGB1. 
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4. Receptor activation and downstream signaling  
 Extracellular HMGB1 transduces cellular signals through plasma 
membrane receptors, Toll like receptor (TLR) 2,4,9, and receptor for advanced 
glycation end products (RAGE) (Hori et al., 1995; Park et al., 2004; Ivanov et al., 
2007). Specific HMGB1 receptor interaction has been identified for RAGE and 
TLR4, COOH-terminal motif and cysteine (C) 106 amino acid, respectively 
(Huttunen et al., 2002; Yang et al., 2010). Within the HMG Box B domain, the 
RAGE binding domain has been mapped comprising amino acids position 150-
183 (Huttunen et al., 2002). Additionally, the reduced form of the amino acid 
residue C106 in the Box B domain and a disulfide bond between C23 and C45 is 
required for the binding of HMGB1 and TLR4 (Yang et al., 2010; Yang et al., 
2011) (Table 2). The disulfide bond between C23 and C45 further increases the 
stability of the folded full length HMGB1 molecule (Sahu et al., 2008).  
Downstream signaling of HMGB1 receptor activation is facilitated by a 
number of adaptor proteins (Sakaguchi et al., 2011), which converge through 
pathways involving MAPK and NFκB, transcriptional regulator p53 (Palumbo et 
al., 2007; Palumbo et al., 2009; Penzo et al., 2010), and further results in the 
production and release of proinflammatory cytokines, TNFα, IL-1, IL-6, IL-8, and 
several chemokines (Andersson et al., 2000; Park et al., 2003; Pedrazzi et al., 
2007; Wu et al., 2010b; Ren et al., 2012). In doing so, HMGB1 produces a broad 
repertoire of immunological and cellular responses that may involve cytokine 
production, cell proliferation, chemotaxis, angiogenesis, and cell differentiation. 
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Table 2: 
 
 
Table 2: HMGB1 redox states and biological activity. Adapted from (Venereau et al., 2012).  
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5. Central nervous system 
 In early nervous system development, HMGB1 functions in neurite 
outgrowth, and neuronal migration and differentiation (Rauvala & Pihlaskari, 
1987; Merenmies et al., 1991; Fages et al., 2000). During early cortical 
development, HMGB1 is highly expressed in migrating neurons of the cortical 
plate and the ventricular zone of the cerebral cortex (Nair et al., 1998; Zhao et al., 
2000; Chou et al., 2004). For instance, during early development (E16), HMGB1 
is localized primarily to the cytoplasm and extracellular space of the cortical 
subplate of the developing primary cortex (Guazzi et al., 2003). Moreover, in vitro 
functional studies have demonstrated that the interaction of extracellular HMGB1 
and RAGE promotes neurite extension in embryonic rat neurons (Rauvala & 
Pihlaskari, 1987; Merenmies et al., 1991; Huttunen et al., 2000; Zhao et al., 
2011).  
 In CNS injuries and diseases, HMGB1 is most likely released locally and 
may function as a neuroinflammatory factor contributing to neuronal death, 
microglia activation, and neuronal degeneration (Kim et al., 2006; Faraco et al., 
2007; Gao et al., 2011; Kim et al., 2011). In animal models of cerebral ischemia, 
early HMGB1 release is evident in damaged neurons and astrocytes (Kim et al., 
2006; Pedrazzi et al., 2007; Kim et al., 2008; Muhammad et al., 2008; Qiu et al., 
2008), and injections of anti-HMGB1 antibody 6 hours after focal cerebral 
ischemia is neuroprotective (Liu et al., 2007). The disruption in the blood-brain 
barrier in CNS ischemia models allows HMGB1 to enter the blood stream 
(Parkkinen & Rauvala, 1991; Qiu et al., 2010). Following spinal cord ischemia a 
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decrease in HMGB1 serum levels is associated with better motor neuron survival 
(Wang et al., 2009; Gong et al., 2012). During the recovery phase after stroke, 
astrocytes may produce HMGB1 to facilitate neurovascular repair (Hayakawa et 
al., 2010a; Hayakawa et al., 2010b). Finally after spinal cord compression injury, 
HMGB1 is elevated in the spinal cord tissue of rodents and further associated 
with neuronal apoptosis (Kawabata et al., 2010; Chen et al., 2011). Recently, it 
has been proposed that HMGB1 may pose as an effective therapeutic target for 
spinal cord injury repair (Kikuchi et al., 2011).  
 Extracellular HMGB1 may also have a critical role secondary inflammation 
by activating microglia activation and secondary infiltration of immune cells. For 
instance, HMGB1 can rapidly activate microglia and is present in microglia for up 
to 4 days after cerebral ischemia (Kim et al., 2006; Kim et al., 2008). HMGB1 
was found to bind Mac1, a microglial membrane receptor, activating NFκB 
signaling resulting in progressive inflammation and dopaminergic 
neurodegeneration (Gao et al., 2011). Neutralizing HMGB1 antibody was able to 
block progressive neurodegeneration, suggesting a novel mechanism for chronic 
Parkinson’s disease progression (Gao et al., 2011).  
HMGB1 functions in other neurological diseases; such as, Alzheimer’s 
disease, Huntington’s disease, Multiple sclerosis, and amyotrophic lateral 
sclerosis (ALS). In ALS, degenerating motor neurons display a decrease in 
immunostaining for HMGB1, whereas in the spinal cord HMGB1 was increased 
in reactive microglia in the spinal cord with ALS (Lo Coco et al., 2007; Casula et 
al., 2011). Interestingly, in Alzheimer’s disease HMGB1 acts as a decoy by 
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stabilizing Aβ42 oligmers and prevents microglial phagocytosis of Aβ42 oligmers 
(Takata et al., 2003). Additionally, elevated levels of HMGB1 in the brain induce 
memory abnormalities by either RAGE or TLR4 (Mazarati et al., 2011), even 
acute application of HMGB1 has been shown to impair long-term potentiation 
(LTP) (Costello et al., 2011). Collectively, increased HMGB1 expression and 
signaling may be the primary cause of cognitive and synaptic dysfunction 
(Costello et al., 2011). 
Recent evidence suggests that HMGB1 has the ability to promote seizure 
activity. Compelling evidence from Maroso and colleagues demonstrates that 
administration of HMGB1 exacerbates seizure activity induced by kainic acid. It 
was further shown that HMGB1 antagonists could dramatically reduce 
spontaneous seizures in epileptic mice for several hours, suggesting a novel 
mechanism for how spontaneous seizures may arise endogenously (Maroso et 
al., 2010). The authors further hypothesized that the constitutive signaling of 
HMGB1 activates the ionotropic glutamate N-methyl-D-aspartate receptor 
(NMDAR). There results demonstrate that injections of ifenprodil, a selective 
blocker of NR2B subunit of the NMDA receptor, effectively eliminated the 
proconvulsant effects of HMGB1. In fact administration of HMGB1 alone can 
increase NR2B phosphorylation (Maroso et al., 2010), and most recently HMGB1 
was found to co-immunoprecipitate with NR2B (Pedrazzi et al., 2012). From 
these recent findings, HMGB1 may contribute to enhanced neuronal excitability 
and likely disrupts neurophysiological function that may contribute to CNS 
disorders/diseases.  
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6. HMGB1 and pain 
 Similar to other cytokines, HMGB1 may contribute to acute and chronic 
pain states. A number of studies demonstrate peri-sciatic or intrathecal 
administration of HMGB1 produces rapid and transient mechanical allodynia and 
thermal hyperalgesia in rodents (Chacur et al., 2001; O'Connor et al., 2003; 
Shibasaki et al., 2010). A high dose of HMGB1 can even produce bilateral 
mechanical allodynia suggesting its potency and indirect nature of inducing pain 
states (Chacur et al., 2001). In animals models of diabetic pain, lower back pain, 
and bone cancer pain, neutralizing HMGB1 antibodies can effectively reverse 
disease-induced pain behavior outcomes (Tong et al., 2010; Otoshi et al., 2011b; 
Ren et al., 2012).  
A recent study by Shibasaki and colleagues demonstrate that 
administration of HMGB1 neutralizing antibody prior to spinal nerve ligation and 
continuous infusion thereafter can prevent the development of neuropathic pain 
(Shibasaki et al., 2010). Within the first week following injury, there was an 
increase of cytoplasmic HMGB1 and RAGE in Schwann cells, injured DRGs and 
satellite glial cells (SGCs) (Shibasaki et al., 2010). Moreover, after sciatic nerve 
transection, HMGB1 is increased at the distal point of transection and appears to 
mediate the neuron-Schwann cell interaction in regenerating peripheral nerves 
(Daston & Ratner, 1991). Additional research is needed to determine whether 
HMGB1 influences the function of primary afferent neurons in different chronic 
pain states. Table 3 provides a summary of relevant rodent pain behavior 
studies examining HMGB1. 
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Table 3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Table 3: Rodent pain behavior studies examining HMGB1. 
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K. Toll-like receptors  
 Toll-like receptors (TLRs) are an evolutionally conserved class of PAMP 
receptors that function to sense and initiate host defense mechanisms 
(Medzhitov et al., 1997). Although the first description of the toll protein in 
Drosophila related to its function in dorsoventral polarity in developing Drosophila 
embryos, it was later discovered that the Toll ligand Spatzle was essential for the 
antifungal innate immune response (Anderson et al., 1985a; Anderson et al., 
1985b; Lemaitre et al., 1996). Thirteen TLRs have been identified in mammals so 
far that recognize a myriad of unrelated exogenous and endogenous molecules, 
including bacteria derived endotoxins or pathogen-specific nucleic acids. TLRs 
are involved in wide range of biological processes from pathogen recognition to 
mediating cellular repair and injury (Gangloff et al., 2003).  
The structure of TLRs are representative of type I integral membrane 
proteins that have three distinct regions; the extracellular domain, 
transmembrane domain, and intracellular domain. Ligand interaction occurs at 
the extracellular domain consisting of leucine rich repeat motifs, which facilitates 
the hetero- and homodimerization of TLRs. Within the intracellular domain, TLRs 
contain a conserved ~200 amino acid region, known as the toll/interleukin 1 
receptor (TIR) domain (Slack et al., 2000). The TIR domain is conserved among 
TLRs and the IL-1R, which mediates protein-protein interactions between TIR 
domain and adaptor proteins (Dunne & O'Neill, 2003). One common adaptor of 
TLRs and IL-1R is myeloid differentiation primary response protein 88 (MyD88), 
which shares similar downstream signaling of NFκB and MAPK activation (Muzio 
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et al., 1997; Adachi et al., 1998; Kawai et al., 1999). Interestingly, evidence 
suggests that adaptor protein binding is influenced by the dimerization and 
cellular localization of TLRs. The nucleic acid-sensing TLRs (TLR3, TLR7, TLR8 
and TLR9) are localized and signal in endosomes. The compartmentalization of 
nucleic acid sensing TLRs is important because of their sensitivity to host DNA, 
which can trigger the development of autoimmune diseases if exposed to it. Host 
DNA is usually excluded from endolysosomes; where as, other nucleic acids 
from viruses are typically localized.  
 TLR downstream signaling has been identified by the adaptor proteins 
recruited to TIR domain and the subsequent gene expression profile. The TLR 
intracellular TIR domain can recruit TIR containing intracellular adaptor proteins 
to mediate signaling; MyD88, TIR domain-containing adapter protein (TIRAP; 
also known as Mal), TIR domain-containing adapter inducing interferon-β (TRIF), 
or TRIF-related adaptor molecule (TRAM). Typically, ligand specific MyD88- and 
TRIF-dependent pathways characterize TLR activation (Sakaguchi et al., 2011). 
With exception of TLR3, all other TLRs can signal through MyD88-dependent 
pathways (Hoebe et al., 2003). 
The MyD88-dependent pathway results in the immediate activation of 
NFκB and further induction of proinflammatory cytokines, TNFα and IL-6 (Adachi 
et al., 1998). MyD88 recruits adaptor protein such as, TIRAP, TNF receptor-
associated factor (TRAF) 6 and IL-1 receptor associated kinases (IRAKs), which 
have an essential role in the activation of NFκB and MAPK signaling (Kawagoe 
et al., 2008; Kawai & Akira, 2010). In particular, IRAK4 is a critical adaptor 
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protein for MyD88-dependent signaling. For instance, macrophages deficient in 
IRAK4 demonstrate significant impairment and stability of cytokine production 
(Suzuki et al., 2002; Kim et al., 2007b; Lye et al., 2008). Reports suggest that 
IRAK4 is responsible for recruiting other IRAK adaptor proteins to facilitate 
adequate proinflammatory cytokine expression (Lye et al., 2004).  
The TRIF-dependent pathway recruits adaptor proteins- TRAF3, TRAF6, 
and TRADD- that activate IFN regulatory factor-3 (IRF3), MAPKs and NFkB 
signaling (Pobezinskaya et al., 2008). IRF3 signaling regulates IFN-β production 
and innate antiviral responses (e.g. viral replication), which is specific to TLR3 
and TLR4 (Doyle et al., 2002; Toshchakov et al., 2002). TRIF-dependent 
pathway results in a delayed activation of NFκB and robust induction of IFN 
inducible genes, such as immunoresponsive gene 1 (IRG1) and a gene encoding 
CXCL10 (Kawai et al., 1999; Kawai et al., 2001).  
Activation of MyD88 and TRIF-dependent pathways is counterbalanced by 
negative regulators of TLR signaling (Lu et al., 2008). For instance, the toll-
interacting protein (Tollip) is a critical negative regulator of TLR signaling. Tollip 
may bind with TLR2/TLR4 or IRAKs suppressing TLR-mediated immune 
responses (Zhang & Ghosh, 2002; Li et al., 2004; Didierlaurent et al., 2006). 
Single-Ig-interleukin 1 related receptor (SIGIRR) also a negative regulator by 
interacting with TLR4 to interfere with the recruitment of MyD88 (Wald et al., 
2003; Qin et al., 2005a; Watson et al., 2010). Taken together, whether TLR 
activation is MyD88- and/or TRIF-dependent, signaling solely depends on the 
availability of adaptor proteins and negative regulators in a given cell type.  
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L. Toll-like Receptor 4 
 Toll-like receptor 4 was the first characterized mammalian Toll (Medzhitov 
et al., 1997). TLR4 is a highly studied PAMP receptor and serves to initiate a pro-
inflammatory cascade in response to various exogenous and endogenous 
ligands. The most prominent exogenous ligand is LPS derived from gram-
negative bacteria. A point mutation in the tlr4 gene was identified in C3h/HeJ 
mice that was hyporesponsive to LPS and further confirmed in TLR4-deficient 
mice (Poltorak et al., 1998; Hoshino et al., 1999). Endogenous ligands or 
DAMPs/ “alarmins” associate with TLR4; including fibrinogen, heparin sulfate, 
HSPs, and HMGB1 (Oppenheim & Yang, 2005; Bianchi, 2007; Yu et al., 2010).  
The leucine rich repeats (LRR) in the extracellular domain of TLR4 form a 
horseshoe structure with a hydrophobic core forming the ligand-binding site to 
the concave surface (Kim et al., 2007a). TLR4 homodimerization may involve two 
accessary proteins, CD14 (glycosylphophatidylinositol-linked anchoring protein) 
and MD2 (myeloid differentiation protein-2; accessory secreted glycoprotein) 
(Wright et al., 1990; Haziot et al., 1996; Shimazu et al., 1999). TLR4 can form a 
complex with MD2 on the plasma membrane that facilitates agonist binding(Park 
et al., 2009; Hutchinson et al., 2010b). CD14 has been shown to bind and deliver 
LPS to the TLR4 binding pocket, however, TLR4 can signal in the absence of 
CD14 primarily through MyD88-dependent pathway (Jiang et al., 2005). In fact, 
TLR4 is unique for it can signal via both Myd88- and TRIF-dependent pathways 
(Figure 5)  (Kawai et al., 1999; Doyle et al., 2002; Yamamoto et al., 2002; 
Yamamoto et al., 2003). 
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1. Subcellular localization and trafficking of TLR4 
 To date, TLR4 localization and trafficking mechanisms are primarily based 
on LPS-TLR4 signaling. In resting cells, TLR4-MD2-CD14 complex cycles 
between the plasma membrane and the Golgi until engaged at the surface by 
LPS (Thieblemont & Wright, 1999; Latz et al., 2002). Upon activation at the 
plasma membrane, in the presence of TIRAP, MyD88 dependent signaling 
activates the NFκB pathway. In addition, TLR4 association with the adaptor 
protein- TRAM recruits TRIF to the plasma membrane resulting in translocation 
to endosome/lysosomes in a dynamin and clathrin-dependent manner (Husebye 
et al., 2006; Kagan et al., 2008; Tanimura et al., 2008). TLR4/TRAM-TRIF 
dependent signaling is mediated in early endosomes activating the interferon 
regulatory factor (IRF) 3 pathway, which is similar to the nucleic acid sensing 
TLRs (Figure 5)  (Kagan et al., 2008). TLR4 and TRAM are further trafficked to 
late endosomes where TAG promotes TLR4 ubiquitination and Triad3A mediated 
degradation (Chuang & Ulevitch, 2004; Medvedev et al., 2007; Palsson-
McDermott et al., 2009).  
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Figure 5: 
 
 
 
Figure 5: Toll like receptor 4 activation and signaling. Upon activation, 
LPS engages with TLR4 in complex with MD2. The receptor complex is 
composed of two copies of the TLR4-MD2-LPS that initially transmits signals for 
the early-phase activation of NFκB by recruiting the TIR domain containing 
adaptors TIRAP and MyD88 (MyD88-dependent pathway). The TLR4-MD2-LPS 
complex is then internalized and retained in the endosome, where it triggers 
signal transduction by recruiting TRAM and TRIF, which leads to the activation of 
IRF3 and late-phase NFκB for the induction of type I interferon (TRIF-dependent 
pathway). Both early- and late-phase activation of NFκB is required for the 
induction of inflammatory cytokines. Other adaptor proteins include: IRAKs, 
TRAF6, TRADD, and TRAF3/6.  
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2. Innate and adaptive immune system 
 The innate immune system works in conjunction with the adaptive immune 
system to maintain physiological homeostasis and protect the host against 
potentially pathogenic organisms. TLR4 as a PAMP, recognizes various invasive 
microorganisms as well an endogenous molecules that result in the activation of 
the innate and adaptive immune system (Medzhitov et al., 1997; Poltorak et al., 
1998). Since, TLR4 is expressed on monocytes, macrophages, poly-
morphonuclear cells, dendritic cells, this provides a great deal of flexibility for the 
immune system to respond accordingly (Hornung et al., 2002; Zarember & 
Godowski, 2002; Caramalho et al., 2003; Shimura et al., 2005). TLR4 is largely 
dedicated to detecting bacterial infections; however, TLR4 can also detect viral 
infections, such as respiratory syncytial virus (RSV) and rhabdoviral (vesicular 
stomatitis virus; VSV) infections (Kurt-Jones et al., 2000; Georgel et al., 2007). 
Overall, immune cells that are activated by TLR4 contribute to infection, 
inflammation, wound healing, and tissue injury. TLR4 expression is found on both 
immune (microglia) and non-immune cell types (glial cells and neurons) that 
collectively influence immune surveillance, pro-inflammatory cytokine production, 
and neurodegeneration (Goethals et al., 2010).  
 
3. Central nervous system 
 Depending on the central nervous system (CNS) disease, TLR4 has been 
implicated in contributing to microglia activation, astrocyte dysfunction, 
neurotoxicity and neuronal excitability to influence a number of CNS pathologies; 
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such as, autoimmune encephalitis, stroke, Alzheimer’s disease, Multiple 
Sclerosis, epilepsy, traumatic brain or spinal cord injury. TLR4 is expressed on 
astrocytes, microglia, neural progenitor cells, cortical, hippocampal, and motor 
neurons (Bowman et al., 2003; Qin et al., 2005b; Rolls et al., 2007; Tang et al., 
2007; Shechter et al., 2008) 
 Astrocytes form the blood-brain barrier, regulate cerebral blood flow, and 
are involved in the tripartite synapse. TLR4 on astrocytes are constitutively 
expressed and activation of astrocytic TLR4 induces pro-inflammatory mediators 
(Carpentier et al., 2005; Gorina et al., 2011). Originating from primitive myeloid 
precursors, microglia are the resident immune cells and comprise approximately 
10% of the total cells within the CNS. Microglial TLR4 is important for generating 
an anti-bacterial response. In vitro exposure of LPS, TLR4 agonist, to microglial 
cultures produces a robust induction of pro-inflammatory cytokine, TNFα and is 
toxic to neurons and oligodendrocytes (Lehnardt et al., 2002; Lehnardt et al., 
2003; Qin et al., 2005b). Additionally, the release of endogenous TLR4 ligands, 
such as HSP60, from injured cells mediates neurodegeneration in the CNS by 
TLR4-dependent microglia activation (Lehnardt et al., 2008).  
Recent evidence suggests TLR4 activation can directly alter neuronal 
function in the CNS. The direct activation of TLR4 in adult cortical neurons 
induces heightened excitability in the form of seizure activity (Sayyah et al., 2003; 
Galic et al., 2008; Maroso et al., 2010). Additionally, the activation of TLR4 by 
HMGB1 and LPS has been reported to attenuate LTP in hippocampal slices 
  66 
(Costello et al., 2011). Collectively, TLR4 activation in the CNS is cell-type 
specific and influences a number of neurophysiological mechanisms.  
 
4. Peripheral nervous system 
 In the periphery, TLR4 is involved in many biological functions including 
peripheral nerve degeneration/regeneration, wound healing, and tissue 
inflammation/ damage. TLR4 is expressed in Schwann cells, myocytes, epithelial 
cells, keratinocytes, fibroblasts, and sensory neurons (Frantz et al., 1999; Cario 
et al., 2000; Tabeta et al., 2000; Song et al., 2002; Wadachi & Hargreaves, 2006; 
Lee et al., 2007; Acosta & Davies, 2008). A break in the epithelial barrier allows 
pathogens to enter, which leads to TLR4 activation of PNS-resident 
macrophages and initiates the inflammatory response to clear the infection. 
During chronic inflammation, such as rheumatoid arthritis, chronic TLR4 
activation of synovial fibroblasts may lead to progressive cartilage and bone 
destruction (Brentano et al., 2009).  
Furthermore after a nerve injury, initial clearance of myelin debris by 
infiltrating macrophages is critical for axonal degeneration. In TLR4-deficient 
mice, chemoattractant MCP1 and macrophage recruitment were diminished at 
the distal nerve stump following a nerve crush injury (Boivin et al., 2007). In 
contrast, injection of TLR4 agonist hastened clearance of degenerating myelin by 
recruiting greater numbers of macrophages (Vallieres et al., 2006). Taken 
together, at the site of injury TLR4 activation has a critical role in promoting 
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clearance of myelin debris by facilitating macrophage recruitment and thereby 
supporting nerve regeneration.  
TLR4-dependent neuronal excitability is not limited to the CNS, as primary 
sensory neurons exposed to the TLR4 specific endotoxins (i.e. LPS or morphine-
3-glucuronide (M3G)) produces varying degrees of increased excitability (Ochoa-
Cortes et al., 2010; Due et al., 2012), concentration-dependent increase in 
intracellular calcium, inward currents, and the release of CGRP (Hou & Wang, 
2001; Qin et al., 2004).  
 
5. TLR4 and pain 
 TLR4 responds rapidly to stressors induced by nerve injury to generate a 
host of proinflammatory mediators that can influence acute and chronic pain 
states. For instance, intrathecal administration of LPS generates acute 
mechanical hypersensitivity lasting up to an hour after injection (Hutchinson et al., 
2009; Saito et al., 2010). Interestingly in an animal model of arthritis, TLR4 
activation was shown to promote the transition from acute to chronic post-
inflammatory pain hypersensitivity (Christianson et al., 2011). Using the K/BxN 
serum transfer arthritis model, TLR4-deficient mice displayed a significant 
reversal in mechanical hypersensitivity after resolution of peripheral inflammation 
compared to wild-type mice (Choe et al., 2003; Christianson et al., 2011). 
Collectively, TLR4 activation may contribute to acute and chronic inflammatory 
pain states.  
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Moreover, the involvement of TLR4 in the generation of neuropathic pain 
is especially highlighted by observations of both diminished spinal cord 
inflammation and pain behavior hypersensitivity in TLR4 knockout mice following 
a peripheral nerve injury (Tanga et al., 2004; Tanga et al., 2005). TLR4 knockout 
mice fail to display behavioral hypersensitivity as early as one day after L5 spinal 
nerve ligation (Tanga et al., 2004; Tanga et al., 2005). Similar observations are 
evident in rats treated with TLR4 antisense oligodeoxynucleotides or siRNA 
following CCI (Tanga et al., 2005; Wu et al., 2010a).  
A recent study by Sorge and colleagues discovered a pronounced gender 
difference in TLR4 activation and pain outcomes. Initial experiments determined 
that intrathecal injections of LPS may produce robust mechanical allodynia, but 
only in male mice. Interestingly, LPS administered through intracerebro-
ventricular or intraplantar routes was able to produce equivalent allodynia in both 
sexes (Sorge et al., 2011), suggesting TLR4-mediated inflammatory pain may 
have a gender specific bias in the spinal cord. Furthermore, after spared nerve 
injury it was shown that only male mice benefited from a TLR4/MD2 antagonist 
(Sorge et al., 2011). With the exception of the findings by Sorge and colleagues, 
neuropathic pain models testing TLR4 agonists utilized male rodents and all 
displayed similar reversal of injury-induced hypersensitivity (Table 4) .  
Thus, the type of injury may impact the role of TLR4 in neuropathic pain.  
Tanga and colleagues first described that following CCI TLR4-deficient mice 
displayed diminished pain hypersensitivity, which was attributed to a decrease in 
microglia activation (Tanga et al., 2004; Tanga et al., 2005). However, after a SNI 
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injury, TLR4-deficient male mice developed pronounced pain hypersensitivity, 
suggesting TLR4-independent or compensatory events by other TLRs (Sorge et 
al., 2011). For instance, TLRs 3,7 and 9 are also expressed on human DRGs. 
Activation of TLRs 3, 7, and 9 have the ability to upregulate the expression of 
TRPV1, and enhance calcium flux by TRPV1-expressing DRGs (Qi et al., 2011). 
Further, TLR3 antisense oligodeoxynucleotides are also capable of suppressing 
nerve injury-induced tactile allodynia (Obata et al., 2008). Overall, additional 
research is needed to discern the differences in TLR4 activation after a chronic 
constriction injury, spared nerve injury and gender. Table 4 provides a summary 
of relevant rodent pain behavior studies examining TLR4. 
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Table 4: 
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Table 4 continued: 
 
Table 4: Rodent pain behavior studies examining TLR4. 
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M. Hypothesis and specific aims 
 Peripheral neuropathic pain is a debilitating disease that dramatically 
impacts quality of life. This type of pain is often due to post-operative 
complications, mechanical trauma, disease, and/or neurotoxic chemicals. After a 
precipitating event, such as nerve injury, pathophysiological changes in 
nociceptive primary sensory neurons are thought to initiate a cascade of events 
leading to a prolonged hyperexcitable state or neuronal hypersensitivity. A 
number of factors present in the peripheral environment may serve to perpetuate 
this peripheral sensitization and may include pro-nociceptive factors released 
from sensory neurons, glial cells or innate immune cells. On the other hand, 
there is the possibility of a signal that can be released by all cells associated with 
injury to the peripheral environment. A molecule that meets this criteria is 
HMGB1.  
HMGB1 is an intracellular protein that is primarily localized to the nucleus 
of most cells and binds DNA to regulate gene expression; however, in times of 
cellular stress, HMGB1 is released as an inflammatory cytokine (Wang et al., 
1999). The cellular secretion of HMGB1 may serve to alert neighboring cells of 
tissue injury and initiate protective responses (Bianchi & Manfredi, 2004). To date 
HMGB1 signaling has been associated with diseases such as sepsis, 
cardiomyopathy, diabetes, and neuropathologies (Bierhaus et al., 2004; 
Buchanan et al., 2010; Huang et al., 2010; Qiu et al., 2010). 
 The effects of extracellular HMGB1 on cells are mediated by its two best-
known receptors, RAGE and TLR4. HMGB1 acts on TLR4 to activate 
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proinflammatory signaling cascades in immune cells such as macrophages; 
however, HMGB1 activation through TLR4 is not limited to non-neuronal cells. 
Recent publications demonstrate that neurons, including pain transmitting 
primary sensory neurons, exhibit TLR4 (Chakravarty & Herkenham, 2005; 
Wadachi & Hargreaves, 2006; Acosta & Davies, 2008; Maroso et al., 2010; 
Diogenes et al., 2011). In the central nervous system elevated levels of HMGB1 
in the brain induce memory abnormalities by either RAGE or TLR4 (Mazarati et 
al., 2011), even acute application of HMGB1 has been shown to impair LTP 
(Costello et al., 2011). Following injury or damage to the nervous system, 
HMGB1 interacting through TLR4 on cortical neurons can produce seizure 
activity (Maroso et al., 2010); a hyperexcitable state not unlike the chronic 
spontaneous activity generated by primary afferent neurons that contribute to 
pain hypersensitivity in pain states. Collectively, excessive HMGB1 likely disrupts 
neurophysiological function that may contribute to nervous system 
disorders/diseases. 
 The ability of HMGB1 to influence neuropathic pain behavior was first 
demonstrated by Shibasaki and colleagues (Shibasaki et al., 2010). They 
provided evidence that HMGB1 injected into the sciatic nerve not only produces 
hyperalgesic behavior, but intrathecal injection of a neutralizing anti-HMGB1 
antibody, potentiated pain hypersensitivity after L5 SNL. Furthermore, TLR4 
knockout mice and rats intrathecally injected with TLR4 antisense 
oligodeoxynucleotides fail to display behavioral hypersensitivity as early as one 
day after L5 SNL (Tanga et al., 2004; Tanga et al., 2005). Initial analysis of these 
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data suggested that the pain behavior attenuation was due to the absence of 
TLR4-dependent microglial activation in the spinal cord. However, given the 
observation that pain-sensing primary sensory neurons also exhibit TLR4 
(Wadachi & Hargreaves, 2006; Acosta & Davies, 2008), it is plausible that 
chronic pain behavior following peripheral nerve injury is due to HMGB1 
dependent neuronal TLR4 activation. Perhaps more importantly, HMGB1 may 
act as a physiological relevant source contributing to peripheral sensitization and 
neuronal hyperexcitability associated with neuropathic pain models. 
 The aim of this dissertation is to determine the degree to which HMGB1 
serves to chronically sensitize nociceptive sensory neurons in the highly 
reproducible TNI model of peripheral neuropathic pain. The work explores the 
central hypothesis that peripheral sensitization of somatic sensory neurons in the 
rat following TNI is dependent on endogenous HMGB1 and TLR4. To investigate 
these goals, the following specific aims are proposed: 
1. Define TNI-induced changes in HMGB1 and TLR4 in primary afferent neurons 
 
2. Determine the degree to which HMGB1 in vitro alters primary sensory neuron 
activity and function 
 
3. Determine the degree to which HMGB1 and/or TLR4 is necessary for tactile 
hypersensitivity following TNI 
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CHAPTER II  
MATERIALS AND METHODS 
The following section describes the methods and materials utilized in the 
experimental research sections (Chapter III, IV).  
A. Animals 
Pathogen-free, adult female Sprague Dawley (S/D) rats (150 to 200 g; 
Harlan Laboratories, Madison, WI, USA) were housed in temperature (23 ± 3°C) 
and light (12-hour light: 12-hour dark cycle; lights on at 07:00 hours) controlled 
rooms with standard rodent chow and autoclaved tap water available. 
Experiments were performed during the light cycle. Animals were randomly 
assigned to the treatment groups. All animal-related experiments were approved 
by the Institutional Animal Care and Use Committee of Indiana University School 
of Medicine. All procedures were conducted in accordance with the Guide for 
Care and Use of Laboratory Animals published by the NIH and the ethical 
guidelines of the International Association for the Study of Pain.  
 
B. Rodent model of neuropathic pain: Tibial nerve injury 
All rodents were anesthetized prior to surgical procedure with isoflurane 
(4% induction, 2% maintenance). To model neuropathic pain we performed a 
tibial nerve injury (Decosterd & Woolf, 2000; Lee et al., 2000; Wang et al., 
2011b). S/D female rats 150 to 200g were anesthetized using isoflurane at 4% 
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induction and 2% maintenance. Under anesthesia, the right sciatic nerve was 
isolated under aseptic surgical conditions by blunt dissection of the femoral 
biceps muscle, without damaging the epimycium. The sciatic nerve and its three 
branches were isolated: the sural, common peroneal and tibial nerves. Only the 
tibial nerve was tightly ligated with 5-0 silk and transected distal to the ligation. 
An additional 2 to 4mm of distal nerve stump was removed to prevent re-
innervation by the proximal nerve (Figure 6) . The overlying muscle and skin 
was then sutured in two separate layers. Sham-injured animals were subjected to 
all preceding procedures with the exception of ligation and transection.  
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Figure 6: 
 
 
 
Figure 6: Schematic of tibial nerve injury. (A) The sciatic nerve is 
comprised of three branches: the sural, common peroneal and tibial nerve. Only 
the tibial nerve is transected and an additional 2-4mm of the distal nerve stump 
removed to prevent re-innervation. L4-L6 DRGs correspond to injured DRGs, 
which comprise both injured and uninjured sensory neurons. (B)  Different zones 
of the plantar surface of the rat hindpaw innervated by the sciatic terminal 
branches. Sural (lateral), tibial (center), saphenous (medial). Saphenous nerve 
(femoral nerve plexus, L3 DRG) has minimal overlap with sciatic nerve branches 
(sciatic nerve plexus L4,5,6 DRGs). Adapted from (Decosterd, 2000). 
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C. Behavioral assessment of tibial nerve injury  
The tibial nerve injury rodent model of neuropathic pain was assessed by 
thermal, cold, and tactile pain hypersensitivity. Tactile hypersensitivity after TNI 
produced reliable and robust pain hypersensitivity and was further assessed in 
experiments outlined in Chapter III and IV . All rodents were habituated to 
testing chambers for at least two days. Rodents were randomly assigned to 
sham or injured test group and baseline testing occurred before and after TNI. 
Upon completion of behavioral testing, animals were euthanized and tissue was 
collected for further analysis. 
 
1. Thermal hyperalgesia 
Thermal hyperalgesia was determined by measuring foot withdrawal 
latency and duration of paw withdrawal response to heat stimulation (Bhangoo et 
al., 2007a). Each rat was placed in a box (22x12x12 cm) containing a smooth 
glass floor. A heat source (Ugo Basile Plantar™ Analgesia Instrument) was 
focused on the plantar surface of the hindpaw and a radiant thermal stimulus was 
delivered to that site. The stimulus shuts off automatically when movement of the 
hindpaw is detected or after 20s to prevent tissue damage. The intensity of the 
heat stimulus was constant throughout all experiments. A thermal stimulus was 
delivered 6 times to each hindpaw at five-minute intervals. The value for the 
response based on thermal latency and duration of paw withdrawal was obtained 
by averaging 5 of 6 measurements per animal.  
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Following TNI, the withdrawal response latency (in seconds) to 
nociceptive heat stimulation decreased at post injury day (PID) 11, 14, and 21 
compared to baseline by 6.7s ± 0.22, 3.4s ± 0.31, and 4.0s ± 0.42 respectively in 
the hindpaw ipsilateral to the injury (Figure 7A; n=5, *P< 0.05). The duration of 
paw withdrawal in response to the heat stimulus increased significantly at PID 14 
over baseline line levels for both the ipsilateral (injured) and contralateral (intact) 
hindpaw by 6.1s ± 2.2 and 4.8s ± 2.5, respectively (Figure 7B; n=5, *P< 0.05). 
Although a change in duration was evident at PID 14 in both hindpaws, where as 
a change in latency was evident at PID 11, 14, and 21 in the ipsilateral hindpaw, 
which may suggest that at PID 14 animals may experience heightened sensitivity 
or irritability to stimuli.     
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Figure 7: 
 
 
Figure 7: Behavioral assessment of thermal hyperalgesia following 
tibial nerve injury (TNI). (A)  The paw withdrawal latency (in seconds) to 
nociceptive heat stimulation at PID 1-28 for the contralateral (intact) and 
ipsilateral (injured) hindpaw. TNI decreased the withdrawal response latency at 
PID 11,14, and 21 in the ipsilateral hindpaw. (n=5; ANOVA, F=4.47, Bonferroni 
multiple comparison test, *P< 0.05) (B)  The duration of the withdrawal (in 
seconds) at PID 1-28 for the contralateral and ipsilateral hindpaw. TNI increased 
the duration of withdrawal at PID 14 for both hindpaws. (n=5; ANOVA, F=3.86-
ipsilateral hindpaw, F=2.57-contralateral hindpaw, Bonferroni multiple 
comparison test, *P< 0.05). Data are expressed as mean ± s.e.m. *Significant 
differences compared with preoperative baseline control values (*P< 0.05). BL: 
baseline.  
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2. Cold allodynia 
To quantify cold sensitivity of the hindpaw, rapid withdrawal in response to 
acetone applied five times (once every 5 minutes) to each paw was assessed 
(Lee et al., 2000). A drop of acetone solution was carefully placed onto the 
plantar surface of the paw, using an angled syringe without touching the skin. 
The frequency of foot withdrawal expressed as a percentage was used as the 
cold allodynia index. The duration of withdrawal response was recorded with an 
arbitrary minimal value of 0.1s and a maximum of 30s (Choi et al., 1994).   
S/D female rats did not respond to acetone stimulation before tibial nerve 
surgery. After TNI, rats developed a marked hypersensitivity to acetone 
stimulation when applied to the hindpaw ipsilateral to the injury as early as one 
day after surgery and continued for each time point assessed PID 1-56. The 
hindpaw contralateral to the injury remained unresponsive to acetone (Figure 
8A; n=3, *P< 0.05). The duration of the withdrawal response significantly 
increased at later time points following injury, PID 14, 21, 28, and 42 in the 
hindpaw ipsilateral to the injury (13.4s ± 1.81, 23.18s ± 1.96, 16.91s ± 2.59, and 
18.1s ± 2.37, respectively) compared to baseline (1.15s ± 0.40) (Figure 8B; n=3, 
*P< 0.05). The duration of the paw withdrawal response in the hindpaw 
contralateral to injury was not affected by acetone stimulation. 
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Figure 8: 
 
 
Figure 8: Behavioral assessment of cold allodynia following TNI. (A) 
Development of cold allodynia in rats following tibial nerve injury. Response rate 
to acetone was used as index of cold allodynia. Acetone stimulation elicited an 
increase in response rate at PID 1-56 (n=3; ANOVA, F=12.01, Bonferroni 
multiple comparison test, *P< 0.05). (B)  The withdrawal duration (in seconds) 
after acetone stimulation to the hindpaw contralateral and ipsilateral to the nerve 
injury. The duration of the withdrawal response increased at PID 14, 21, 28 and 
42. (n=3; ANOVA, F=14.99 Bonferroni multiple comparison test, *P<0.05). Data 
are expressed as mean ± s.e.m. Circles and squares indicated ipsilateral and 
contralateral sides, respectively. *Significant differences compared with 
preoperative baseline control values (*P< 0.05). BL: baseline. 
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3. Tactile hypersensitivity  
The incidence of foot withdrawal in response to mechanical indentation of 
the plantar surface of each hindpaw was measured with a flat-tipped cylindrical 
probe or von Frey probe measuring 0.2 mm in diameter (Song et al., 1999). Von 
Frey filaments capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN with a 
uniform tip diameter was applied to a designated loci present on the plantar 
surface of the foot. During each test, the rodent was placed in a transparent 
plastic cage with a floor of wire with approximately 1cm2 openings. The cage was 
elevated so that stimulation was applied to each hindpaw from beneath the 
rodent. The filaments were applied in order of ascending force. For baseline 
measurements, von Frey probes were applied to 6 designated loci distributed 
over the plantar surface of the foot representative of sciatic nerve innervation into 
the hindpaw- saphenous, tibial, and sural (medial to lateral) (Song et al., 1999; 
Ma et al., 2003). Each filament was applied alternately to each foot for baseline 
measurements. Following TNI, von Frey probes were applied to 4 designated loci 
corresponding to most lateral regions of the hindpaw due to animal 
compensatory weight bearing on medial hindpaw (Wang et al., 2011b). Each 
filament was applied ipsilateral to the nerve injury. The duration of each stimulus 
was approximately one second and the interstimulus interval was approximately 
10 to 15 seconds.  
The incidence of foot withdrawal was expressed as a percentage of the 
four applications of each stimulus and the percentage of withdrawals was then 
plotted as a function of force. A Hill equation (y=100*x^n/(k^n+x^n) was fitted 
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(Origin Version 6.0, Microcal Software) to the function relating the percentage of 
indentations eliciting a withdrawal to the force of indentation (Ma et al., 2003). 
The von Frey withdrawal threshold (force corresponding to a 50% withdrawal) 
was defined as the force that evoked a minimum detectable withdrawal observed 
on 50% of the tests given at the same force level. For cases in which none of the 
specific filaments used evoked withdrawals on exactly 50% of the tests, linear 
interpolation will be used to define the threshold. Tactile hyperalgesia was 
defined as a postoperative decrease in threshold of 20 mN from the mean. TNI 
produces a robust increase in mechanical hypersensitivity that begins on day 3 
and lasts for at least 4 weeks after surgery (Figure 9)  (Wang et al., 2011b).  
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Figure 9: 
 
 
Figure 9: Behavioral assessment of tactile hypersensitivity following 
TNI.  Tibial nerve injury results in a decrease in paw withdrawal threshold (PWT) 
beginning at day 3 after injury and each time point measured thereafter (PID 7, 
24, 21, and 28) (n=6; ANOVA, F=125.2, Bonferroni multiple comparison test, *P< 
0.05). Data are expressed as mean ± s.e.m. *Significant differences compared 
with preoperative baseline control values (*P< 0.05). BL: baseline. 
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D. Drug administration and treatment paradigm 
Pre-TNI baseline behavioral assessment was established in all rodents. 
For some experiments, animals were injected with glycyrrhizin (GL; Sigma 
Aldrich, St. Louis, MO, USA). Glycyrrhizin is a natural anti-inflammatory and 
antiviral triterpene that binds directly to HMGB1 (Mollica et al., 2007). 
Glycyrrhizin was prepared in saline solution on the day of the experiment (pH 
7.5). Sham-control animals and TNI-induced animals were given intraperitoneal 
(i.p.) injections of saline (vehicle) or GL (50 mg/kg), respectively. Our dosing 
paradigm following TNI was either a single injection of GL or a once daily 
injection of GL for four consecutive days (see Chapter III; Figure 17) .   
 
E. Tissue processing immunostaining 
For immunohistochemistry, animals were sacrificed and transcardially 
perfused with saline followed by 4% paraformaldehyde. Fixed tissue was then 
embedded for sectioning and processed using immunocytochemical and 
immunohistochemical methodologies (Bhangoo et al., 2007a). Lumbar L4/L5 
dorsal root ganglia (DRG) tissue from naïve, sham control, and injured animals 
(ipsilateral to the nerve injury) were serially sectioned at 14µm for 
immunohistochemical experiments. At least 6 sections per DRG such that DRG 
sections on each slide were at intervals of 80µm.  
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F. Preparation of dissociated dorsal root ganglion neurons 
The L4 to L6 DRGs, ipsilateral to the injury or sham-injury, were 
dissociated using methods described by Ma and LaMotte (Ma & LaMotte, 2005). 
Briefly, L4 to L6 DRGs were removed from sham or TNI animals at post-injury day 
(PID) 7, 14, and 28. The DRGs were treated with collagenase A and collagenase 
D Hanks’ balanced salt solution (HBSS) for 20 minutes (1 mg/ml; Roche Applied 
Science, Indianapolis, IN, USA), followed by treatment with papain (30 U/ml; 
Worthington Biochemical Corp., Lakewood, NJ, USA) in HBSS containing 0.5 
mM EDTA and cysteine at 35°C. The cells were then dissociated by mechanical 
trituration in culture media containing 1 mg/ml bovine serum albumin and trypsin 
inhibitor (Worthington Biochemical). The culture media was Ham’s F-12 mixture, 
DMEM, supplemented with 10% fetal bovine serum, penicillin and streptomycin 
(100µg/ml and 100U/ml) and N2 (Life Technologies, Corp., Carlsbad, CA, USA). 
The cells were then plated on coverslips coated with poly-L lysine and laminin 
(BD Biosciences, Franklin Lakes, NJ, USA) and incubated for two to three hours 
before additional culture media was added to the wells. The cells were incubated 
for 12 to 15 hours to adhere at 37°C (with 5% CO2). In some experiments 
primary sensory neuron cultures grown on coverslips and after experimental 
treatments were fixed with PBS/4% paraformaldehyde for 15 minutes. 
 
G. F11 cell line 
A F11 cell line was utilized to study a purely neuronal cell population. 
Typically, DRG population is comprised of a heterogeneous cell population of 
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neuronal and non-neuronal cells. The F11 cells represent a homogenous 
population, exhibiting markers and receptors of nociceptive sensory neuron 
lineage (Boland & Dingledine, 1990; Jahnel et al., 2003) and exhibit neuronal 
activity in response to nociceptive stimuli (Bender et al., 2005; Vetter & Lewis, 
2010). F11 cells are a fusion product cell line of a mouse N18TG2 
neuroblastoma and a rat DRG sensory neuron hybrid cell line (Francel et al., 
1987). F11 cells were grown on glass coverslips under 5% CO2 in Ham’s F-12 
medium supplemented with 20% fetal bovine serum (FBS; Hyclone Laboratories, 
Inc., Logan, UT, USA), 100 pM hypoxanthine/1 pM aminopterin/l2 pA4 thymidine, 
and 50 IU/ml of penicillin/streptomycin. Cells were differentiated preceding an 
experiment with Ham’s F-12 medium supplemented with 50 ng/ml of NGF and 
0.5 mM dibutyryl cyclic AMP (db-cAMP). F11 cells that were used for 
experiments were differentiated with NGF and db-cAMP for 48 hours prior to 
stimulation. In some experiments, F11 cells were cultured on coverslips and after 
experimental treatments were fixed with PBS/4% paraformaldehyde for 15 
minutes. 
 
H. Immunostaining 
Fixed tissue sections, F11 cells or primary sensory neuron cultures were 
blocked with natural horse serum blocking buffer (Thermo Scientific SuperBlock® 
Blocking Buffer in PBS, natural horse serum (3% v/v), and Triton-X (0.4% (v/v)). 
Primary antisera used was the rabbit anti-HMGB1 (1:1,000; Sigma Aldrich), goat 
anti-TLR4 (1:1,000; sc-16240; Santa Cruz Biotechnology), rabbit anti-ATF3 
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(1:1,000; Santa Cruz Biotechnology), monoclonal anti-NeuN, polyclonal anti-
CGRP, Griffoniasimplicifolia IsolectinB4 conjugated to FITC IB4-FITC (1:1,000; 
Sigma Aldrich), and Hoescht nuclear stain (1:1,000; Invitrogen Corporation). 
Sections were incubated in secondary antibodies conjugated to CY3 or FITC 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Slides or 
coverslips were washed in PBS for 10 min (2X) before and after each incubation 
step and then coverslipped with a PBS/glycerol solution. The working 
concentration for each antibody was determined by performing a dilution series 
that displayed minimal background and autofluorescence. For each experiment, 
control sections were incubated with only primary or secondary antibody to 
ensure specificity of immunoreactivity.     
 
I. Western blot analysis 
Animals were sacrificed and transcardially perfused with saline and tissue 
was removed and frozen immediately with liquid nitrogen and stored at -80◦C.  
The fresh frozen L4/L5 DRG tissue samples, ipsilateral to the injury, were 
homogenized in radioimmunoprecipitation assay (RIPA) buffer with 
protease/phosphatase inhibitors and protein concentration was determined using 
the bicinchoninic acid BCA protein assay (Thermo Fisher Scientific, Rockford, 
IL). Samples (40µg/lane) were separated by 10% SDS-PAGE and transferred to 
a nitrocellulose membrane. After incubation in 10% non-fat milk blocking solution 
overnight at 4°C, the membrane was probed with rabbit anti-HMGB1 
(1:1,000;Sigma Aldrich), goat anti-TLR4 (1:1,000; sc-12511; Santa Cruz 
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Biotechnology) followed by incubation with horseradish peroxidase-coupled anti-
rabbit secondary antibody (Jackson ImmunoResearch). The membrane was 
reprobed with a monoclonal anti-β actin antibody (1:5,000; Sigma-Aldrich, St. 
Louis, MO) or monoclonal antibody to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (1:5,000; Ambion Applied Biosystems). Immuno-
positive bands were detected by enhanced chemiluminescence (ECL) and 
measured by a densometric analysis (Unscanit; Silk Scientific Inc., Orem, UT). 
 
J. Nuclear and cytoplasmic extraction 
Nuclear and cytoplasmic extracts were prepared using NE-PER Nuclear 
and Cytoplasmic Kits (Thermo Fisher Scientific). Fresh L4/5 DRG tissue ipsilateral 
to the injury were collected and stored at 80◦C. Monoclonal lamin B, nuclear 
protein, (1:1,000; Santa Cruz Biotechnology) and monoclonal αTubulin, 
cytoplasmic protein (1:1,000; Santa Cruz Biotechnology) were used as loading 
controls.  
 
K. Extracellular HMGB1 release measurement 
F11 neuronal cell line was differentiated for 48 hours in a 24 well plate. 
F11 neuronal cells were washed twice with a balanced sterile solution (BSS) 
[NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), glucose (10 
mM), KCl (5 mM)]. To stimulate F11 cells, a high concentration of potassium 
solution (50 mmol/L KCL, denoted as 50K hereafter) was prepared by adjusting 
concentration of KCl from 5 to 50, and NaCl from 145 to 100. 50K, balanced 
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saline solution (BSS), and ionomycin (2µM) were applied for one hour. 
Extracellular supernatants were collected and briefly spun. Samples were 
concentrated using a centrifugal filter device (Amicon Ultra 4-10K; Millipore 
Corp., Billerica, MA, USA). Western blot analysis was performed to detect 
HMGB1 protein levels in extracellular supernatants. Ponceau staining was used 
to assess efficiency of transfer of proteins to the nitrocellulose membrane prior to 
immunoblotting (Figure 10). Additionally, ponceau staining was also used as to 
check equal loading as an alternative to standard intracellular housekeeping 
proteins, actin and GAPDH (Romero-Calvo et al., 2010).    
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Figure 10: 
 
 
 
Figure 10: Diagram of assay for extracellular HMGB1 release 
measurement. F11 neuronal cell line was differentiated for 48 hours in a 24 
well plate. F11 cells were stimulated with high concentration of potassium 
solution (50K), balanced saline solution (BSS) -as a negative control, and 
ionomycin (2µM) -as a positive control was applied for one hour. Extracellular 
supernatants were collected and briefly spun. Samples were concentrated 
followed by western blot analysis to detect HMGB1 protein levels in extracellular 
supernatants. 
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L. Cell count analysis 
Images were taken with an intensified CCD camera (Photometrics 
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) using Nikon 
Elements software (Nikon Instruments Inc., Melville, NY, USA). Tissue sections 
were illuminated with a Lamda DG-4 175 W xenon lamp (Sutter Instruments, 
Novata, CA, USA). The image of each section was set to a maximum threshold 
between 8000 and 8500, and total cell counts for each section were then taken 
using the grid function to aid in total cell count analysis. HMGB1, TLR4 and ATF3 
immunopositive cell counts were conducted using Image Pro Software (Media 
Cybernetics, Inc., Bethesda, MD, USA). The following parameters were used for 
cell counts: intensity range (40 to 255), smoothness (20), and measurement 
window size (10µM). Fluorescent artifacts such as axons and cell debris were not 
included in cell counts. HMGB1, TLR4 and ATF3 immunopositive cell counts 
were taken from independent tissue section images and combined to reach the 
total percentage of neurons per ganglia. The criteria for neuronal HMGB1 
cytoplasmic localization counts include: 1) presence of Hoescht nuclear label, 
and 2) complete cellular membrane morphology, and size of cell (> 10µm).  
 
M. Cell size distribution 
 Cell size was measured using Nikon Elements Software (Nikon 
Instruments Inc., Melville, NY), long and short diameters (LD, SD) of each 
counted cell were measured and used to estimate cell cross-sectional area (area 
= p[LD/2] [SD/2], measured in lm2). LD and SD were perpendicular to each other 
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and passed through the center of the cell soma. Neurons that were > 1000µm2 in 
cross-sectional area were classified as large-sized neurons. They are presumed 
to maintain myelinated axons and mostly to function as low-threshold 
mechanoreceptors (Djouhri, Lawson 2004). Neurons < 1000µm2 were classified 
as small and medium-sized cells (Nitzan-Luques et al., 2011).  
 
O. Recombinant HMGB1  
Recombinant HMGB1 was purchased from R&D Systems (Minneapolis, 
MN; <1.0 endotoxin per 1g of the protein by the LAL method; 50% binding of 
biotinlyated HMGB1 at 0.35 to1.4µg/ml) and supplied as a 0.2µm filtered solution 
in PBS, EDTA and DTT (reducing agent). Stock solutions of HMGB1 were 
reconstituted in sterile PBS. 
 
P. Intracellular calcium imaging  
The dissociated DRG cells were loaded with fura-2AM (3mM, Invitrogen 
Corp., Carlsbad, CA USA) for 25 minutes at room temperature in a balanced 
sterile solution (BSS) (NaCl (140mM), Hepes (10mM), CaCl2 (2mM), MgCl2 
(1mM), glucose (10mM), KCl (5mM). The cells were rinsed with the BSS and 
mounted onto a chamber that was placed onto the inverted microscope. 
Intracellular calcium was measured by digital video microfluorometry with an 
intensified CCD camera coupled to a microscope and MetaFluor software 
(Molecular Devices Corp., Downington, PA USA). Cells were illuminated with a 
150W xenon arc lamp, and the excitation wavelengths of the fura-2AM (340/380 
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nm) were selected by a filter changer. Sterile solution was applied to cells prior to 
HMGB1 application; any cells that responded to buffer alone were not used in 
neuronal responsive counts. HMGB1 was applied directly into the coverslip 
bathing solution with a final concentration of 0.65µg/ml. After HMGB1 application, 
high potassium-50K (50mM) and capsaicin (3nM) were applied. Calcium imaging 
traces were analyzed by two independent analyzers and only responses that 
were in agreement between two individuals were used in the counts. Only 
calcium imaging traces that reflected at least a 50% increase over baseline were 
included in the analysis. A 50% increase over baseline was an arbitrary criteria 
set to reflect a response and minimize subjective variability in calcium image 
analysis. If no response or increased from baseline was seen within one minute, 
HMGB1 was washed out with BSS. 
 
Q. Statistics 
GraphPad Software (LaJolla, CA, USA) was used to determine the 
statistical significance. Results were expressed as mean ± s.e.m. When two 
groups were compared a Student’s t-test was used. Multiple comparisons were 
evaluated by post-hoc Bonferroni test after one-way ANOVA. F values reflect a 
ratio of explained variance to unexplained variance. The F value is greater when 
the null hypothesis tested in not true. *P< 0.05 was considered to be statistically 
significant. GraphPad Software (LaJolla, CA) was used to determine the 
statistical significance of differences in calcium response among naïve and 
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injured groups using Chi-square test- yates correction, with a *P< 0.01 set as 
statistical significance. 
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CHAPTER III  
THE PERSISTENT RELEASE OF HMGB1 CONTRIBUTES TO 
TACTILE HYPERALGESIA IN A RODENT MODEL OF 
NEUROPATHIC PAIN  
A. Introduction 
High mobility group box 1 protein is an ‘alarmin’ or DAMP molecule that 
rapidly mobilizes and activates innate and adaptive host immune defense 
mechanisms (Yang et al., 2007). HMGB1 is a highly conserved 215 amino-acid 
non-histone nucleosomal regulatory protein that is important for DNA repair and 
replication. Though HMGB1 is typically associated with chromatin, it can be 
quickly released into the cytoplasm following injury. More importantly, the 
cytoplasmic HMGB1 can also act as a cytokine when released by macrophages 
following injury, inflammation, or disease (Wang et al., 1999; Gardella et al., 
2002b; Vezzoli et al., 2010). Recent studies have demonstrated that HMGB1 
release is not limited to leukocytes but can also be released from activated or 
injured neurons (Vezzani et al., 2011).  
Release of HMGB1 by neurons in the CNS plays a crucial role as potential 
source of an endogenous inflammatory mediator that can influence adjacent 
neurons and glia (Kim et al., 2006). Recent evidence also suggests that HMGB1 
signaling in cortical cells may contribute to lower membrane thresholds and 
mediate rapid changes in neuronal excitability (Maroso et al., 2010; Vezzani et 
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al., 2011). There is also the suggestion that HMGB1 may contribute to the 
development of neuropathic pain states (Shibasaki et al., 2010). For example, 
perisciatic or intrathecal administration of HMGB1 produces rapid thermal 
hyperalgesia and mechanical allodynia in the rat (O'Connor et al., 2003; 
Shibasaki et al., 2010). In contrast, spinal nerve ligation-induced mechanical 
allodynia, but not thermal hyperalgesia, can be partially reversed if animals are 
pre-treated with intrathecal anti-HMGB1 antibody (Shibasaki et al., 2010). 
Though HMGB1 may contribute to the development of neuropathic pain, the 
cellular source of HMGB1 that contributes to ongoing chronic pain behavior and 
the underlying role of HMGB1 in neuropathic pain are unknown. 
In the present investigation, I examined the degree to which HMGB1 
contributes to the peripheral sensitization of sensory neurons in a rodent TNI 
model of neuropathic pain. I observed that HMGB1 protein is upregulated in a 
number of sensory neurons for an extended period of time. Though not vesicle 
bound, release of HMGB1 from a neuronal cell line was found to occur in 
response to activity. Exogenous administration of HMGB1 increased excitability 
in acutely dissociated sensory neurons. Finally, I asked whether treatment with 
glycyrrhizin (GL) a natural anti-inflammatory and antiviral triterpene that binds 
directly to HMGB1 (Mollica et al., 2007), could influence neuropathic pain 
behavior in the rodent. We found that GL effectively reverses TNI-induced 
mechanical allodynia both at fourteen days and three months following nerve 
injury. 
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B. Original experimental results  
1. TNI induces cytoplasmic HMGB1 in many sensory neurons   
HMGB1 is limited largely to the nuclei of non-neuronal cells and sensory 
neurons in the naïve DRG (Figure 11A,A1) . Following TNI, HMGB1 is 
observed in both the cytoplasm and nucleus of numerous sensory neurons in the 
L5 DRG in addition to some non-neuronal cells at post injury day (PID) 14 
(Figure 11B,B1) . The number of primary afferent neurons that exhibit 
cytoplasmic HMGB1 increased significantly when compared to naïve and sham-
injured animals. The percentage of positive cytoplasmic HMGB1-
immunoreactivity (IR) sensory neurons is increased after TNI at PID 14 
compared to sham and naïve (Figure 11C).  
The expression of activating transcription factor 3 (ATF3), a cellular 
marker of nerve injury was used to reveal the primary afferent fibers that are 
engaged by TNI (Tsujino et al., 2000; Braz & Basbaum, 2010). After TNI injury 
PID 14, ATF3-IR is present in 31.3% (126/403) of total L5 DRG neurons 
ipsilateral to the injury (n=3) (Figure 12B) . ATF3 expression was present in 
heterogeneous population of sensory neurons. Sham and naïve DRGs did not 
exhibit ATF3 immunoreactivity (Figure 12A) . The relatively low number of 
ATF3 immunopositive sensory neurons in the sensory ganglia relative to the 
percentage of neurons exhibiting cytoplasmic HMGB1 immunoreactivity following 
TNI, suggests that direct nerve injury is not necessary for neuronal translocation 
of HMGB1. 
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Figure 11: 
 
 
Figure 11: Subcellular localization of HMGB1 in L5 dorsal root 
ganglion (L5 DRG) primary afferent neurons following TNI in rats.  (A) 
Sections of L5 DRG stained for HMGB1 immunoreactivity (IR) are localized 
primarily to the nuclei of both neuronal and non-neuronal cells (A1; arrows) in the 
naive L5 DRG. Scale bar, 50µm. (B)  By post-injury day (PID) 14, HMGB1-IR is 
localized to the cytoplasm of L5 DRG neurons (B1; arrowheads). There are some 
nuclei of non-neuronal cells that also exhibit HMGB1-IR (B; arrows). (C) Cell 
counts performed on sections of sensory ganglia derived from naïve, sham and 
TNI animals revealed that a large number of sensory neurons exhibit HMGB1 in 
the cytoplasm (n=3 for each condition; ANOVA; Bonferroni’s multiple comparison 
test, *P< 0.01.  
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Figure 12: 
 
 
Figure 12: TNI-induced ATF3 expression in L5 DRG primary afferent 
neurons. (A) Naïve sections of L5 DRG stained for activating transcription factor 
3 (ATF3)-IR. (B) By PID 14, ATF3-IR is localized to the nucleus of L5 DRG 
neurons, n=3. Scale bar, 50µm. 
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To confirm that HMGB1 indeed exhibits a subcellular redistribution, 
nuclear and cytoplasmic extracts from L4/5 DRGs ipsilateral to the injury were 
prepared from sham-injured and TNI animals at PID 14. Immunoblots of HMGB1 
in the specific extracts revealed that there was a decrease in nuclear HMGB1 
protein expression compared to sham control (Figure 13B)  and an increase in 
cytoplasmic HMGB1 protein expression compared to sham control (Figure 
13A). However, total HMGB1 protein content in the L4/5 DRG was not altered by 
nerve injury (Figure 14) . 
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Figure 13: 
 
 
Figure 13: Distribution of HMGB1 in dorsal root ganglion tissue 
derived from TNI rats. Nuclear and cytoplasmic cellular compartments were 
extracted from L4/L5 DRGs ipsilateral to the injury. (A)  HMGB1 levels in the 
cytoplasm increased compared to sham L4/5 DRGs lysates post injury day (PID) 
14 (n=3, Student’s t-test, *P< 0.05) (B) On the other hand, HMGB1 levels in the 
nucleus decreased compared to sham L4/5 DRGs lysates PID 14 (n=4, Student’s 
t-test, *P< 0.01).  
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Figure 14: 
 
 
Figure 14: Total HMGB1 protein content in dorsal root ganglion 
tissue derived from TNI rats. Western blot analysis of total HMGB1 protein 
contents in naïve, sham-injured and TNI L4/5 DRGs ipsilateral to the injury at PID 
14. (naïve and sham n=3 each; TNI (PID 14) n=6, ANOVA, F=3.38; P> 0.05). 
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2. HMGB1 release in F11 cells is activity dependent 
I used the F11 cell line as a surrogate sensory neuron to determine the 
ability of HMGB1 to function as a cytokine by testing whether HMGB1 is capable 
of extracellular release following exposure to high K+ -50 mM (50K). Not unlike 
naïve DRG sensory neurons, HMGB1-IR was present in the nucleus and absent 
in the cytoplasm of differentiated F11 cells (Figure 15A,A1) . Following 
depolarization with 50K for one hour, HMGB1 accumulation was observed in the 
cytoplasm of numerous F11 cells (Figure 15B,B1) . Moreover, HMGB1 was 
further released as evidenced by pronounced levels of HMGB1 in the 
extracellular supernatant (Figure 16) . Blebbing of F11 cell nuclei, an indicator 
of cell death, was absent following one-hour exposure to 50K. Despite evidence 
demonstrating extracellular release of HMGB1 from F11 cells, the combination of 
50K and glycyrrhizin (GL; 100µM), a triterpenoid saponin glycoside known to 
neutralize HMGB1, did not affect HMGB1 nuclear translocation. Taken together, 
this suggests that the presence of HMGB1 alone may be sufficient but not 
necessary to mediate extracellular release upon neuronal stimulation.  
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Figure 15: 
 
 
Figure 15: Immunofluorescent imaging of cytoplasmic HMGB1 from 
F11 neuronal cell line. (A, A1)  HMGB1 is confined in the nucleus of F11 
differentiated neuronal cell line in the BSS control sample (arrows). (B, B1) 
HMGB1 protein relocates into the cytoplasm following a one-hour exposure to 
50K (arrows). Co-labeled with Hoechst stain-nuclei marker. Scale bar, 50µm. 
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Figure 16: 
 
 
 
Figure 16: Extracellular release of HMGB1 from F11 neuronal cell 
line. Western blot analysis of extracellular supernatant of HMGB1 after a one-
hour exposure to 50K, ionomycin (2µM) and a balanced sterile solution (BSS) of 
F11 differentiated cells. Extracellular supernatants exhibited an increase level of 
HMGB1 after 50K stimulation. Two sets of 12-well plates of cultured F11 cells 
were used. F11 cells exposed to 50K lane were duplicated within each 12-well 
plate. Lysates per condition and 12-well plate were loaded on a nitrocellulose 
membrane for HMGB1 detection by westernblot analysis. Nitrocellulose 
membrane was stained with ponceau staining, as an alternative to actin blotting. 
The 30kDa region is shown, which corresponds to molecular weight of HMGB1.    
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3. HMGB1 activates calcium mobilization in sensory neurons  
Using calcium mobilization techniques (see Chapter II), it is possible to 
functionally characterize sensory neurons that respond to acute administration of 
HMGB1. Following HMGB1 application, capsaicin (transient receptor potential 
cation channel subfamily V member 1;TRPV1 agonist) and high K+ (50K) 
(activates voltage-gated calcium channels) were added to further characterize 
the phenotype of the imaged cells. A response to 50K is indicative of a non-
nociceptive neuron, while a response to capsaicin and 50K is characteristic of a 
nociceptive neuron. Numerous nociceptive neurons responded to HMGB1 while 
significantly fewer non-capsaicin neurons exhibited HMGB1-induced calcium 
mobilization (Table 5) . 
As an additional control experiment, we addressed the feasibility of GL to 
effectively neutralize the direct effects of HMGB1 on sensory neurons. Using the 
described calcium mobilization paradigm, we bath applied acutely dissociated 
sensory neurons with GL/HMGB1. Following washout of GL/HMGB1, the cells 
were then exposed to capsaicin. The experimental outcome of these experiments 
suggested that most capsaicin-sensitive sensory neurons (>90%) did not 
respond to HMGB1 in the presence of 200 or 400µM GL.  
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Table 5: 
 
 
Table 5: Acute administration of HMGB1 elicits an intracellular 
calcium flux in primary sensory neurons. Dissociated naïve sensory 
neurons were incubated with fura-2AM to visualize calcium mobilization. HMGB1 
was applied and response was measured in capsaicin and non-capsaicin 
sensory neurons. Capsaicin-sensitive neurons had a greater sensitivity to 
exogenous HMGB1. Excitation wavelengths of 340/380 nm were measured. Only 
calcium imaging traces that reflected at least a 50% increase over baseline were 
included in the analysis. Dissociated DRGs were incubated overnight in media 
that did not contain NGF. DRGs were isolated and calcium response was tested 
from 6 individual S/D rats (n=6).  
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4. HMGB1 increases the excitability of primary afferent 
neurons  
Increased excitability of peripheral sensory neurons is thought to 
contribute to chronic pain states following nerve injury. To determine the degree 
to which HMGB1 can induce an increase in sensory neuron excitability, 
electrophysiology was performed using sharp electrodes in current clamp mode. 
All recordings were performed by Dr. Michael Due, for figures refer to (Feldman 
et al., 2012). Following repeated current pulse combined with HMGB1 
application, a significant increase in the excitability of some small to medium 
diameter sensory neurons was observed compared to baseline levels in both 
naïve (14.3% cells respond to HMGB1; 1.36 action potentials (APs) for control 
vs. 5.22 APs for HMGB1; (Feldman et al., 2012)) and TNI derived sensory 
neurons (37.5% cells respond; 1.20 APs for control vs. 7.33 APs for HMGB1 
(Feldman et al., 2012)). 
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5. Glycyrrhizin reduces pain hypersensitivity in the TNI model 
of neuropathic pain  
 
TNI produces a significant reduction in the paw withdrawal threshold 
(PWT) to tactile stimulus which lasts for several months (PID 3 to 64) (Wang et 
al., 2011b). To investigate the degree to which HMGB1 modulates TNI-induced 
tactile hyperalgesia, we utilized a treatment paradigm described by Ohnishi and 
colleagues (Ohnishi et al., 2011) that included either a one-time injection of 
glycyrrhizin (GL) via an intraperitoneal (i.p.) route, (50 mg/kg) at PID 7 or one 
injection per day over four consecutive days, PID 11 to 14 (Figure 17A) . This 
same treatment paradigm was again repeated over four consecutive days, PID 
61 to 64 (Figure 17B) . Interestingly, a single injection of glycyrrhizin produced 
only a partial reduction in the PWT to tactile stimulus at PID 7 and PID 56 
(Figure 17C,D) . However, four consecutive days of glycyrrhizin at either PID 
11 to 14 or PID 61 to 64, produced PWTs that returned nearly to pre-injury 
baseline levels. This behavior represented strongly significant differences when 
compared to vehicle controls (Figure 17C,D) .  
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Figure 17: 
 
 
Figure 17: Pre-treatment of glycyrrhizin once daily for 4 days 
reduces TNI-induced pain hypersensitivity. Glycyrrhizin treatment 
paradigm. (A) Treatment includes a one-time injection of glycyrrhizin (i.p.; 
50mg/kg) or treatment with glycyrrhizin one injection per day over four 
consecutive days. Single injection at PID 7 or one injection per day PID 11-14. 
Tactile behavior sensitivity was measure before and after injection on PID 7 and 
14. (B) Single injection at PID 56 or one injection per day PID 61-64. Tactile 
behavior sensitivity was measured before and after injections on PID 7 and 14. A 
one-time injection of glycyrrhizin at TNI PID 7 (C) or PID 56 (D) produced only a 
partial effect on the paw withdrawal threshold (PWT) (n=6; *P< 0.01, ANOVA, 
F=19.1, Bonferroni’s multiple comparison test. Treatment with glycyrrhizin 
injections over four consecutive days PID 11-14 (C) or PID 61-64 (D) 
successfully reversed TNI decreases in PWT (n=6; *P< 0.01, ANOVA, F=265.9; 
Bonferroni’s multiple comparison test. Data are expressed as mean ± s.e.m. 
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C. Discussion 
Previous studies have implicated HMGB1, a cytokine mediator of 
inflammation, as having a critical role in neuropathic pain (Chacur et al., 2001; 
Shibasaki et al., 2010; Otoshi et al., 2011a). In the present investigation, we 
found that HMGB1 undergoes a chronic subcellular redistribution from the 
nucleus to the cytoplasm of primary afferent neurons following peripheral nerve 
injury. Given evidence that cytoplasmic HMGB1 can undergo exocytosis in other 
cell types (Gardella et al., 2002b; Lee et al., 2010), we further determined that 
activity can contribute to the release of cytoplasmic HMGB1 from a sensory 
neuron cell line. We also observed that HMGB1 administration to acutely 
dissociated primary afferent neurons directly increases the excitability of some 
sensory neurons. Finally we demonstrated that systemic treatment paradigms 
using GL, a natural anti-inflammatory triterpene that binds directly to HMGB1, 
can partially reverse pain behavior at PID 7 and PID 56. Though a single dose of 
GL can elicit a statistically significant reversal of stimulus dependent pain 
behavior, a four-day treatment paradigm produces a near complete recovery to 
pre-injury PWT baseline at PID 14 and PID 64 days. Together these results 
suggest that HMGB1 has a significant role in sensitizing primary afferent neurons 
and may contribute to neuropathic pain behavior. 
After cellular damage or injury, the subcellular redistribution of HMGB1 
from the nucleus to the cytoplasm, following passive and active secretion occurs 
in a variety of cell types, including neurons (Gardella et al., 2002b; Bonaldi et al., 
2003; Lotze & Tracey, 2005; Andersson & Harris, 2010; Lee et al., 2010; Maroso 
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et al., 2010). Passive secretion of HMGB1 is often a result of cellular damage 
and occurs instantaneously (Schiraldi et al., 2012). Active secretion occurs in 
cells undergoing profound stress, such as, exposure to inflammatory mediators, 
including TNFα, IL-1, and IFN-γ (Wang et al., 1999; Muller et al., 2004). More 
recent studies in the nervous system demonstrate that when glutamate-exposed 
primary cortical neurons undergo excitotoxic cell death and secrete HMGB1 
(Maroso et al., 2010). Herein, we demonstrated that following peripheral nerve 
injury or exposure to a depolarizing event, HMGB1 can translocate from the 
nucleus to the cytoplasm in both sensory neurons and a sensory neuron-like cell 
line. More importantly, a depolarizing event in vitro can elicit neuronal release of 
HMGB1 into the extracellular environment. Unlike cultured cortical neurons 
treated with glutamate, this neuronal depolarization did not elicit sensory neuron 
cell death. Though the mechanisms of HMGB1 release in neurons are largely 
unknown, cytoplasmic HMGB1 may be further phosphorylated by the PKC and 
secreted by a calcium-dependent mechanism via CaMKs (Tsung et al., 2007; 
Muraki et al., 2009). 
That HMGB1 can be released by both injured and non-injured sensory 
neurons suggests a possible influence on nearby neurons, adjacent nerve fibers, 
and possibly non-neuronal cells in the nervous system. Strong evidence 
supporting such a signaling event by HMGB1 was discovered by Maroso and 
colleagues in a chronic epilepsy model. This group elegantly demonstrated that 
blockade of HMGB1 markedly reduced seizure duration and frequency in rodent 
cortical neurons (Maroso et al., 2010). Our results herein parallel findings in 
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cortical neurons in that exposure to HMGB1 can elicit robust states of excitability 
in primary afferent neurons. These data suggest that HMGB1 is likely to play a 
modulatory role in ongoing states of peripheral sensitization following nerve 
injury.  
A number of studies have provided evidence of a role of HMGB1 signaling 
in nervous system pathology following injury within either the peripheral or central 
nervous system (Mabuchi et al., 2009; Vezzani et al., 2011). Shibasaki and 
colleagues demonstrated that injection of HMGB1 into the sciatic nerve produced 
dose-dependent thermal and tactile hyperalgesia (Shibasaki et al., 2010), while 
direct administration of HMGB1 into the central nervous system by intrathecal 
route produced robust mechanical hyperalgesia that lasted for up to two hours 
(O'Connor et al., 2003; Tong et al., 2010). More importantly, multiple exposures 
to HMGB1 neutralizing antibodies partially reverse SNL-induced mechanical 
hyperalgesia and bone cancer pain (Shibasaki et al., 2010; Tong et al., 2010). 
Taken together, it appears that ongoing HMGB1 release after a nerve injury may 
be a critical factor for the maintenance of neuropathic pain and may be due to a 
feed-forward regulation state (Faraco et al., 2007). 
Like other proinflammatory mediators HMGB1 exhibits both active and 
passive release (Gardella et al., 2002a; Scaffidi et al., 2002). The basis of these 
molecular mechanisms that contribute to these release kinetics are largely 
unknown. That GL is effective after repeated injections suggests that the release 
of HMGB1 is an ongoing feed-forward mechanism (Gardella et al., 2002b). The 
presence of extracellular HMGB1 serves to activate HMGB1 receptor activation 
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that may continue the expression, production and translocation of HMGB1. Since 
TNI contributes to both nuclear and cytoplasmic HMGB1, it is likely that HMGB1 
is undergoing transcription and translation. More importantly, we observed that 
total HMGB1 protein expression did not change suggesting that production of 
HMGB1 is ongoing after injury; otherwise a decrease in total protein expression 
would be evident. 
Oral GL is metabolized in the intestine to 18β-glycyrrhetinic acid (GA) and 
intravenous (i.v.) glycyrrhizin is metabolized into GA when excreted through the 
bile into the intestines (Ploeger et al., 2001). Both GA and GL are known to 
directly interact with HMGB1 and inhibit its inflammatory actions in leukocyte 
chemotaxis, cancer, and post-ischemic liver and brain (Mollica et al., 2007; Sitia 
et al., 2007; Mabuchi et al., 2009; Ohnishi et al., 2011; Kim et al., 2012; Schiraldi 
et al., 2012). Interestingly, only the metabolite GA is able to cross the blood-brain 
barrier (Tabuchi et al., 2012). GA is produced by bacteria in the intestine after 
oral administration of GL and exhibits a bioavailability of only 1% in plasma 
(Yamamura et al., 1995). However, GL bioavailability following intraperitoneal 
administration is estimated to be 65-90%. Given the manner in which we 
administer the compound, it is unlikely that GL directly impacts neural or non-
neural cells in the spinal cord or brain.  
HMGB1 neuronal signaling in neuropathic pain may be dependent on 
either of two receptors, RAGE and/or TLR4. It is known that functional RAGE is 
present in sensory neurons (Vincent et al., 2007). Shibasaki and colleagues have 
demonstrated that after SNL, RAGE expression was increased in the primary 
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afferent neurons, satellite glial cell in the DRG, and Schwann cells in the spinal 
nerve (Shibasaki et al., 2010). Based on these findings, this group theorized that 
HMGB1-RAGE signaling might be a promising therapeutic strategy for the 
management of neuropathic pain. However, the injury-induced release of 
HMGB1 and its receptor interaction is not restricted to the RAGE as TLR4 is 
another major receptor of HMGB1 in neuropathic pain models (Kuang et al., 
2012).  
The characterization of HMGB1-TLR4 interactions has led to the discovery 
of a cysteine residue at position 106 within HMGB1, which directly binds to TLR4 
and induces cytokine release in macrophages (Yang et al., 2010). This same 
activation of TLR4 site is present on adult cortical neurons and induces 
heightened excitability in the form of seizure activity (Sayyah et al., 2003; Galic et 
al., 2008; Maroso et al., 2010). TLR4-dependent neuronal excitability is not 
limited to the CNS as primary sensory neurons exposed to the endotoxin LPS, 
the prototypical agonist of TLR4, produces increased excitability (Ochoa-Cortes 
et al., 2010), concentration-dependent increase in calcium (Qin et al., 2004), 
inward ion currents and the release of calcitonin gene-related peptide (CGRP) 
(Diogenes et al., 2011). Subsequently, there is evidence for the central 
involvement of TLR4 function in both spinal cord inflammation and pain behavior 
hypersensitivity (Tanga et al., 2004; Tanga et al., 2005; Tong et al., 2010; Kuang 
et al., 2012).  
The subsequent cell signaling function initiated by HMGB1 through its 
respective receptors may lead to a cascade of metabolic responses (Rauvala & 
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Rouhiainen, 2007) or the increased production of pro-inflammatory mediators 
that sustain a chronic inflammatory state (Klune et al., 2008). Further 
investigation is necessary to elucidate HMGB1 signaling through TLR4 and/or 
RAGE in the injured PNS, which may reveal novel mechanisms of neuronal 
HMGB1 activation that contribute to ongoing peripheral sensitization and 
neuronal hyperexcitability in chronic pain states. 
Our present study has definitively found that HMGB1 is actively released 
and serves as a relevant ligand for the maintenance of neuropathic pain. We 
have also discovered that ongoing HMGB1 release within the peripheral nervous 
system contributes to mechanical behavioral hyperalgesia, such that multiple 
injections of GL (HMGB1 neutralizing agent) effectively attenuated injury-induced 
mechanical hyperalgesia. Taken together, we believe that HMGB1 can directly 
alter sensory neuron function and that the ongoing release of HMGB1 in the 
periphery contributes to neuropathic pain. 
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CHAPTER IV  
 
TLR4 EXPRESSION AND FUNCTION IN SENSORY NEURONS 
FOLLOWING PERIPHERAL NERVE INJURY 
 
A. Introduction and hypothesis rationale 
Neuropathic pain is a highly complex pain state that involves 
neuroimmune interactions in both the central and peripheral nervous system. 
There is increasing evidence that neuropathic pain arising from nerve injury has 
a central nervous system component that involves spinal glial activation (Watkins 
& Maier, 2002). Further, TLR4 has been implicated as the mechanistic link 
between nerve transection, microglia activation, and behavioral hypersensitivity. 
The involvement of TLR4 function in the generation of neuropathic pain is 
especially highlighted by observations of both diminished spinal cord 
inflammation and pain behavior hypersensitivity in rodent lacking TLR4 (Tanga et 
al., 2004; Tanga et al., 2005). Initial interpretations of these data suggest that 
elimination or suppression of TLR4 signaling in microglial cells may directly 
contribute to the nerve injury-induced pain hypersensitivity. However, the injury-
induced rodent behavior changes are evident as early as 1 day, while microglial 
activation elicited by endogenous inflammatory agents is typically delayed until 3 
days after the insult (Colburn et al., 1997). The absence of pain behavior in 
injured TLR4 knockout animals prior to day 3 suggests that the contribution of 
TLR4 to neuropathic pain may be dependent on cell types other than microglial.  
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Much of what is known about TLR4 signaling is limited to non-neuronal 
cells, such as immune, glia, epithelial cells. Only recently has the expression of 
TLR4 in neurons been definitively characterized (Wadachi & Hargreaves, 2006; 
Rolls et al., 2007; Acosta & Davies, 2008) and only a few studies have 
demonstrated its functional role in sensory neurons. For instance, Maroso and 
colleagues demonstrated that TLR4 activation in cortical neurons results in 
enhanced seizure activity (Maroso et al., 2010). In sensory neurons, other 
investigators have found that LPS can directly activate DRG neurons leading to 
production of inflammatory cytokines by neurons and increased neuronal 
excitability (Ochoa-Cortes et al., 2010; Diogenes et al., 2011). A very recent 
finding from White and colleagues, demonstrates that LPS and M3G (TLR4 
agonists) administration has the ability to directly enhance sensory neuron 
excitability by modulating sodium channel function that may contribute to evoked 
pain hypersensitivity (Due et al., 2012). Interestingly, it has been reported that a 
low degree of TLR4 activation can promote sensory neuron survival, whereas a 
high degree of TLR4 activation results in pronounced neuronal dysfunction and 
death (Nowicki et al., 2010). Collectively, recent studies suggest TLR4 on 
sensory neurons has a prominent role in neuronal function, but little is known 
about its function and expression in injured sensory neurons.   
In this study, I reasoned that since TLR4 historically functions to generate 
an immune response and the induction of proinflammatory mediators, then 
neuronal TLR4 might also serve to alter the functional response of sensory 
neurons in a neuropathic pain state. Specifically, I explored the hypothesis that 
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the hyperexcitable state of sensory neurons following a peripheral nerve injury 
(TNI) is in part attributed to TLR4 in injured DRGs. To test my hypothesis I used 
immunolabeling and immunoblot techniques, calcium imaging, and pain-related 
behavior assessment outlined in the previous chapter (Chapter II). Using 
immunohistochemical methodology, I demonstrated that TLR4 expression 
decreased in nociceptive neurons after a tibial nerve injury. Moreover, in vitro, 
injured sensory neurons displayed a diminished intracellular calcium response to 
application of a TLR4 agonist, HMGB1. Finally, unlike intrathecal injections of 
TLR4 inhibitors, we demonstrated that systemic administration of a small 
molecule inhibitor for TLR4 did not have an effect on injury-induced tactile 
hypersensitivity in female rats.   
 
B. Original experimental results 
1. Toll-like Receptor 4 is present on sensory neurons 
TLR4 expression has been identified in sensory ganglia (Wadachi & 
Hargreaves, 2006; Ochoa-Cortes et al., 2010). Here, I first examined the extent 
to which TLR4 protein expression is present in lumbar and trigeminal sensory 
ganglia in vivo (Figure 18A) . TLR4 expression present in DRG is localized 
exclusively in sensory neurons. TLR4-immunopositive sensory neurons exhibit 
peptidergic and non-peptidergic neuronal phenotypes in the rat lumbar DRG 
(Figure 18B-M) . To characterize a peptidergic sensory neuron subpopulation, 
TLR4 expression was co-labeled with a CGRP marker. Further to characterize a 
non-peptidergic sensory neuron population, TLR4 expression was co-labeled 
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with Isolectin B4 (IB4). NeuN was used as a neuronal marker. Taken together, 
TLR4 is present on nociceptive neurons derived from lumbar dorsal root ganglia.  
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Figure 18: 
 
 
Figure 18: TLR4 expression in sensory neurons. (A) Western blot analysis of TLR4 isolated from trigeminal 
(TRG) and lumbar L3-6 dorsal root ganglion (DRG) lysates. (B-M) Immunofluorescent images of TLR4 in peptidergic 
and non-peptidergic DRG populations from sectioned naïve L4 or L5 DRGs. NeuN is a neuronal marker (B, green 
arrows), which co-labeled with TLR4 (C, red arrows). Nuclei are stained with DAPI (D, H, L, blue). Merged images 
demonstrate co-labeling of NeuN with TLR4 (E, yellow arrows). CGRP is a marker for peptidergic containing 
sensory neurons (F, green arrows), which co-labeled with TLR4 (G, red arrows). Merged images demonstrate co-
labeling of CGRP containing neurons with TLR4 (I, yellow arrows). IB4 is a marker for nonpeptidergic sensory 
neurons (J, green arrows), which co-labeled with TLR4 (K, red arrows). Merged images show co-labeling of IB4 
non-peptidergic sensory neurons with TLR4 (M, yellow arrows (n=6; S/D rats) Scale bar, 60µm (B-M). 
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2. Tibial nerve injury induces a decrease in TLR4 protein 
expression 
?
I next compared the injury-induced effects on TLR4 protein expression in 
injured L4/5 DRGs. TLR4 protein levels in the injured DRGs at PID 3 and 7 
exhibited a statistically significant decrease in protein expression when compared 
with naïve protein levels (Figure 19A,B) . Additionally, relative to naïve and 
sham tissue TLR4 protein expression levels were slightly decreased by TNI at 
PID 14 (Figure 20A,B)  but did not demonstrate a significant change at PID 28 
(Figure 20C,D). To verify this observation, I investigated the extent to which 
TLR4 protein expression was decreased in L4/5 DRGs ipsilateral to the injury by 
immunofluorescent imaging (Figure 21A). TLR4 expression was localized 
primarily in sensory neurons of L5 DRGs. Following TNI, the percentage of 
positive TLR4-immunoreactive (IR) sensory neurons decreased when compared 
to sham-injured animals by 19.6%, (sham: 53.6 ± 2.6, injured: 34.0 ± 2.81) 
(Figure 21B) .  
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Figure 19: 
 
 
 
 
 
   
 
 
 
Figure 19: Protein analysis of TLR4 expression following TNI at post 
injury days 3 and 7. (A) Immunoblot of TLR4 in L4/5 DRGs from naïve, sham 
injured and TNI ipsilateral to the injury at PID 3 and PID 7. GAPDH was used as 
a loading control to which samples were normalized. (B) Representative graph. 
(n=3 for each group; ANOVA, F=51.34, *P< 0.001, Bonferroni’s multiple 
comparison test). 
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Figure 20: 
 
 
 
 
 
 
 
 
 
 
      Figure 20: Protein analysis of TLR4 expression following TNI at post injury days 14 and 28. (A,C) Immunoblot 
of TLR4 in L4/5 DRG lysates from naïve, sham, and TNI ipsilateral to the injury at PID 14 and PID 28. Actin was used 
as a loading control to which samples were normalized. (B) Representative graph of TLR4 immunoblot of L4/5 lysates 
PID 14. (n=3 for naïve and sham, n=6 for TNI PID 14; ANOVA, F=5.70, *P< 0.05, Bonferroni’s multiple comparison 
test). (D) Representative graph of TLR4 immunoblot of L4/5 lysates PID 28. (n=2 for naïve and sham, n=3 for TNI PID 
28; Naïve and sham groups were combined to perform a Student’s t-test comparing TNI PID 28; P> 0.05,). 
 
127 
Figure 21: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: TLR4 immunoreactivity in L5 DRG primary afferent 
neurons following TNI in rats. (A) Sections of L5 DRG stained for TLR4 
immunoreactivity are localized primarily to neurons cells in sham-injured and 
injured L5 DRGs at PID 14. Scale bar, 50?m. (B) Neuronal cell counts were 
performed on sections of L5 DRGs derived from sham-injured and TNI at PID 14 
animals. Injured L5 DRGs exhibited a decrease in the percentage of neurons 
positive for TLR4 compared to sham-injured; sham n=3, PID 14 n=3, Student’s t-
test, *P< 0.05. 
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I next evaluated the degree to which a small/medium and large TLR4-
immunopositve cells were altered after injury. Cell size was determined by 
measuring the cross sectional area of each sensory neuron, small and medium 
diameter neurons were categorized with a cross sectional area of <1000µm2.  
Following TNI, the percentage of small and medium diameter TLR4-IR L5 DRGs 
decreased compared to sham-injured controls (sham: 52.0 ± 2.28, injured: 33.0 ± 
2.83) (Figure 22A,B) , where as TLR4-IR in large diameter neurons were not 
altered following injury. Cell counts are shown in Table 6 . Although the cell 
count analysis is based on a relatively small total number of sensory neurons 
accounting for bias in methodology, this initial data collection suggests a possible 
difference in TLR4 expression in a subset of injured sensory neurons. 
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Figure 22: 
 
 
Figure 22: TLR4 immunoreactivity in L5 DRG small, medium and 
large primary afferent neurons following TNI in rats. (A) Injured L5 
DRGs exhibited a decrease in the percentage of small/medium (S/M) diameter 
sensory neurons compared to sham-injured (S/M) neurons at PID 14 (*P< 0.05), 
unlike large (L) diameter sensory neurons from L5 DRGs ipsilateral to the injury. 
Percentage of neurons for each group small/medium, and large represent 
#TLR4-immunopositive per group/ #neurons per group*100. S/M diameter 
neurons <1000µm2. Large diameter neurons > 1000µm2. (sham n=3, PID 14 n=3, 
Student’s t-test, *P< 0.05). (B) Cell size distribution of TLR4-IR in small, medium, 
large diameter sensory neurons from L5 DRGs ipsilateral to the injury. The cell 
distribution is based on 629 neurons (n=6) were categorized as 392 from TNI PID 
14 rats, 237 from sham-injured rats. Cell counts are shown in Table 4.  
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Table 6: 
 
 
Table 6: TLR4-immunoreactivity in L5 DRGs 14 days following tibial 
nerve Injury. The table represents the values for the data shown in Figure 24 
for small, medium, and large DRG neuron cell count analysis. For cell counts in 
the DRG comparisons were made per animal followed by calculation of group 
means. Each values is the average mean ± SEM. * denotes statistical 
significance, P< 0.05. 
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3. TLR4 is present in injured and uninjured neurons after 
injury  
Tibial nerve injury involves complete transection of the tibial nerve that 
correspond to injured neurons, however uninjured nerves sural, saphenous, 
common peroneal co-mingle and overlap to an extent innervating adjacent 
denervated skin (Swett & Woolf, 1985). Injury to the tibial nerve results in injured 
neurons that lie within the associated L4-6 DRGs, which can further release pro-
nociceptive mediators in a paracrine manner (e.g. TNFα) that can further act on 
uninjured sensory neurons to change excitability and function (Sorkin et al., 
1997; Schafers et al., 2003). Accordingly, I examined whether TLR4 expression 
was present on injured and uninjured neurons following TNI, by co-labeling with a 
well-known marker for neuronal injury, activating transcription factor 3 (ATF3). 
ATF3 is known for its role in axonal outgrowth (Seijffers et al., 2007) and may 
function as a negative regulator of TLR signaling in immune cells (Gilchrist et al., 
2006). Results from Chapter III, indicate that roughly 31% of sensory neurons 
express ATF3 after TNI (Chapter III; Figure 12). More importantly, TLR4 co-
labeled in both injured (ATF3-IR) and uninjured neurons derived from injured L5 
DRGs (Figure 23) .   
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Figure 23: 
 
Figure 23: TLR4-immunoreactivity in injured and uninjured in L5 DRG primary afferent neurons. Sectioned L5 
DRGs from TNI at PID 14 stained with (A) TLR4 (B) ATF3- a marker for neuronal injury (C) DAPI- a nuclei marker. White 
arrows represent colocalization of TLR4 and ATF3 immunoreactivity. TLR4 is present in injured and uninjured neurons. 
Some injured neurons were negative for TLR4-immunoreactivity. n=3; S/D rats. Scale bar, 30µm. 
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4. Diminished calcium mobilization by TLR4 endogenous 
agonist, HMGB1, in dissociated injured sensory neurons  
 
As outlined in Chapter III, HMGB1, an endogenous TLR4 agonist, in naïve 
dissociated sensory neuron cultures activates calcium mobilization in a number 
of nociceptive neurons (70%) (Chapter III; Table 5) . Using 
electrophysiological current clamp techniques, under suprathreshold conditions 
HMGB1 was able to increase the excitability of small and medium diameter 
neurons in naïve and TNI acutely dissociated sensory neurons (Feldman et al., 
2012). 
 I further examined the extent to which HMGB1 can elicit an intracellular 
calcium response at multiple time points after a tibial nerve injury. HMGB1 is 
highly sensitive to the redox environment and cytokine activity is optimal in mildly 
reduced conditions (Venereau et al., 2012), HMGB1 was supplied in the 
presence of DTT (reducing agent) and reconstituted in PBS. The same HMGB1 
batch was used throughout each experiment and post injury day tested. 
Following HMGB1 application, capsaicin (TRPV1 agonist) and high K+ (50K) 
(activates voltage-gated calcium channels) were added to further characterize 
the phenotype of the imaged cells (Figure 24). A response to 50K is indicative 
of viable sensory neurons, while a response to capsaicin and 50K is 
characteristic of a nociceptive neuron. Application of HMGB1 to injured 
dissociated sensory neurons from L4-5 DRGs PID 7, 14, and 28 resulted in a 
decrease in the percentage of sensory neurons capable of eliciting a calcium 
response when compared to naïve conditions. Specifically, in the capsaicin-
sensitive subpopulation the diminished response was evident at PID 7, 14, and 
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28 when compared to naïve conditions (Χ2[PID 7]= 16.89, Χ2[PID 14]= 22.02, 
Χ2[PID 28]= 37.86, *P<0.01). In the non-capsaicin sensitive population, a 
pronounced decrease in the percentage of neurons that elicited an intracellular 
calcium flux upon exposure to HMGB1 occurred at PID 28 when compared to 
naïve conditions (Χ2[PID 28]= 12.02, *P<0.01) (Table 7) . 
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Figure 24: 
 
 
Figure 24: Representative calcium trace in response to the 
application of HMGB1. The ratio 340/380 (bound/unbound calcium) as a 
function of time. Each trace represents a single dissociated sensory neuron. 
HMGB1 was applied directly into the coverslip bathing solution with a final 
concentration of 0.65µg/ml followed by the application of capsaicin (3nM). 
Baseline was determined at the beginning of the experiment. A 50% increase 
over baseline is a positive response to HMGB1 (purple).  
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Table 7: 
 
  
Table 7: Intracellular calcium mobilization is diminished after 
acute exposure to HMGB1. L4/L5 DRGs, ipsilateral to the injury, were 
dissociated and incubated overnight (~18hrs) in media that did not contain 
NGF. Sensory neurons were incubated with fura-2AM to visualize calcium 
mobilization .TNI post injury day (PID) 7, 14, and 28 significantly decreases 
the percentage of HMGB1 responsive neurons as measured by a change in 
intracellular calcium influx. * # ^ denotes statistical significance, *P< 0.01. 
Naïve (n=6); PID 7 (n=4); PID 14 (n=4); PID 28 (n=4). Excitation wavelengths 
of 340/380nm were measured. Calcium imaging traces that reflected at least 
a 50% increase over baseline were included in the analysis. 
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To verify the state of acutely dissociated sensory neurons, I examined the 
expression of ATF3, in a five-hour and an overnight dissociated sensory neuron 
preparation. Recently, Ono and colleagues demonstrated that prolonged 
dissociated sensory neuron cultures induces ATF3 expression and can alter 
neuronal excitability similar to neuropathic pain states (Ono et al., 2012). ATF3 is 
known for its role in neurite outgrowth (Seijffers et al., 2006), ability to distinguish 
injured neurons (Tsujino et al., 2000), and negatively regulating TLR4 signaling 
(Gilchrist et al., 2006). To determine whether the cultured neurons used in 
calcium imaging experiment expressed ATF3, L3-L6 were isolated from a single 
S/D rat and dissociated for either 5hrs or overnight (O/N), ~18hrs. Dissociated 
sensory neurons were cultured without the presence of NGF. In acutely 
dissociated cultures (5hrs) ATF3 expression was not present. However, ATF3 
was observed in nearly every sensory neuron in O/N cultured conditions. Non-
neuronal cells did not express ATF3, suggesting the increase in ATF3 expression 
is specific to neurons (Figure 25). Taken together, the presence of ATF3 may 
impact the degree to which HMGB1 may elicit a calcium-mediated response in 
injured nociceptive neurons.  
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Figure 25: 
 
 
Figure 25: Dissociated primary sensory neuron culture express 
neuronal injury marker, ATF3. Dissociated primary sensory neurons 
cultured for 5hrs (left column) and overnight (~18hrs) (right column). Primary 
sensory neurons cultured overnight begin to express ATF3 (middle panel; blue 
arrows) and extend neurite processes (top panel; blue arrow). ATF3 is specific to 
neurons, glia are present in cell cultures as depicted by nuclei-DAPI staining 
(bottom panel; blue arrows). A single S/D rat was used for this experiment, L3-6 
were collected and cultured for 5hr or overnight (O/N) groups, DRGs were 
cultured without the presence of NGF. Scale bar, 50µm. 
     139 
5. Systemic administration of TLR4 small molecule inhibitor 
does not alter pain hypersensitivity in the TNI model of 
neuropathic pain 
 
Intrathecal administration of TLR4 inhibitors and TLR4 KO animals has 
been shown to diminish the pain hypersensitivity in neuropathic pain animal 
models, attributing TLR4 microglia activation in the spinal cord (Tanga et al., 
2005; Bettoni et al., 2008; Hutchinson et al., 2008; Wu et al., 2010a). The effect 
of systemic administration of a TLR4 small molecule inhibitor (compound 15 or 
HY09) following TNI was tested. HY09 has been shown to disrupt the TLR4/MD-
2 complex formation and selectively block TLR4 signal transduction without 
affecting other homologous TLR family proteins (Bevan et al., 2010). HY09 also 
demonstrates high specificity and low toxicity in vitro and in vivo (Wang et al., 
2012a), with negligible non-specific inhibitory effects (Chavez et al., 2011).  A 
single injection of HY09 (10mg/kg; i.p.) in baseline uninjured naïve animals did 
not alter baseline paw withdrawal threshold (PWT). Further a single injection of 
HY09 (10mg/kg; i.p.) at TNI PID 14 and 28 also did not alter the reduction in 
PWT (Figure 26) . 
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Figure 26: 
 
            
Figure 26: Systemic administration of TLR4 small molecule inhibitor 
does not alter injury-induced pain hypersensitivity in female rats. A 
single injection of HY09 (10mg/kg; i.p.) did not have an effect on TNI-induced 
tactile hyperalgesia at PID 14 and PID 28. HY09 in uninjured animals did not 
have an effect on effect on tactile sensitivity when compared to each time point 
PID 14 and 28. PID 14 n=6; PID 28 n=3, female S/D rats. (Student’s t-test, P> 
0.05). Both injections and tactile behavior were performed by Matthew Ripsch. 
BL: baseline.   
 
 
   141 
C.  Discussion 
TLR4 has been detected on neuronal and non-neuronal cell types in 
several pathogenic conditions. Recent reports have begun to elucidate the 
function role of TLR4 on neurons (Maroso et al., 2010; Ochoa-Cortes et al., 
2010; Due et al., 2012). In this present investigation, I found that in the DRG 
TLR4 is indeed expressed exclusively on sensory neurons. Most notably, TLR4 
protein expression in injured ganglia is decreased after a peripheral nerve injury. 
The results further indicate that small and medium diameter injured sensory 
neurons may be more susceptible to such a decrease in TLR4 protein expression. 
Correspondingly, I further observed a diminished calcium response to TLR4 
agonist, HMGB1, in injured sensory neurons. We further demonstrated that 
systemic injections of TLR4/MD2 antagonist in female rats did not reverse injury-
induced pain hypersensitivity at PID 14 or 28 suggesting that the TLR4/MD2 
interaction may not contribute to chronic injury-induced tactile hypersensitivity. 
The lack of TLR4 expression and calcium-mediated functional responses may 
suggest that TLR4 undergoes negative regulation in injured sensory neurons. 
Taken together, the present investigation suggests that TLR4 expression and 
function is altered in injured sensory neurons, which may contribute to a 
neuropathic pain state.  
After a peripheral nerve injury, previous literature has demonstrated that 
TLR4 in the CNS influences the establishment of neuropathic pain. For instance, 
TLR4 mRNA expression is upregulated primarily on microglia (Lehnardt et al., 
2003) and intrathecal injections of TLR4 antagonists can reverse injury-induced 
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pain hypersensitivity (Tanga et al., 2005; Bettoni et al., 2008; Hutchinson et al., 
2008). Neuronal TLR4 either in the spinal cord or dorsal root ganglia is also a 
prime candidate for perpetuating sensitization, which is a critical component in 
neuropathic pain states. Neuronal TLR4 expression is found in both central and 
peripheral nervous system (Tang et al., 2007; Acosta & Davies, 2008; Due et al., 
2012). Herein, I demonstrated that unlike in spinal cord, injured dorsal root 
ganglia decrease TLR4 protein expression. At first glance, a decrease in TLR4 
proteins expression suggests termination of downstream signaling or a cessation 
in TLR4 transcription. Further investigation is necessary to elucidate the precise 
TLR4 signaling that may transpire in order to account for the decrease in TLR4 
protein expression observed in injured DRGs. 
Interestingly, TLR4 expression was observed in injured and uninjured 
neurons by co-labeling with ATF3, a prominent neuronal injury marker (Tsujino et 
al., 2000). In vivo only a fraction of tibial nerve injured DRGs express ATF3, 
which is comparable to other injury models (Tsujino et al., 2000; Shortland et al., 
2006). TLR signaling and ATF3 have been implicated in delayed macrophage 
recruitment/activation, myelin debris clearance, and axonal regeneration 
(Seijffers et al., 2006; Boivin et al., 2007). More importantly, ATF3 is involved in 
suppressing TLR signaling mainly by inhibiting the production of proinflammatory 
cytokines (Gilchrist et al., 2006; Whitmore et al., 2007). Although, sensory 
neurons express ATF3 in cultured conditions (Ono et al., 2012) (Figure 25), 
which may function as a negative regulator of TLR signaling (Gilchrist et al., 
2006; Whitmore et al., 2007), TLR4 neuronal activation may persist. In this study, 
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nearly every dissociated sensory neuron cultured overnight was immunoreactive 
for ATF3 (Figure 25). Indirect evidence presented demonstrates that in vitro 
sensory neurons acutely exposed to a TLR4 agonist-HMGB1, was capable of 
eliciting a calcium response. However, injured sensory neurons were observed to 
have a diminished calcium response to HMGB1, nevertheless, injured neurons 
still elicited a response.   
Furthermore, these correlational studies are consistent with the working 
hypothesis that TLR4 signaling in injured DRGs may result in distinct neuronal 
subpopulations. The different subpopulations may depend on the degree of ATF3 
mediated TLR4 negative regulation. On one hand TLR4 activation may support 
axonal regeneration, and on the other hand TLR4 activation may influence 
calcium regulation/neuronal excitability (Figure 27). Additionally, non-capsaicin 
sensitive injured sensory neurons displayed an overall latency in diminished 
calcium response with exposure to HMGB1 (Table 7), suggesting peptidergic 
and non-peptidergic injured sensory neurons may also have distinct calcium-
mediated properties in response to endogenous TLR4 agonists.  
The basis for the observed altered calcium response most likely depends 
on the state of calcium regulation in injured sensory neurons. Other investigators 
have found that the influx of extracellular calcium through voltage-gated channels 
(Lirk et al., 2008) and/or depletion of intracellular calcium stores increase 
neuronal excitability after a peripheral nerve injury (Fuchs et al., 2005; Gemes et 
al., 2009; Rigaud et al., 2009). In particular, Gemes and colleagues demonstrate 
a compensatory role of store-operated calcium entry (SOCE) in calcium 
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homeostasis and functional regulation, which is hypothesized to enhance 
excitability in injured sensory neurons (Gemes et al., 2011). One recent study 
has further identified nuclear calcium-CREB signaling in mediating the function of 
ATF3 activity-dependent transcriptional repression of genes, which are critical for 
neuronal survival (Zhang et al., 2011). Together with what is known about 
calcium regulation in injured sensory neurons, suggests that the observed results 
of diminished calcium response may in fact be a consequence of calcium 
dysregulation in injured sensory neurons. 
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Figure 27: 
 
 
Figure 27: Possible in vivo sensory neuron populations after a tibial 
nerve injury. (A) Injured neuron positive for both TLR4 and ATF3. Negative 
regulation of TLR4 signaling, involved in axonal regeneration and is less 
excitable; (B) Injured neurons positive for ATF3, no effect on TLR4 signaling; 
(C) Injured neurons positive for TLR4, TLR4 signaling occurs; (D) Injured 
neuron delayed ATF3 expression and not positive for TLR4. In this situation 
TLR4 activation/degradation rate may outcompete TLR4 transcription, neuron is 
seen as negative for TLR4; (E) Uninjured neuron positive for TLR4, TLR4 
signaling occurs; (F) Uninjured neuron that does not express TLR4 or ATF3. 
The red outline depicts an injured sensory neuron. P: peripheral axonal branch, 
C: central axonal branch, and the double lines correspond to the site of injury. 
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 TLR4 also has the unique ability to signal not only at the plasma 
membrane (via Myd88-dependent signaling) but also in intracellular endosomal 
compartments (via TRIF-dependent signaling) to activate NFκB and IFN pro-
inflammatory signaling pathway. TLR4 internalization into endosomal 
compartments can lead to TLR4 lysosomal degradation (Chuang & Ulevitch, 
2004), which may account for the partial decrease in TLR4 protein expression 
evident at PID 3, 7, and 14. Other TLRs (TLR3/7/9) are also known to signal 
through endolysosomal compartments and agonist stimulation of TLR3/7/9 has 
recently been shown to sensitize sensory neurons, in vitro (Qi et al., 2011). 
Further investigation is necessary to determine if injured sensory neurons 
engage in TLR4 signaling at the plasma membrane and intracellular 
compartments.  
TLR4-deficient animals and siRNA have demonstrated the importance of 
TLR4 in microglia activation in the development of neuropathic pain (Tanga et al., 
2005; Wu et al., 2010a). Hutchinson and colleagues provided further evidence 
that inhibition of TLR4 is also important for well-established neuropathic pain 
(Hutchinson et al., 2008). The majority of studies examine the central mechanism 
of TLR4 in neuropathic pain by utilizing TLR4 inhibitors and/or knockdown TLR4 
siRNA that are either permeable to the blood brain barrier or administered 
intrathecally. Herein, we demonstrated that systemic administration of a well-
established TLR4/MD2 complex small molecule inhibitor (Bevan et al., 2010; Due 
et al., 2012) did not prevent injury-induced pain hypersensitivity. Thus, TLR4 in 
the periphery may have alternative means of activation that is less dependent on 
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MD2. To date, specific ligand interaction have been structurally identified for only 
a few exogenous TLR4 agonists, including LPS, morphine, morphine derivate- 
M3G, which require MD2 (Shimazu et al., 1999; Akashi et al., 2003; Hutchinson 
et al., 2010a; Lewis et al., 2010; Due et al., 2012). However, under naïve 
conditions evidence indicates that neurons appear to have minimal MD2 
expression (Acosta & Davies, 2008). Thus, the precise mechanism of 
endogenous TLR4 activation is not known and may require other accessory 
proteins, such as CD14, for neuronal activation after peripheral nerve injury.  
Most recently, Mogil and colleagues have discerned a gender difference in 
animals after spared nerve injury, such that intrathecal injection of a TLR4 
antagonist, LPS-RS was effective in reversing injury-induced mechanical 
allodynia, but only in male rats (DeLeo & Rutkowski, 2000; Sorge et al., 2011). 
Similarly, in our studies female rats were subjected to a TNI and a systemic 
injection of TLR4/MD complex antagonist was not able to reverse injury-induced 
pain hypersensitivity. Taken together, these findings suggests that in a rodent 
model of neuropathic pain, female rats may have an alternative TLR4 signaling 
mechanism, which may dependent on the hormonal environment.  
 In conclusion, TLR4 expression and function in sensory neurons may be 
dependent on a number of factors, including TLR4 negative regulation and/or 
presence of endogenous ligands. Better understanding of these TLR4-mediated 
signaling events in injured sensory neurons may further provide specific targets 
for therapeutic interventions for neuropathic pain states without disrupting TLR-
mediated inflammatory responses.     
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CHAPTER V 
 
GENERAL DISCUSSION 
 
A. Overview of results 
The major goals of this dissertation were to understand the role of an 
endogenously secreted cytokine, HMGB1 and to determine the role of one 
HMGB1-receptor, TLR4 in the dorsal root ganglion in a rodent model of 
neuropathic pain. A tibial nerve injury model was utilized to examine mechanisms 
of neuropathic pain. In Chapter II, the tibial nerve injury (TNI) model was 
characterized on three nociceptive behavior outcomes, thermal hyperalgesia, 
cold allodynia, and tactile hypersensitivity. Cold allodynia and tactile 
hypersensitivity was evident soon after the injury and remained thereafter for 
each experimental time point (> two months). Thermal hyperalgesia was evident 
beginning at PID 11 lasting for at least 10 days. These results are in line with 
previous reports (Decosterd & Woolf, 2000; Lee et al., 2000), and establish TNI 
as an effective model to study a chronic neuropathic pain state.  
Chapter III examined the role of HMGB1 in intact and injured sensory 
neurons and determined if HMGB1 was necessary for TNI-induced pain 
hypersensitivity. This dissertation found that HMGB1 undergoes subcellular 
redistribution from the nucleus to the cytoplasm in sensory neurons derived from 
injured DRGs. In a F11 sensory neuron cell line, HMGB1 was actively released in 
a feed-forward manner. Furthermore, current-clamp recordings (performed by Dr. 
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Michael Due) found that exogenous application of HMGB1 can increase neuronal 
excitability in naïve and injured sensory small and medium sensory neurons. 
Moreover, calcium imaging demonstrated that exogenous application of HMGB1 
can elicit intracellular calcium responses of small and medium naïve and injured 
sensory neurons. These functional studies involving exogenous application of 
HMGB1 suggests it may have a direct role in peripheral sensitization. Finally, it 
was found that systemic administration of glycyrrhizin (GL), an HMGB1 
neutralizing agent, can partially reverse injury-induced hypersensitivity; whereas, 
systemic administration of GL for four consecutive days nearly completely 
reversed injury-induced pain hypersensitivity. These results indicate that the 
release of HMGB1 is an ongoing process that may contribute to the development 
and/or maintenance of neuropathic pain.  
Chapter IV examined TLR4 in intact and injured sensory neurons and 
determined if TLR4 was necessary for TNI-induced pain hypersensitivity. It was 
first established that TLR4 was expressed primarily in sensory neurons and 
further co-labeled with peptidergic and non-peptidergic subpopulations in naïve 
DRGs. Furthermore, after TNI injury TLR4 protein expression decreased from 
PID3-14, returning to baseline expression by PID 28. The decrease in TLR4 
protein expression was found to be restricted to small and medium diameter 
sensory neurons. Additionally, TLR4 was present on directly injured neurons 
(ATF3 positive) and uninjured DRG neurons. In vitro, it was found that brief 
exposure of HMGB1, a TLR4 agonist, diminished calcium responses in injured 
sensory neuron compared to naïve, suggesting a decrease in HMGB1 receptor 
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signaling. One possibility is injured sensory neurons are influenced by TLR4 
negative regulation, which may be the case due to the increased expression of 
ATF3 (a negative regulator of TLR4 signaling) in injured sensory neurons. Finally, 
systemic administration of a TLR4/MD2, small molecule inhibitor, did not reverse 
injury-induced hypersensitivity in female rats. Given that TLR4 may exhibit 
gender specific issues (Sorge et al., 2011), further studies are needed to 
determine the precise mechanism of TLR4 activation in injured sensory neurons.  
In summary, the presence of HMGB1 and TLR4 in injured DRGs may 
contribute to a neuropathic pain state. Based on the findings in this dissertation, I 
am able to draw a number of conclusions: (1) HMGB1 is a dynamic ligand for 
cytokine function, (2) HMGB1 and TLR4 subcellular localization is context 
dependent, and (3) there is potential glial bias in neuronal TLR4 activation. Note 
that HMGB1 signaling is not limited to TLR4 activation, HMGB1 may indeed 
signal through TLR2, TLR9, and RAGE. The focus of the following discussion is 
on HMGB1 and TLR4.  
 
   151 
B. HMGB1 is a dynamic ligand for cytokine function in sensory 
neurons  
1. Extracellular release   
HMGB1 is released as an extracellular cytokine in a number of different 
disease models (Ohnishi et al., 2011; Kim et al., 2012). These data presented 
here, in conjunction with Shibasaki and colleagues demonstrate that continuous 
release of HMGB1 is indeed a contributing factor for neuropathic pain states 
(Shibasaki et al., 2010) (Chapter III). I presented evidence that cytoplasmic 
HMGB1 accumulates in the cytoplasm after a peripheral nerve injury and F11 
cells release extracellular HMGB1 (Figure 14,15). Moreover, consecutive 
injections of an HMGB1 neutralizing agent, glycyrrhizin, effectively reversed 
injury-induced pain hypersensitivity (Figure 17). Recently, glycyrrhizin has been 
shown to inhibit HMGB1 phosphorylation and secretion (Youn & Shin, 2006; Kim 
et al., 2012), suggesting that progressive inhibition of HMGB1 extracellular 
release may dampen pain behavior outcomes. Although phosphorylation and 
acetylation of HMGB1 mediates active release of HMGB1, the precise 
mechanism of nuclear translocation is unknown. A recent study examining IL-1β- 
stimulated release of HMGB1 in cortical astrocytes suggests that a nuclear 
protein exporter chromosome region maintenance 1 (CRM1), when upregulated, 
may facilitate the release of HMGB1 (Hayakawa et al., 2010a). Future studies 
should be directed to understanding nuclear translocation of HMGB1.  
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2. Extracellular HMGB1 alters neuronal function 
 Despite evidence of HMGB1 extracellular release by neurons, only a few 
investigators have explored its role in neuronal function. Recent evidence 
demonstrates that HMGB1 has a key role in hippocampal function and neuronal 
excitability in cortical neurons (Maroso et al., 2010; Costello et al., 2011). The 
data presented in this dissertation provides the first evidence that acute exposure 
of HMGB1 can alter sensory neuron excitability and function. In naïve conditions, 
application of HMGB1 resulted in nociceptive neurons to elicit an influx of 
intracellular calcium and an increase in sensory neuron excitability (Chapter III; 
Table 3) . However injured sensory neurons exposed to HMGB1 increased 
neuronal excitability in small and medium sensory neurons (Feldman et al., 
2012); but displayed an overall diminished calcium response (Table 5). 
Peripheral nerve injury is known to alter calcium regulation by either VGCCs or 
intracellular calcium stores in injured sensory neurons (Lirk et al., 2008; Gemes 
et al., 2011). Future experiments should delineate whether HMGB1 changes in 
calcium responses are mediated through intracellular calcium stores or a calcium 
influx at the plasma membrane.  
Moreover, it is unclear whether the increase in neuronal excitability is 
mediated directly or indirectly by the transactivation of ion channels. HMGB1-
TLR4 having direct effects on sensory neuronal excitation may involve a number 
of ion channels downstream of TLR4 activation that can contribute to changes in 
neuropathic pain states. Both work in the White laboratory and others have 
demonstrated that lipopolysaccharide (LPS) and morphine-3-glucuronide (M3G), 
(TLR4-MD2 agonists) increase neuronal excitability in cultured sensory neurons 
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by TRPV1 and sodium channels NaV1.6, 1.7 and 1.9 (Hua et al., 2007; Diogenes 
et al., 2011; Due et al., 2012). The activation of TLR4 in the dorsal horn can also 
indirectly influence the purinergic P2X7, ATP gated ion channel (Clark et al., 
2010). Additionally, two potassium channels have also been implicated in TLR 
receptor signaling, inwardly rectifying potassium channel Kir3.1 and large-
conductance calcium- and voltage-activated potassium channel MaxiK (Blunck et 
al., 2001; Seydel et al., 2001; Scheel et al., 2006). For instance, Kir3.1 channel 
activity at the plasma membrane may regulate TLR4-mediated signal at an early 
event by facilitating the recruitment of TLR4 into lipid rafts (Jo et al., 2011).  
Most recently, HMGB1 was shown to have a direct interaction with the 
NMDAR- GluN1 and GluN2B subunits, in isolated hippocampal nerve terminals 
and in a neuroblastoma cell line to facilitate NMDAR opening and NMDAR-
mediated activation of intracellular calcium (Maroso et al., 2010; Pedrazzi et al., 
2012). Interestingly, NMDAR receptors are found on primary sensory neuron 
peripheral terminals, central terminals and the soma (Sato et al., 1993; Liu et al., 
1994; Carlton et al., 1995; Ma & Hargreaves, 2000). Here I speculate, HMGB1 
may modulate NMDAR in injured DRGs, further contributing to the spontaneous 
activity of primary afferent neurons  
An important question that remains unresolved is which HMGB1 
receptor(s) or channel interactions at the plasma membrane are most 
responsible for neuronal excitability and/or calcium-dependent changes in injured 
sensory neurons. To distinguish which receptors alter sensory neuron function 
following a nerve injury, utilizing specific receptor antagonists alone or in 
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combination to inhibit HMGB1 receptor interaction may provide insight to specific 
HMGB1-related maladaptive changes in primary sensory neurons.  
 
3. Feed-forward regulation 
A working hypothesis states that HMGB1 establishes pro-inflammatory 
feed-forward cycle that sustains HMGB1-mediated activation of the immune 
response leading to tissue damage (Faraco et al., 2007). To test this hypothesis 
preliminary experiments were performed, such that, differentiated F11 cells were 
exposed to HMGB1 at various concentrations. The application of HMGB1 
resulted in the nuclear translocation of HMGB1 into the cytoplasm in F11-
neuronal cells, suggesting that extracellular HMGB1 exposure is sufficient to alter 
its intracellular localization (Appendix; Figure 29) . Additionally, evidence 
presented here demonstrates that following a peripheral never injury the level of 
HMGB1 protein expression remains; however, the subcellular distribution of 
HMGB1 is subsequently localized to the cytoplasm in injured DRGs (Figure 
11,14). Collectively these findings support the notion that transcription of 
HMGB1 is ongoing and released into the cytoplasm in injured DRGs.  
HMGB1 transcription is facilitated by a strong TATA-less promoter with a 
repressor element upstream and an enhancer element, which also contains two 
oestrogen response elements (Borrmann et al., 2001; Lum & Lee, 2001; 
Nagatani et al., 2001). HMGB1 is under the control tumor suppressor p53- which 
down regulates promoter activity, whereas, p73α upregulates promoter activity 
(Uramoto et al., 2003). Krüppel-like factor 4 (KLF4) is a novel transcription factor 
that has two binding sites on the HMGB1 promoter and is also capable of 
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regulating transcription of HMGB1 and translocation of HMGB1 in response to 
LPS (Liu et al., 2008). Whether HMGB1 transcription differs according to cell-
type or environmental context is unknown. 
At the same time, the release of HMGB1 may regulate gene transcription 
of its known receptor TLR4. For example, effector molecules downstream of 
HMGB1 receptor activation, such as ERK, p38 and NFκB signal transduction can 
further regulate TLR4 transcription (An et al., 2002). TLR4 gene contains 
consensus-binding sites for Ets family transcription factors, octamer-binding 
factors, and a composite interferon response factor/Ets motif (Rehli et al., 2000; 
Roger et al., 2005; Bondeva et al., 2007).  
One possibility to prevent feed-forward signaling of HMGB1 is through the 
negative regulation of HMGB1 receptor signaling. In support of this notion, ATF3 
negative regulation has been mathematically predicted to help discriminate 
between transient and persistent TLR4-induced signals (Litvak et al., 2009). As a 
negative regulator, ATF3 can act by blocking NFκB binding sites (Gilchrist et al., 
2006; Whitmore et al., 2007). In part ATF3 negative regulation may explain the 
contradictory findings presented in this thesis. I presented data that injured 
sensory neurons were less responsive to calcium mobilization upon exposure to 
HMGB1 (Table 5); where as, a brief exposure of HMGB1 increased neuronal 
excitability in injured sensory neurons (Chapter IV) . A caveat to these findings 
is that nearly all sensory neurons cultured overnight express ATF3 (Figure 25) 
(Ono et al., 2012). Collectively, I speculate that prolonged ATF3 expression in 
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cultured injured sensory neurons may in fact negatively regulate HMGB1-TLR4 
signaling by possibly altering calcium-dependent neuronal function. 
 
4. Bioavailability of HMGB1-receptor activation 
Like most proteins, HMGB1 can undergo posttranslational modifications to 
alter its cytokine bioavailability and functional response. Acetylation, methylation, 
and riboslylation of HMGB1 are characteristic posttranslational modifications that 
regulate secretion of HMGB1 in activated or necrotic immune cells. Moreover, 
recent evidence support that the redox properties of HMGB1 functions to 
promote inflammatory pathways and chemotaxis (Venereau et al., 2012). The 
experiments presented in the study utilized a reduced form of HMGB1, however 
the limitation to these experiments is the unknown variable of the precise redox 
state of HMGB1 prior to application (Table 5,7). Close examination of the post-
translational modifications and corresponding bioactivity of HMGB1 are essential 
for future studies given the diverse functions of HMGB1 (Table 2).  
During inflammation, the predominant form of HMGB1 is C106 thiol 
(reduced) and disulfide bond C23-45, however during inflammatory resolution 
HMGB1 is inactive active with a terminally oxidized cysteine residues (Antoine et 
al., 2010; Yang et al., 2011). Since TLR4 binds HMGB1 specifically at C106 thiol 
(reduced), this emphasizes the importance of HMGB1 bioavailability. RAGE is 
the other receptor that has been specifically identified to bind HMGB1 (Chapter 
1; Figure 4) and it has recently been shown than in a completely reduced 
environment HMGB1-RAGE interaction can promote cytotoxicity in cancer cells 
(Tang et al., 2010a; Tang et al., 2010b) (Table 2) . Future studies should be 
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directed towards manipulating the molecular properties of HMGB1 to attain 
specific biological activity.  
A candidate for HMGB1 redox regulation is apurinic/apyrimidinic 
endonuclease 1/Redox factor-1 (APE1), functions as a redox factor to regulate 
inflammatory responses and neuronal survival (Vasko et al., 2005). Recently, 
APE1 has been shown to regulate the release of extracellular HMGB1 and 
cytokine production (Yuk et al., 2009). The redox state of HMGB1, dictates its’ 
ability of inducing cytokine production to promote inflammation or chemotaxsis 
(Venereau et al., 2012). However, the redox state of HMGB1 after a peripheral 
nerve injury is unknown; thereby, I speculate that after a peripheral nerve injury, 
the redox state of HMGB1 may be distinct from the redox state of HMGB1 during 
inflammation. 
  Another factor that may impact the bioavailability of HMGB1 is the 
presence of HMGB1 decoy receptors. HMGB1 receptor RAGE can exist in a 
truncated form that lacks the intracellular signaling domain (dominant negative 
receptor) either as an endogenous secretory splice variant of RAGE (esRAGE) 
(Yonekura et al., 2003) or soluble RAGE (sRAGE), which is formed when the 
RAGE receptor is cleaved at the plasma membrane by metalloprotease 10, 
ADAM 10 (Raucci et al., 2008). Both of which are present in plasma and 
neutralize the effects of HMGB1, further providing a level of feedback regulation 
to prevent HMGB1 receptor signaling. For instance, rheumatoid arthritis patients 
display lower blood levels of sRAGE compared to health controls and non- 
inflammatory joint disease patients suggesting the lack of inhibition by sRAGE 
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may maintain HMGB1-receptor interaction (Pullerits et al., 2005). Whether or not 
plasma levels of sRAGE and esRAGE are altered after a peripheral nerve injury 
is unknown.   
 
5. HMGB1 functions as a protein complex 
It is believed that HMGB1 alone actually lacks cytokine function and 
instead acts as an extracellular molecular chaperone to facilitate proinflammatory 
responses (Hreggvidsdottir et al., 2009; Tsan, 2011). Evidence suggests that 
HMGB1 binds with LPS and enhances LPS-TLR4 mediated TNFα 
proinflammatory response (Youn et al., 2008). IL-1β bound to HMGB1 has also 
been suggested to enhance proinflammatory activity (Sha et al., 2008). 
Additionally, when HMGB1 is in complex it can promote activation of the partner 
receptor (Hreggvidsdottir et al., 2011). For instance, the reduced form of HMGB1 
interacts with SDF1 to promote monocyte migration through the SDF receptor, 
chemokine (C-X-C motif) receptor (CXCR) 4 not TLR4 (Campana et al., 2009; 
Schiraldi et al., 2012). Although reports suggest that the co-clustering of CXCR4 
and TLR4 is crucial for TLR4 signaling (Kishore et al., 2005; Triantafilou et al., 
2008), it is equally possible that the redox state of HMGB1 complexed to partner 
molecules can further influence cytokine production and leukocyte recruitment 
following injury or tissue damage (Venereau et al., 2012).  
A proteomic analysis has revealed putative proteins that bind with HMGB1. 
From this analysis one interesting protein Rab10, an endosomal trafficking 
protein and positive regulator of TLR4, was found to associate with HMGB1 
(Hreggvidsdottir et al., 2009; Lee et al., 2010). Understanding the physiological 
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properties of HMGB1 on its own or as a multi-protein complex will be critical to 
interpret its role in different disease pathologies.   
 
6. HMGB1-TLR4 interaction at the plasma membrane 
The majority of studies have examined TLR4 activation at the plasma 
membrane by LPS activation. Less is known about the interaction of endogenous 
ligands with TLR4, CD14 and MD2. It is believed that LPS-MD2-CD14-TLR4 
forms a tertiary complex to promote signaling. Unlike MD2, CD14 is not always 
necessary for LPS mediated signaling (Shimazu et al., 1999; Akashi et al., 2003). 
MD2 is also important for other exogenous TLR4 agonists, such as M3G and 
morphine. It is also known that RP105 a dominant negative TLR4 homologue 
binds to myeloid differentiation protein (MD) 1 and may inhibit TLR4/MD2 
signaling (Divanovic et al., 2005). There is minimal evidence suggesting HMGB1-
mediated TLR4 activation requires CD14 or MD2, although HMGB1 
demonstrates the ability to bind to TLR4/MD2 complex in macrophages (Yang et 
al., 2010). Recent findings suggest that MD2 mainly recognizes exogenous 
PAMPs and is capable of discriminating between PAMPs and DAMPs; whereas, 
CD14 serves as a universal adaptor for both PAMPs and DAMPs (Chun & Seong, 
2010).  
The question remains as to which accessory proteins, if any, are required 
for HMGB1-mediated TLR4 signaling in sensory neurons. Interestingly, dorsal 
root ganglia (DRG) neurons express CD14 and MD1 and have a minimal 
expression of MD2. It has been demonstrated that TLR4 can form a complex with 
MD1 (Acosta & Davies, 2008), and it is believed that this combination mediates 
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non-canonical TLR4 signaling in neurons (Okun et al., 2011). To further suggest 
this possibility, neurons stimulated with LPS do not translocate NFκB to the 
nucleus, transcribe IFN-β or activate c-Jun N-terminal kinases (JNK) (Tang et al., 
2007). TLR4 has preferential ligand interaction, for instance HSP60 (TLR4 
agonist) binds specifically to TLR4 on microglia not neurons, in vitro.  (Lehnardt 
et al., 2003; Lehnardt et al., 2008). Here we tested the possibility whether 
TLR4/MD2 in the periphery contributes to injury induced pain hypersensitivity. 
Results in this dissertation demonstrate that a specific TLR4/MD2 antagonist 
injected systemically was not able to reverse injury-induced pain hypersensitivity 
(Figure 26) . From these observations, I speculate that after peripheral nerve 
injury TLR4 signaling may involve non-canonical receptor activation. 
 
C. HMGB1 and TLR4 subcellular localization is context dependent 
1. Subcellular localization of HMGB1 
Most cytokines are externalized through the classical endoplasmic 
reticulum (ER)-golgi exocytotic route. However, HMGB1 lacks an ER localization 
sequences and is released most likely by secretory lysosomes following immune 
cell activation (Gardella et al., 2002a). Secretory lysosomes are specific to cells 
derived from a haematopietic lineage, such as leukocytes and platelets, and 
generally display features of both lysosomes and secretory granules. Neurons do 
not contain secretory lysosomes but do contain typical endocytic organelles, 
early endosomes, late endosomes and lysosomes. However, in injured neurons 
cytoplasmic HMGB1 is diffusely spread throughout the entire cytosol (Bonaldi et 
al., 2003; Maroso et al., 2010). It is unclear whether cytoplasmic HMGB1 is 
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released directly from the cytoplasm or whether cytoplasmic HMGB1 is able to 
engage with endocytic pathways in neurons.  
Presented in this thesis, cytoplasmic HMGB1 is localized throughout the 
morphology of injured sensory neurons and thus has the possibility to localize to 
intracellular organelles (Figure 11) . A preliminary observation demonstrates 
that after exposure of HMGB1 to F11 cells, TLR4 accumulates in the cytoplasm 
(see Appendix; Figure 30) . Though it has been previous suggested that 
HMGB1 may internalize with TLR4 complex after cell surface binding (Yang et al., 
2010), whether HMGB1 can traffic to intracellular organelles upon cellular 
damage or injury in neurons is unknown.  
 
2. TLR4 regulation is dependent of adaptor proteins and 
negative regulation 
TLR4 is the only TLR that signals at the plasma membrane and in 
intracellular compartments. Upon activation TLR4 can engage in endocytic 
pathways via clathrin-mediated endocytosis (Latz et al., 2002; Husebye et al., 
2006; Tanimura et al., 2008; Wang et al., 2012b). In neurons, Tang and 
colleagues first demonstrated that TLR4 is localized to both the cell surface and 
cytosolic compartments (Tang et al., 2007). Further, preliminary observations 
presented here demonstrate that brief exposure to HMGB1 results in distinct 
TLR4 localization to the cytosol (see Appendix; Figure 30) . However, it is 
unknown whether TLR4 trafficking in sensory neurons is involved in receptor 
recycling and/or lysosomal degradation.  
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Intracellular TLR4 signaling is highly regulated and engages TRIF-
dependent pathways resulting in the late NFκB and IRF3 pathway (Figure 5). In 
fact, TLR4-TRIF dependent signaling is terminated by TAG binding to TRIP 
preventing downstream IRF3 signaling, which occurs in the late endosome 
(Palsson-McDermott et al., 2009). Another possible mechanism to inhibit TLR4 
signaling is by intracellular negative regulation. For instance, Rab7 is a negative 
regulator of TLR4 signaling by promoting the translocation of TLR4 to lysosomes 
for degradation (Wang et al., 2007). On the other hand, Rab10 appears to be a 
positive regulator of TLR4 by regulating the trafficking rate of TLR4 to the plasma 
membrane (Wang et al., 2010). Interestingly, I demonstrated a partial decrease 
in total TLR4 protein expression after tibial nerve injury (PID 3-14), and a 
decrease in immunoreactivity of TLR4 in small and medium diameter neurons at 
PID 14 (Figures 19-22). The decrease in protein expression may be a result of 
TLR4 receptor degradation by Rab trafficking proteins; however, it is equally 
possible that transcription of TLR4 is decreased after injury. However, the 
decrease of TLR4 protein expression in injured DRGs was transient, lasting for 
two weeks post injury.  
The question remains whether TLR4 signaling or activation is altered in 
injured DRGs at a time point beyond two weeks. One possible mechanism may 
involve negative regulation of TLR4 signaling. For instance, SARM1 (SAM and 
an Armadillo repeat motif (ARM) 1) is a unique negative regulator of TLR4. It is 
highly expressed in neurons and inhibits TRIF-dependent signaling. Recent 
evidence suggests that SARM1 in axons actively promote their own destruction 
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after injury (Osterloh et al., 2012). Another prominent negative regulator is Tollip, 
which may inhibit TLR4 or IRAKs (Zhang & Ghosh, 2002) and regulate 
intracellular trafficking (Yamakami et al., 2003; Ohnuma et al., 2005; Brissoni et 
al., 2006). However, most evidence for TLR4 negative regulation was examined 
in non-neuronal cells. Findings presented in this dissertation, provides evidence 
of a specific neuronal TLR4 negative regulator, ATF3, following peripheral nerve 
injury (Figure 12,23) . In vitro experiments demonstrate that dissociated 
sensory neurons cultured overnight express ATF3 and injured sensory neurons 
display a diminished calcium response to HMGB1, suggesting that the level of 
ATF3 may contribute to the degree of HMGB1 elicited calcium mobilization in 
injured sensory neurons (Figure 25, Table 7) . Taken together, I speculate 
that the negative regulation of TLR4 signaling in injured sensory neurons may 
contribute to calcium dysregulation and neuronal excitability. Future experiments 
should focus on determining which negative regulators are present in injured 
sensory neurons and how TLR4 negative regulators may influence neuronal 
function after a peripheral nerve injury. 
 
3. Glia bias in neuronal TLR4 activation 
Neuropathic pain state involves both the central nervous system and 
peripheral nervous system. Accumulating evidence has demonstrated a major 
difference in TLR4 activation may depend on the cell type, either neuronal or 
non-neuronal. This difference is evident within the central nervous system. 
Lehnardt and colleagues were unsuccessful in labeling neurons derived from the 
spinal cord, with TLR4 agonist HSP60 (Lehnardt et al., 2003; Lehnardt et al., 
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2008). Furthermore, LPS exposure did not promote a typical TLR4 
proinflammatory response in spinal neurons, unlike astrocytes and microglia 
(Faraco et al., 2007; Tang et al., 2007). Thus, I speculate that in sensory neurons 
TLR4 activation may be distinct from microglia. 
HMGB1-TLR4 activation in glia cells may contribute to neuronal function in 
a paracrine manner. For instance, after chronic constriction injury, TLR4-deficient 
animals display diminished injury induced pain hypersensitivity. Initial analysis of 
these data suggested that the pain behavior attenuation was due to the absence 
of TLR4-dependent microglial and astrocytic activation in the spinal cord 
contributing to neuronal central sensitization (Tanga et al., 2004; Tanga et al., 
2005). In addition, Shibasaki and colleagues and evidence in this dissertation 
demonstrate that HMGB1 is expressed in satellite glial cells (Shibasaki et al., 
2010) (Figure 11) , which surround sensory neurons in the DRG, and may also 
influence neuronal function in a paracrine manner. I further presented evidence 
that after TNI, HMGB1 was also present in SGC before and after peripheral 
nerve injury (Figure 11).  
Furthermore, it is not known whether HMGB1 is found in synaptic vesicles. 
However, given what is known about HMGB1 subcellular localization, it is less 
likely that HMGB1 is released from central primary afferent terminals. Instead, 
the source of extracellular HMGB1 in the spinal cord is most likely glial cells or 
interneurons (Kim et al., 2006). Moreover, the recent finding suggesting that 
HMGB1 can interact with NMDA receptors (Pedrazzi et al., 2012) supports the 
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notion that HMGB1 released by glia cells or interneurons may influence neuronal 
function at the level of the spinal cord.  
 
D. Unconventional cytokines 
HMGB1 is a dynamic protein that influences transcription in the nucleus 
and functions as an important alarmin to signal tissue damage. Other alarmins 
may function in a similar manner as HMGB1. A new candidate, hepatoma 
derived growth factor (HDGF) has similar biochemical features to that of HMGB1. 
For instance, HDGF has two nuclear localization signals and shares 32% amino-
acid sequence homology with HMGB1 (Zhou et al., 2004). Additionally, HDGF 
not only stimulates growth in several cell types, but can also act as a 
neurotrophic factor for neurons (Marubuchi et al., 2006). HDGF has also been 
shown to display similar nuclear localization and secretion characteristics as 
HMGB1 (Abouzied et al., 2004). Many alarmins, including HMGB1, are 
leaderless cytokine proteins that generally are not trafficked through classical ER 
and Golgi secretory pathways (Nickel & Rabouille, 2009). In inflammatory cells, 
HMGB1 is trafficked from the nucleus to secretory lysosomes and multivesicular 
endosomes that fuse with the plasma membrane (Scaffidi et al., 2002; Liu et al., 
2006). Similarly, the leaderless cytokine galectin 1 (Gal1) also involves direct 
translocation from the cytoplasm across the plasma membrane, bypassing 
classical endocytotic pathways (McGraw et al., 2004; McGraw et al., 2005). 
Some leadless cytokines, such as HMGB1, IL-1β, migration inhibitory factor 
(MIF) are oxidation sensitive than may require free cysteine residues for their 
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bioactivity (Harris & Raucci, 2006). Thus, a reducing environment and the 
presences of extracellular thiols may promote pathological bioactivity. Taken 
together, many alarmins may function as cytokines that may undergo 
unconventional secretion from the cell and respond to various cues from the 
environment.  
E. HMGB1 release in pathological conditions 
The release of extracellular HMGB1 reflects the cellular condition. 
Necrotic cells or inflammatory cells trigger HMGB1 release to signal tissue injury 
and initiate the inflammatory response or wound repair (Wang et al., 1999; 
Scaffidi et al., 2002). On the other hand, during apoptosis HMGB1 is retained in 
the nuclei and does not initiate inflammation in apoptotic cells (Bustin, 2002). 
Bianchi and colleagues further revealed that by preventing histone H2B serine 14 
phosphorylation, this inhibits HMGB1 chromatin interaction in the nucleus and 
thereby can generate an inflammatory response in apoptotic cells (Scaffidi et al., 
2002). In many pathological conditions the HMGB1 cellular condition may 
change over time. For instance, a neuropathic pain state may involve an 
inflammatory, repair, and cell death HMGB1 response in both neuronal and non-
neuronal cell types. Furthermore, the extracellular release of HMGB1 is not 
necessarily unique to a neuropathic pain state. Other neurodegenerative 
conditions, such as Alzheimer’s disease and multiple sclerosis, may involve 
HMGB1 release by activating an inflammatory response, immune and neuronal 
cells. Overall, HMGB1 is most likely released locally and may function as a 
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neuroinflammatory factor contributing to neuronal death, microglia activation, and 
neuronal degeneration (Kim et al., 2006; Faraco et al., 2007; Gao et al., 2011; 
Kim et al., 2011). However, the underlying cellular condition over time may lead 
to alternative downstream signaling events that contribute to the role of HMGB1 
in specific disease pathology.   
F. Proposed mechanism 
The precise mechanism of HMGB1-mediated TLR4 signaling in neurons is 
not known, determining interaction with accessory proteins, adaptor proteins, 
negative regulators will be critical for determining the maladaptive state of injured 
sensory neurons. My working hypothesis is as follows: Depending on the sensory 
neuron phenotype and redox environment, HMGB1 preferentially binds TLR4 at 
the plasma membrane that (1) may influence neuronal excitability/calcium 
regulation at the membrane, (2) engage in endocytic pathways contributing to the 
maintenance of pro-nociceptive cytokines/mediators following peripheral nerve 
injury. Figure 30 summarizes my working hypothesis regarding the potential 
mechanisms of HMGB1 signaling in injured sensory neurons that may contribute 
to chronic neuropathic pain states.  
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Figure 28: 
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Figure 28: Proposed mechanism in injured sensory neurons. (1) 
Extracellular release of HMGB1 in injured neuron binds to TLR4. HMGB1 may 
bind in particular redox state, or in complex. Accessory proteins, MD1, and/or 
CD14, less likely MD2, are involved in receptor activation. (2) Upon TLR4 
activation, TIRAP and MyD88 adaptor proteins are recruited. MyD88-dependent 
signaling activates early NFκB downstream signaling. HMGB1-TLR4 activation at 
the plasma membrane engages transactivation of ion channels to transiently alter 
neuronal excitability and function. HMGB1 may interact directly with ion channels. 
(3) Alternatively, HMGB1-TLR4 activation may recruit adaptor protein 
TRAM/TRIF resulting in the internalization of the HMGB1-TLR4 complex into 
early endosomes- (Rab5-early endosome marker). TRIF-dependent signaling 
activates late NFκB and IRF3 downstream signaling. Rab10 facilitates 
replenishment of TLR4 to the plasma membrane. (4) IRF3 downstream signaling 
results in the production of IFN-β. NFκB downstream signaling results in the 
induction of pro-inflammatory cytokines (i.e. TNFα, IL-6, IL-1, MCP1) and 
HMGB1, TLR4 transcription/translation. (5) Feed-forward regulation of HMGB1 
release (6) HMGB1-TLR4 complex is trafficked to late endosomes (Rab7-late 
endosome marker). TAG is involved in terminating TLR4 downstream signaling 
by Triad3A mediated degradation. Potential neuronal negative regulators of 
TLR4 signaling, including but not limited to Rab7, SARM1, ATF3 (7) 
Cytoplasmic HMGB1 may also traffic to endosomal compartments. 
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G. Summary 
The aims of this dissertation were to understand the role of physiologically 
relevant endogenous ligand HMGB1 and cognate receptor -TLR4 in a tibial nerve 
injury model of chronic neuropathic pain. In summary the findings of this 
dissertation show: 
• HMGB1 undergoes a subcellular redistribution from the nucleus to the 
cytoplasm in sensory neurons following peripheral nerve injury. Further, a 
sensory neuron -surrogate cell line can release HMGB1 into the 
extracellular environment. 
 
• Direct exposure to HMGB1 increases neuronal excitability in injured and 
intact sensory neurons. However, in vitro there was a diminished calcium 
response in the presence of exogenous HMGB1 in injured sensory 
neurons cultured overnight; these observations suggest extracellular 
HMGB1 may contribute to sensitization of sensory neurons.  
 
• Chronic systemic administration of a HMGB1 neutralizing agent effectively 
reverses injury-induced tactile hyperalgesia.  
 
• TLR4 protein expression is decreased in injured dorsal root ganglia early 
in the development of TNI-induced hyperalgesia. More specifically, the 
decrease of TLR4 protein expression was specific to small and medium 
diameter sensory neurons.  
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• Systemic administration of a small molecule TLR4/MD2 inhibitor does not 
reverse TNI-induced tactile hyperalgesia in female rats.   
 
In conclusion, HMGB1 is a relevant endogenous source in the periphery 
that contributes to the progression of neuropathic pain states. Endogenous 
neuronal HMGB1-TLR4 activation is indeed far more complicated and may utilize 
mechanisms that are distinct from that of the immune system. HMGB1-TLR4 
signaling has evolved multiple regulatory mechanisms that may be context 
dependent. Better understanding HMGB1-mediated signaling events in injured 
sensory neurons may reveal novel functional roles for immune elements at the 
level of the nervous system.  
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APPENDIX 
The following is a set of preliminary observations testing whether acute 
exposure of exogenous HMGB1 can influence endogenous HMGB1 subcellular 
localization and TLR4 intracellular trafficking. 
 
A. Feed-forward regulation of endogenous HMGB1 
A working hypothesis states that HMGB1 establishes pro-inflammatory 
feed-forward cycle that sustains HMGB1-mediated activation of the immune 
response leading to tissue damage (Faraco et al., 2007). To test this hypothesis 
in sensory neurons, I used a differentiated F11 cell line as a surrogate sensory 
neuron to determine whether exogenous application of HMGB1 could impact the 
endogenous HMGB1 subcellular localization. In normal conditions, HMGB1 is 
localized to the nucleus (Figure 29A). Application of exogenous HMGB1 at 
0.35µg/ml and 1.4µg/ml was able to promote nuclear subcellular translocation of 
endogenous HMGB1 into the cytosol (Figure 29B,C). This preliminary 
observation suggests a possible autonomous feed-forward mechanism that may 
regulate HMGB1 release. 
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Figure 29: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Exogenous HMGB1 induces endogenous HMGB1 nuclear translocation into cytoplasm.  
HMGB1 was applied to F11 cells at 0.35µg/ml and 1.4µg/ml for 30 mins following cell fixation and labeling with 
anti-HMGB1 (red). HMGB1 is localized to the nucleus in control conditions, exogenous HMGB1 results in 
localization throughout the entire morphology of F11 cells (red arrows). A single experiment was performed using 
2 wells/coverslips per treatment condition. F11 cells differentiated for 48hrs. Scale bar, 50µm.    
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B. TLR4 internalization following exposure to exogenous HMGB1 
Upon activation TLR4 may undergo internalization into endosomes to 
facilitate TRIF-dependent signaling (Husebye et al., 2006). To test this 
phenomenon in sensory neurons, I used a differentiated F11 cell line to 
determine whether exogenous application of HMGB1 could impact the 
localization of TLR4 either at the plasma membrane or internalization into 
intracellular compartments. Differentiated F11 cells express TLR4, 14% of F11 
cells (94/668), the signal is spread diffusely throughout the entire morphology of 
the cell (Figure 30A). Following exposure of HMGB1 for 30 mins, TLR4 
localization densely accumulated in the cytoplasm with close proximity to the 
nucleus (Figure 30B,C). This preliminary observation suggests that TLR4 
activation in vitro results in receptor internalization in a sensory neuron-like cell 
line. Taken together, it is hypothesized that sensory neurons are likely to engage 
in TLR4 signaling at the plasma membrane and through intracellular 
compartments.  
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Figure 30: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Exogenous application of HMGB1 leads to TLR4 internalization. (A) TLR4-immunoreactivity in 
F11 cell line. Anti-TLR4(green) and DAPI(blue). (B,C) HMGB1 was applied to F11 cells at 0.35µg/ml and 
1.4µg/ml for 30 mins following cell fixation and labeling with anti-TLR4(green) and DAPI(blue). Both 
concentrations resulted in TLR4 accumulation in cytoplasm. Experiment was performed twice. Each experiment 
used 2 well/coverslips per treatment condition. F11 cells differentiated for 48hrs. Scale bar, 30µm. 
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